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Summary 
 
Regulatory B cells, producing IL-10, have been studied in many autoimmune diseases. 
However, less is known about these cells in Type 1 diabetes (T1D), a disease 
characterized by the destruction of beta-cells by the immune system, leading to deficient 
production of insulin. Although B cells play a role in development of T1D, most 
previous investigations have focused on their pathogenic involvement.  B cell depletion 
has been shown to be protective against diabetes development. 
To examine regulatory B cells in T1D, we used Non-Obese Diabetic (NOD) mice and 
non-diabetes-prone B6
g7
 mice as controls. We compared both strains for the production 
of cytokines and expression of putative regulatory phenotypes in spleen B cells cultured 
with various stimulants, at different ages. We observed that NOD mice that were > 35 
weeks old and naturally protected against T1D had more IL-10-producing B cells than 
B6
g7
 and diabetic NOD mice, and this number increased even more on stimulation with 
lipopolysaccharide (LPS) stimulation. When LPS-stimulated B cells from protected 
mice were cultured in vitro with CD8 T cells and DCs, their potential for suppression of 
T cell cytotoxic activity was higher than unstimulated B cells and B cells from diabetic 
mice. This inhibitory effect was associated with higher levels of IL-10. 
Lastly, we carried out an investigation where B cells were transiently depleted in 
transgenic NOD mice expressing human CD20, to enable depletion using a human anti-
CD20 monoclonal antibody. We evaluated the effect of depletion and repopulation on 
regulatory B cells, testing whether the protection afforded by B cell depletion was due 
to a change in regulatory B cell number or function. B cells with putative regulatory 
phenotypes were susceptible to depletion and, although the treatment with anti-CD20 
reduced the incidence and delayed the onset of diabetes, there was no difference in the 
IL-10 producing B cell population by the time of full repopulation of B cells. Thus, this 
protective effect of B cell depletion was unlikely to be due to IL-10-producing B cells. 
In conclusion, for the first time, regulatory B cells were extensively studied in NOD 
mice and we demonstrated that protected NOD mice had higher frequencies of spleen B 
cells producing IL-10 than diabetic NOD mice. Further investigation is warranted to 
understand how these IL-10-producing B cells contribute to protection against type 1 
diabetes. 
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1. Introduction  
 
1.1 The origin and development of B cells 
The immune system comprises a complex set of cells responsible for defending the 
individual against exogenous harm. Lymphocytes are competent and specialized cells 
whose major role is to carry out this function. There are two types of lymphocytes: T 
and B cells, the latter being the main subject of this study. 
The primary function of B cells is to produce antibodies and they are characterized by 
the expression of immunoglobulins (that include IgM, IgD, IgG, IgA and IgE) on their 
surface, which, in combination with Igα and Igβ, make up the B cell receptor (BCR). 
These cells can be generated in two locations: bone marrow (BM) or the fetal liver. 
They are divided into different subsets based on their origin and their generation 
throughout life (Hardy 2006). However, studies have shown that a small percentage of 
B cells also develops from progenitors in the thymus (Perera et al. 2013). 
 
1.1.1 B-2 cells 
B-2 cells originate in the bone marrow during the individual’s entire life and they are 
known as conventional B cells. Their precursors are hematopoietic cells that populate 
the bone marrow during the embryonic phase. B cell development is associated with the 
BCR rearrangements that generate a very large (capable of recognizing more than 
5x10
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 antigens) repertoire of antibodies (Pieper et al. 2013). 
B cell progenitors are found in the bone marrow and fetal liver during fetal development 
(and also in the bone marrow of adult individuals, for renewal). When these cells 
commit to the B cell lineage, they are called pro-B cells. Pro-B cells do not yet produce 
immunoglobulins (Ig), but they express CD19 (Nera et al. 2006). This is the stage when 
recombination of the V(D)J genes generates a variety of μ heavy chains. Once pro-B 
cells are able to produce Ig polypeptides, they are designated pre-B cells. The 
combination between μ heavy chain and surrogate light chains comprises the pre-B cell 
receptor and the first checkpoint for B cell maturation is passed once the cells express 
functional pre-BCR (Melchers 2005). The molecules Igα and Igβ also appear first in 
pre-B cells. 
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As the maturation continues, κ and λ light chains go through VJ combinations, and one 
of them will bind to the μ heavy chain to form the BCR (Almqvist and Martensson 
2012). 
Thus, immature B cells with low-affinity self-receptors or receptors for external 
antigens can differentiate into transitional B cells (designated T1 and T2 B cells) and 
they home to the spleen where they will become follicular or marginal zone B cells. The 
strength of BCR signals will determine the fate of these immature B cells once they 
reach the spleen (Figure 1.1).  
B cells showing strong BCR signals to exogenous antigens will become Follicular zone 
(FO) B cells. In the white pulp of the spleen, they are located in follicles close to the T 
cell zone, which facilitate communication and the onset of T cell-dependent responses, 
forming germinal centres and generating plasma cells. FO B cells are short-lived and 
also known as the recirculating subset, migrating from spleen, to lymph nodes (LNs) 
and bone marrow (where they can be found around sinusoids) (Allman and Pillai 2008). 
On the other hand, B cells with BCRs that signal weakly will become Marginal zone 
(MZ) B cells, a subpopulation more distinct in rodents than in humans. These cells are 
located between the red pulp and the follicles in the spleen.  
Although the BCR signalling strength is important for distinguishing between FO and 
MZ B cells, B cells also need other signals to migrate and remain in the marginal zone, 
such as Notch2 and sphingosine 1-phosphate receptor (S1PR1). S1PR1 is important for 
migration and retention of B cells in the marginal zone, as sphingosine 1-phosphate is a 
chemokine found more frequently close to the marginal sinus (Pillai and Cariappa 2009; 
Ramos-Perez et al. 2015). 
Due to their proximity to the blood vessels in the spleen, MZ B cells are responsible for 
acting against blood-borne pathogens and for T-independent responses. Marginal zone 
B cells express higher frequencies of Toll-like receptors (TLRs) in comparison to FO B 
cells. These molecules are related to interaction with microbial fragments and rapid 
response to pathogens, in contrast to the slower, but more specific response provided by 
FO B cells (Cerutti et al. 2013). They also express a higher frequency of the CD1d 
molecule. This MHC-like receptor is responsible for presenting lipid antigens to 
invariant NKT (iNKT) cells (Chaudhry and Karadimitris 2014). 
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1.1.2 B-1 cells 
B-1 cells were first described at the beginning of the 1980’s as B cells expressing high 
levels of IgM, low levels of IgD and a surface marker that, up until then, was only 
detected in T cells: Ly-1 (now called CD5). They were identified as a small population 
in the spleen of all mice studied and they were able to secrete natural antibodies 
(Hayakawa et al. 1983). 
30 years later, more is known about B-1 cell function, origin and development. 
Although they were discovered in the spleen, these cells are mainly found in the 
peritoneal and pleural cavity of mice (Hayakawa et al. 1985). The expression of CD5 in 
murine B-1 cells is important, but not essential. Hence, the B1 cell subtype is then 
subdivided into B-1a (CD5
+
 B-1 cells) and B-1b (CD5
-
 B-1 cells) (Baumgarth 2011).  
B-1 cells exert an analogous function to Marginal zone B cells:  they constitute the 
defence against blood-borne pathogens before the adaptive immune response is 
initiated. The production of natural antibodies comprises mainly the synthesis of IgM. 
However, differently from immunoglobulins secreted after T cell-dependent 
mechanisms, their repertoire is restricted, the antibodies are polyreactive and their 
production is not necessarily dependent on stimulation (Boes et al. 1998).  
With such similar functions, the differences between B-1 and marginal zone B cells lies 
in their origin and how they are renewed throughout the individuals’ life. 
In fetal liver, the organ where most of the B-1 cells are generated, pre-B cells do not 
produce/produce low quantities of the enzyme responsible for making their BCR as 
diverse as the B cells in the bone marrow. The presence or absence of certain growth 
factors (IL-7 and Notch2, for example) could also be involved in the fate of B cell 
precursors, favouring B-1 or B-2 B cells (Hardy 2006). In adult mice, while B-2 B cells 
are constantly renewed by new cells being generated in the bone marrow, B-1 B cells 
are self-renewable (Hayakawa et al. 1986). 
In humans, the expression of CD5 is not as useful for distinguishing B-1 cells, as this 
marker is expressed by human B-2 cells. After further investigation, some researchers 
have agreed that, in humans, B-1-like B cells are CD20
+
CD27
+
CD43
+
CD70
-
, and 
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among these cells, most of them are also CD5
+
. They have the same main function of 
producing natural IgM, as seen in mice (Rothstein and Quach 2015).  
 
 
Figure 1.1 B cell origin, development and maturation.  B-1 and B-2 B cells have 
different origins and forms of renewal in adult life (a). B -1 cells are generated 
mainly during fetal  life in the liver, while B-2 cells derive from B cell progenitors 
in the bone marrow. During adult life, B-1 cells in the peritoneal cavity are self -
renewable and do not depend on the new B cells being generated in the bone 
marrow, unlike the B-2 cells. The process of B cell precursors in the bone marrow 
becoming B-2 cells in the spleen is illustrated in (b). B cells receive their 
designations as the B cell receptor is undergoing maturation. When the cells are 
ready to leave the bone marrow, immature B cel ls home to the spleen; the strength 
of their BCR reactivity to exogenous antigens will determine their location in the 
spleen. Different B-2 cells in the spleen express different  surface markers.  
 
1.2 B cell functions and intercellular interactions 
1.2.1 Antibody production 
As explained previously, producing antibodies against exogenous pathogens is the main 
function of B cells. Antibodies were discovered to be γ-globulins in 1938, even before 
the cells responsible for their production were identified (Tiselius and Kabat 1938). 
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Plasma cells were then described 10 years later as the antibody-secreting cells (Fagraeus 
1948). 
Although all B cells, by nature, can potentially produce antibodies, plasma cells 
resulting from T cell-dependent responses are mainly derived from Follicular zone B 
cells. 
The transformation of FO B cells into plasma cells occurs in structures called germinal 
centres (GCs). Inside the germinal centre, these cells are converted into GC B cells and 
after going through clonal expansion, somatic hypermutation and affinity maturation, 
they become high-affinity plasma cells or memory cells (Gatto and Brink 2010). 
This process starts when naïve FO B cells circulate through the body and scan for 
antigens in the lymph nodes, guided by chemokines. Antigens can be found in the LNs 
and spleen as soluble molecules or can be transported by dendritic cells (DCs); in the 
spleen, marginal zone B cells can also transport antigens to the follicular area. When B 
cells encounter their specific antigen, they migrate to the boundary between B and T 
zones (Okada and Cyster 2006). In this area, B cells are activated by a number of 
stimuli.  These include interactions with activated T cells (called T follicular helper cells 
– Tfh), binding through the receptor CD40 in B cells and CD40L (CD154) in T cells 
and by the secretion of cytokines (such as IL-21 and IL-4) by T cells. Activated B cells 
then start to proliferate and the fast mitosis of these cells pushes the other non-dividing 
cells aside to form the structures known as germinal centres (Klein and Dalla-Favera 
2008). 
A transcriptional regulator called Bcl-6 (B cell lymphoma-6) is essential for the 
establishment of the germinal centres. Bcl-6 is responsible for the regulation of various 
genes and its role is to make the antigen-engaged B cells commit to functions that are 
important for the formation of GCs. For example, DNA-damage-induced apoptosis is 
inhibited as well as differentiation of activated B cells to short-lived plasma cells or 
memory cells. This transcriptional repressor has also a role in the interaction between B 
cells and Tfh cells (Kitano et al. 2011). After the germinal centre is established, Bcl-6 is 
downregulated. 
During GC B cell proliferation, two areas become evident: The dark zone, the place 
where B cells are heavily dividing, and the light zone, where non-proliferating B cells, 
T cells and follicular DCs are found. During the clonal expansion in the dark zone, B 
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cells also undergo somatic hypermutation, a process by which the variable region of the 
B cell receptor gene is rearranged, producing an antibody with the highest affinity 
possible to the antigen of interest (Brink 2007). 
These B cells with rearranged receptors migrate then to the light zone, where the Tfh 
cells and follicular DCs will select high-affinity antibody-producing B cells. In the light 
zone, a new step into maturation is accomplished: The chosen B cells have their IgM 
and IgD substituted for IgG, IgA or IgE, a process called class-switch recombination 
(Klein and Dalla-Favera 2008). At this stage, the full differentiation of GC B cells into 
plasmablasts occurs as an outcome of the upregulation of some transcription factors 
(such as Blimp-1 – B lymphocyte-induced maturation protein-1) and downregulation of 
others (Bcl-6 and PAX5 – Paired box protein 5). When committed to the plasma cell 
path, B cells cannot go back to previous stages (Nera et al. 2006).  
B cells that do not downregulate PAX5 at this point become memory B cells. In case of 
a second encounter with the antigen, these memory B cells are many steps ahead of a 
naïve B cell to become plasma cells, assuring a faster response (Nutt et al. 2015). 
A diagram summarising the process of T-dependent generation of plasma cells, through 
germinal centres, is shown in Figure 1.2. 
Along with their class-switched receptor, plasma cells also express CD138
+
 on their 
membrane, which is important for their identification in assays (Nutt et al. 2015). These 
antibody- secreting cells can stay in the spleen temporarily or home to the pathogen-
infected organ. After the end of the immune response, long-lived plasma cells will be 
found in the bone marrow, while memory cells tend to remain at the local site of 
infection (Shapiro-Shelef and Calame 2005).  
While the formation of plasma cells through the germinal centre could take several 
days, T-independent antibody production by Marginal zone and B-1 B cells occurs 
rapidly after encounter with blood-borne pathogens. 
TLRs are very important for the development of T-independent responses. In humans, 
these receptors are upregulated upon infection and, in mice, they are expressed 
constitutively in all B cells. However, although murine FO B cells are able to respond 
to, for example, LPS or CpG stimulation in vitro (stimulants for TLR-4 and TLR-9, 
respectively), only MZ and B-1 B cells differentiate into plasma cells after being 
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activated via their TLRs (Genestier et al. 2007). Stimulants like LPS can also induce T-
cell independent responses through both BCR and TLR activation, acting synergistically 
to generate class-switched antibodies – mainly IgA in the gut and IgG (Pone et al. 
2012). 
The mechanisms of antibody-action include: 1) Binding to the pathogen antigen, 
neutralization and impairment of antigen ligation to the target cell; 2) The constant part 
of the antibody, called Fc, can induce complement-mediated death following binding of 
complement and 3) Antibody Fc regions can also bind to Fc receptors in cells like 
macrophages and Natural Killer cells, causing antibody-dependent cellular cytotoxicity 
(Chan and Carter 2010). Thus, for their high specificity and mechanisms of action, 
monoclonal antibodies have been used as treatment for various diseases, including 
autoimmune diseases; which will be further explained in this chapter and chapter 5. 
 
1.2.2 Antigen-presenting B cells 
Lanzavecchia discovered in 1985 that B cells, similarly to dendritic cells and 
macrophages, were able to present antigens to helper T cells in an MHC-restricted 
manner. Interestingly, specific B cells had the advantage of being able to capture 
antigen through their BCR and process them in much lower concentrations than DCs or 
macrophages (Lanzavecchia 1985). 
B cells also express co-stimulatory molecules, such as CD40 (binding to CD40L on T 
cells), CD80 and CD86 (both binding to CD28 on T cells) and these receptors are 
upregulated when B cells are activated (Constant 1999). 
Studies where mice were genetically modified to be B cell-depleted from birth 
confirmed the importance of B cells as APCs. When B cells were absent, the activation 
of CD4 T cells was impaired, but reversed when B cells were transferred back to those 
mice (Rivera et al. 2001). These studies have also demonstrated the role of B cells as 
APCs in autoimmune diseases like type 1 diabetes (Serreze et al. 1998) and will be 
discussed later in this chapter. 
During T cell maturation in the thymus, thymic epithelial cells are the main cell type 
responsible for negative selection of T cells. However studies have shown that APCs, 
such as DCs and macrophages, but also B cells, could exert this function in the process 
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of deleting autoreactive T cells as well (Frommer and Waisman 2010; Perera et al. 
2013). This role for B cells was demonstrated in both murine models (Frommer and 
Waisman 2010) and humans (Gies et al. 2017). 
 
 
Figure 1.2 The generation of plasma and memory cells from follicular B cells, 
through germinal centres. When naïve B cells encounter antigens, they travel to 
the boundary between B and T cell zones  and become activated (a).  The process of 
rapid mitosis generates a micro structure called germinal centre, which is divided 
into two zones: The place where B cells undergo clonal expansion and somatic 
hypermutation is called the dark zone (b). Somatic hypermutation induces the 
rearrangement of BCR genes in order to create a new receptor with higher affinity 
for the antigen. When B cells leave the dark zone, they are tested by F ollicular 
DCs and T cells, in the light zone, for affinity. Those B cells whose BCRs are not 
advantageous are induced to apoptosis (c). The BCR with the highest affinity is 
then stimulated to downregulate or upregulate genes which lead to antibody 
isotype switch (d). These B cells will then become antibody-secreting cells 
(plasma cells) or memory cells (modified from (Kuppers 2003). 
 
 
1.2.3 Cytokine-producing B cells 
Although the interaction cell-cell between B and T cells (binding through surface 
markers) has been the main focus so far in this chapter, B cells are also able to produce 
and secrete cytokines to modulate immune responses. 
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1.2.3.1 Effector cytokines 
In inflammation and infection, B cells can be influenced to produce effector cytokines 
depending on the microenvironment. 
When cultured in the presence of polarized T cells (Th1 or Th2), B cells were induced 
to polarize. Thus, after being cultured for 3 days in contact with Th1 cells, B cells 
secreting IFN-γ were detected and designated Be1. On the other hand, a small 
percentage of B cells cultured with Th2 cells produced IL-4 and were called Be2. IL-6, 
IL-10 and IL-2-producing B cells were seen among both Be1 and Be2, but these 
cytokines were produced more by Be2 cells. B cells producing IL-5 were not detected. 
Most importantly, polarized B cells were also able to polarize naïve T cells in a 
cytokine-dependent way (Harris et al. 2000). 
One subset of B cells produces IFN-α, which is essential for the activation of NK cells 
and their subsequent secretion of IFN-γ. Although this cytokine was previously 
considered to be specifically secreted by plasmacytoid DCs, pDC-like B cells produce 
IFN-α as well, in cases of viral or intracellular bacterial infection (Vinay et al. 2010; 
Bao et al. 2011) 
Cytokines produced by B cells are also responsible for the maturation of other cells and 
lymphoid structures. For example, in the spleen and lymph nodes, B cells producing 
lymphotoxin α1β2 (LT α1β2) and TNF, respectively, are necessary for the development 
of follicular DCs (Shen and Fillatreau 2015). Lymphotoxins secreted by B cells are also 
associated with the organization and maturation of lymphoid tissues in the gut (such as 
Peyer’s patches) (McDonald et al. 2005). 
 
1.2.3.2 Regulatory cytokines 
B cells producing regulatory cytokines are the main subject of this thesis and the most 
important regulatory cytokine is IL-10. 
The concept of B cells producing IL-10 is not new. Although B cells are seen mainly as 
fundamental components of pro-inflammatory responses, reports indicating that these 
cells were able to produce IL-10, a suppressive cytokine, date back to the beginning of 
the 1990’s. O’Garra and Howard discussed the presence of murine CD5+ peritoneal and 
aged splenic B cells able to produce IL-10 when stimulated with LPS. This IL-10 was 
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able to inhibit macrophage activities and, consequently, T effector cells (O'Garra and 
Howard 1992).  
This function, however, was not fully further explored until 10 years later, when 
Mizoguchi and colleagues used the term regulatory B cells (Bregs) for the first time to 
designate a subpopulation of B cells expressing CD1d and able to produce IL-10. These 
Bregs were able to suppress chronic intestinal inflammation by downregulating pro-
inflammatory cytokines, such as IL-1β (Mizoguchi et al. 2002). IL-10 producing B cells 
became an interesting subject in autoimmune diseases, especially after studies showing 
that in a mouse model of multiple sclerosis, B cell deficient mice did not recover as 
usual after the acute phase (remission). This effect was proven to be due to the absence 
of B cells producing IL-10 (Fillatreau et al. 2002). 
Despite their promising role in protection from autoimmune diseases, the first problem 
in characterizing these regulatory B cells was agreeing on a definite phenotype. Unlike 
natural regulatory T cells (Tregs) and their expression of Foxp3, at this time, no 
transcription factor for regulatory B cells has, as yet, been described (Rosser and Mauri 
2015). Therefore, regulatory B cells are defined by their ability to produce IL-10 upon 
stimulation and some phenotypes seem to be more involved in this production. 
Following the studies by Mizoguchi, Tedder and colleagues showed that murine B cells 
expressing CD1d
hi
CD5
+
 were the main responsible cells for IL-10 production after LPS 
stimulation for 5 hours (they called these B cells B10 cells). They also discovered that 
mice prone to develop autoimmune diseases had a higher frequency of these B10 cells, 
compared with C57BL/6 mice (Yanaba et al. 2009). B cells expressing CD1d, as 
discussed, are mostly found in the marginal zone (Chaudhry and Karadimitris 2014). In 
experimental autoimmune encephalomyelitis (EAE), transfer of CD5
+
 B10 cells to 
mice, even after the clinical signs of EAE had appeared, were capable of reducing the 
disease, while CD5
-
 B cells did not alter disease progression (Yoshizaki et al. 2012). 
Furthermore, transitional 2 (T2) B cells (CD19
+
CD21
hi
CD23
hi
IgM
hi
) were also 
identified as a source for regulatory B cells in a model of collagen-induced arthritis. In 
this model, the percentage of B cells producing IL-10 decreased during the acute phase 
and increased again during remission of the disease (Evans et al. 2007). This phenotype 
is usually seen in regulatory B cells that were previously stimulated in vitro with anti-
CD40 for 48h, mimicking a T cell interaction. As shown by the low frequency of IL-10-
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producing B cells when stimulated with IgM, BCR-dependent stimulation is not 
necessary for the production of IL-10 (Blair et al. 2009). 
One new marker recently associated with the production of IL-10 by B cells is Tim-1 (T 
cell Ig and mucin domain-1), a molecule commonly expressed by T cells. When 
detected in B cells, however, Tim-1 was associated with promotion and maintenance of 
their production of IL-10 (Ding et al. 2011; Xiao et al. 2015). Other B cell phenotypes, 
including plasmablasts (Matsumoto et al. 2014), were described in mice as being able to 
produce IL-10 under specific conditions, reviewed by (Rosser and Mauri 2015). 
In humans, the expression of CD24
hi
CD38
hi
 – characteristic of immature B cells – seem 
to identify the IL-10-producing B cells in the peripheral blood, when cultured and 
stimulated with anti-CD40. In patients with Systemic Lupus Erythematosus (SLE), 
regulatory B cells were less suppressive than healthy controls  (Blair et al. 2010). The 
expression of CD24
hi
CD27
hi 
in human B cells has also been related to IL-10 production 
(Iwata et al. 2011).  
Relating to phenotype heterogeneity and the fact that no transcription factor has yet 
been discovered, it is believed that regulatory B cells are more of an inducible 
population than one committed to this fate from the early stages of development. To 
confirm this theory, Rosser and colleagues demonstrated that the differentiation and 
optimal function of IL-10 producing B cells in a mouse model of arthritis was 
dependent on an inflammatory environment containing IL-1β and IL-6 (Rosser et al. 
2014). In healthy controls, plasmacytoid DCs are responsible for differentiation of 
immature B cells into Bregs or IL-10-producing plasmablasts by secreting IFN-α, which 
acts as a negative feedback for inflammation. However, in cases of patients with SLE, 
pDCs produce much higher quantities of IFN-α, which induce B cells to differentiate 
into pathogenic plasma cells instead (Menon et al. 2016). 
Although our focus here is on regulatory B cells and autoimmune diseases, it should be 
noted that IL-10-producing B cells have also been studied in asthma, allergies (as a 
beneficial factor) and cancer (as an aggravator), in mice and humans (van de Veen et al. 
2016). 
In addition to IL-10, which has been the main focus when studying Bregs, two other 
cytokines were described to have roles in the regulatory function of B cells: TGF-β and, 
more recently, IL-35. 
12 
 
Murine B cells stimulated with LPS were able to induce anergy in CD8 T cells by the 
expression of TGF-β1 on their surface. When cultured in the presence of these LPS 
stimulated-B cells (but not B cells stimulated with anti-CD40), CD8 T cells had 
impaired cytotoxic function and lower production of inflammatory cytokines (Parekh et 
al. 2003). In human gastric cancer, B cells expressing CD24
hi
CD38
hi
 were detected in 
the tumour area. Besides increased IL-10, these B cells also produced TGF-β1 and this 
cytokine was responsible for the conversion of CD4 T cells into regulatory T cells 
(Wang et al. 2015). 
The ability of LPS-stimulated B cells to induce apoptosis in T cells in a TGF-β-
dependent way was also observed in type 1 diabetes (T1D) and will be discussed later in 
this chapter and chapter 3 (Tian et al. 2001). 
More recently, the role of IL-35 produced by B cells was studied. Shen and colleagues 
demonstrated that upon stimulation with TLR4 and anti-CD40, B cells produced IL-35 
(formed by two molecules: EBi3 and p35) and transgenic mice that were B-p35
−
/
−
 or B-
EBi3
−
/
−
 had more severe cases of EAE, compared to wild type mice. The mechanism of 
action of IL-35-producing B cells and plasma cells are not fully understood, but it is 
known that IL-35 can enhance the production of IL-10 (Wang et al. 2014). 
A summary of the phenotypes and functions of regulatory B cells is illustrated in Figure 
1.3.  
Regulatory B cells have been studied in many autoimmune diseases (such as arthritis, 
EAE and SLE) for the last 15 years. However, less is known about Bregs in the context 
of type 1 diabetes. What is known so far will be addressed later in the chapter. 
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Figure 1.3 Regulatory B cell functions divided by cytokine. Regulatory B cells 
act differently to suppress inflammatory responses, depending on the cytokine 
produced. The references for each one of these mechanisms can be found in the 
text. Forward arrows (→) indicate enhancement and closed arrows (─׀) indicate 
inhibition.    
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1.3 Tolerance and the role of B cells in autoimmune diseases  
1.3.1 Central Tolerance for B cells 
B cells undergo gene rearrangements to create an infinite repertoire of B cell 
receptors/antibodies in the bone marrow. As these combinations are done at random, 
BCRs with affinity for self-peptides are also generated and mechanisms to avoid 
autoimmunity are needed (Giltiay et al. 2012). 
One study by Wardemann and colleagues estimated that, in healthy donors, 75% of all 
the immature B cells in the bone marrow were self-reactive. At the first checkpoint for 
B cell tolerance, these immature BCRs are tested for affinity to self-antigens and around 
half of these autoreactive B cells are stopped from getting to the circulation 
(Wardemann et al. 2003). 
Central tolerance includes: a) Apoptosis – B cells responding with high affinity to self-
antigens are induced to undergo clonal deletion by apoptosis; b) Receptor editing – As 
an alternative to deletion, B cells can reactivate their machinery for receptor 
rearrangements in the light chain and create a new, non-autoreactive BCR. It is believed 
that most B cells in the periphery had their BCR edited before they left the bone 
marrow; c) Induction of anergy – When the autoantibodies have low affinity for 
autoantigens, they can be induced to be anergic. This means these B cells can bind, but 
are unresponsive for their self-antigens. It happens as a consequence of presenting the 
phenotype IgD
+
/IgM
-
, and a lack of co-stimulatory molecules or signalling elements in 
their activation pathway. However, anergy is reversible and harmless anergic B cells 
have the potential to become pathogenic and start autoimmune responses (Meffre and 
Wardemann 2008; Pelanda and Torres 2012; Rosenspire and Chen 2015). 
 
1.3.2 Peripheral Tolerance for B cells 
Central tolerance is important, but not sufficient to delete all autoreactive B cells exiting 
the bone marrow and heading to the spleen and other lymphoid organs. Therefore, 
mechanisms to delete or suppress these cells in the periphery are also essential. 
The second checkpoint for B cell tolerance is administered by regulatory T cells. 
Patients with a deficiency in their regulatory T cells have more autoreactive B cells in 
the periphery than healthy controls. Under normal conditions, Treg cells would be able 
to induce apoptosis of these B cells or downregulate the function of effector T cells that 
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help autoreactive B cells (Kinnunen et al. 2013). The involvement of Treg cells in B cell 
peripheral tolerance was observed in mice as well (Ludwig-Portugall et al. 2008). 
Increased concentration of BAFF (B-cell activating factor), a cytokine responsible for B 
cell maturation, was also related to the survival of self-reactive B cells in autoimmune 
diseases like SLE (Meffre and Wardemann 2008). 
IgM produced naturally by B-1 B cells has affinity for both self and foreign antigens. 
Autoreactive natural IgM has a role in binding to apoptotic cell debris, facilitating their 
phagocytosis. It was demonstrated that a deficiency in natural IgM can lead to 
autoimmune diseases, such as SLE (Boes et al. 2000). 
Mechanisms of central and peripheral tolerance also occur for autoreactive T cells; 
however, they will not be described in this thesis. 
 
1.3.3 Autoreactive B cells and autoimmune diseases 
Central and peripheral tolerance should be sufficient to remove or silence all self-
reactive B and T cells. However, when they do not function properly, self-reactive 
lymphocytes may escape and start an autoimmune disease. The simple existence of 
autoreactive cells does not characterize autoimmune disease, unless they cause 
pathology (Salinas et al. 2013). Diseases like SLE, arthritis or Graves’ disease are more 
affected by autoreactive B cells, as autoantibodies are their main trigger. 
Nevertheless, self-reactive B cells are not only found in autoimmune diseases that are 
dependent predominantly on autoantibodies. Studies demonstrated that in NOD mice, 
an experimental model for type 1 diabetes, central tolerance mechanisms of clonal 
deletion and receptor editing were not impaired. Hence, the presence of islet 
autoantibody-producing B cells was due to a problem with peripheral tolerance. 
Although self-reactive B cells in NOD mice respond similarly to B cells in B6 mice to 
membrane-bound autoantigens, they are not deleted or kept anergic upon encounter with 
soluble self-antigens, which constitute an error in the maintenance of the 
tolerance/autoimmunity homeostasis (Silveira et al. 2004). 
In concordance with these findings in mice, insulin-binding B cells with cross reactivity 
to chromatin and LPS appear to lose their anergic state in pre-diabetic and newly-
diagnosed patients with T1D (Smith et al. 2015). 
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1.4 Type 1 diabetes – Experimental models and Immunopathogenesis 
Type 1 diabetes is an autoimmune disease characterized by the destruction of beta cells 
by the immune system, compromising insulin production. Insulin is responsible for 
allowing the uptake of glucose by the cells and its partial or total loss causes the main 
sign of diabetes - hyperglycaemia. Untreated, persistent hyperglycaemia leads to 
chronic complications such as blindness, nephropathy, neuropathy, accelerated 
arthrosclerosis, and arteriopathy. To date, type 1 diabetes has no cure and the treatment 
consists of daily injections of exogenous insulin (Cooke 2009). 
 
1.4.1 Epidemiology of Type 1 Diabetes 
According to the World Health Organization, it is estimated that 347 million people in 
the world have diabetes and autoimmune diabetes accounts for 10% of the cases (World 
Health Organization 2014). Incidence of T1D is higher in developed countries, with 
Finland presenting the highest incidence. China, India and Venezuela, on the other 
hand, have the lowest number of cases per 100,000 people (Atkinson et al. 2014).  
T1D occurs as a combination of the effects of both genetic and environmental factors. 
Autoimmune diabetes has a polygenic pathology and genome-wide association studies 
have identified more than 40 genes related to the disease (Barrett et al. 2009). Genes 
associated with the highest risk factors are related to the HLA class II (Human 
Leucocyte Antigen) region, where alleles can confer susceptibility (DR3/4-DQ8) in 
Caucasian population or be considered protective (DR7) against type 1 diabetes (Erlich 
et al. 2008). 
The next most important gene region related to diabetes in humans encodes insulin. 
Polymorphisms in the Variable Number of Tandem Repeats (VNTRs) region, close to 
the insulin gene, are associated with susceptibility (shorter repeats) or protection (longer 
repeats) to T1D. The size of the VNTR influences the expression of insulin RNA 
(Bennett et al. 1995). The majority of other genes linked to susceptibility to type 1 
diabetes are related to the immune system (genes for CTLA-4, cytokines and cytokine 
receptors, for example), reviewed by Van Belle and colleagues (van Belle et al. 2011). 
Type 1 diabetes incidence is not consistent, even in homozygous twins and NOD (Non-
Obese Diabetic) mice need to be kept in specific pathogen free conditions to develop 
diabetes. These observations highlight the importance of environmental factors 
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(Castano and Eisenbarth 1990). Although it is difficult to pin-point their exact 
contribution, many environmental factors have been studied. 
Deficiency in vitamin D intake during fetal development and childhood results in a 
higher risk of developing T1D. This condition is suggested by the seasonality of this 
disease and the higher incidence of type 1 diabetes in countries where the exposure to 
sunlight is compromised (Mohr et al. 2008). Infections may also influence diabetes 
onset. The role of viruses, bacteria and parasites in the development of type 1 diabetes 
has been investigated for decades. They could trigger the disease or result in protection, 
depending on the species (Cooke 2009). In the microorganism field, more recently, 
there has been an increased interest in the relevance of gut microbiota. Studies in 
humans and mice demonstrated that variations in the gut microbiota, caused by diet, 
gender and use of antibiotics, could interfere with the progression of type 1 diabetes 
(Alkanani et al. 2015; Candon et al. 2015). It is still not fully clear how these alterations 
lead to susceptibility to T1D. One new study indicated that bacteria from the gut 
microbiota produce proteins that mimic islet autoantigens, like the Islet-specific 
Glucose-6-phosphatase catalytic subunit–Related Protein (IGRP), and are able to 
activate islet autoantigen-specific CD8 T cells and accelerate diabetes in mice (Tai et al. 
2016). 
 
1.4.2 Experimental model: NOD mouse 
Many of the findings relating to genetics, immunology and pathogenesis of type 1 
diabetes have been derived from investigation of animal models, particularly those 
whose disease develops spontaneously. The main models for Type 1 diabetes are BB 
(BioBreeding) rats and NOD mice. 
NOD mice were developed in Japan, from a cataract-prone strain (JcI-ICR mouse), 
selecting mice that had spontaneous hyperglycaemia during the inbreeding. This strain 
starts to develop signs of insulitis (inflammation in the pancreatic islets) by the 4
th
 week 
of age and the beta cell destruction progresses silently until around the 12
th
 week. When 
diabetic, mice present with polyuria, glycosuria, hyperglycaemia and loss of weight, as 
signs of advanced deficiency of insulin (Anderson and Bluestone 2005). It is rare to see 
new onset of diabetes in NOD mice older than 35 weeks of age. 
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The incidence of type 1 diabetes in NOD mice is gender-dependent and, in a colony, it 
varies usually around 60-80% in female mice by the age of 35 weeks and it is always 
less in male mice (Castano and Eisenbarth 1990; Young et al. 2009). The gender 
difference is reported to be related to the influence of hormones on the gut microbiota, 
as germ-free NOD mice and castrated male mice present a similar incidence between 
males and females. The gut microbiota play a role in the modulation of the immune 
system (Yurkovetskiy et al. 2013). 
The genetic influences on diabetes incidence in the NOD mouse strain, as in humans, 
are polygenic and more than 40 susceptibility loci have been mapped, although many of 
them still need to be fully identified (Pearson et al. 2016). The main genes influencing 
susceptibility to diabetes in NOD mice are located in the H-2 region on chromosome 17 
(in NOD mice, it is called H-2
g7
). One proposed role for the MHC molecule in the 
pathogenesis of autoimmune diseases can be seen when a polymorphism results in 
expression of MHC class II molecules (designated I-A
g7
 in NOD mice) that bind weakly 
to the autoantigen, its presentation in the thymus is not effective and autoreactive T cells 
escape negative selection (Ridgway et al. 1999). 
The polygenic background (although the genes linked to T1D in humans and mice are 
not exactly the same) and the importance of the genes related to the MHC (HLA in 
humans), together with the main autoantigens identified in T1D (including insulin and 
glutamate decarboxylase – GAD) are some of the similarities between the NOD mouse 
model and humans (Thayer et al. 2010). Furthermore, inflammation can be detected in 
the islets before the clinical signs of diabetes. NOD mice can also develop other 
autoimmune diseases, such as sialitis and thyroiditis (Anderson and Bluestone 2005), 
and humans who develop type 1 diabetes have an increased propensity to other 
autoimmune diseases. 
However, as in any animal model, there are some important differences and limitations: 
Even though the insulitis in both cases is caused by similar subsets of cells, the 
infiltration in human pancreas is more sparse and less organized, when compared to the 
inflammation in murine pancreatic islets, where it is possible to observe an 
accumulation of cells around the islets; NOD mice do not suffer with ketoacidosis, in 
contrast to the severe ketoacidosis seen in patients not treated with insulin; while Type 1 
diabetes is gender-dependent in NOD mice, showing a striking difference between the 
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incidence in females and males; in humans, there is no gender-difference in the 
incidence during childhood and a small bias towards men after puberty (Atkinson and 
Leiter 1999; Patterson et al. 2009). 
 
1.4.3 Immunopathogenesis 
Since Type 1 diabetes has been shown to develop as a result of autoimmunity and with 
the discovery of insulin autoantibodies in diabetes patients (Palmer et al. 1983), there 
have been investigations into how T1D develops and progress in humans and mice. The 
most commonly cited hypothesis for T1D immunopathogenesis was postulated by 
Eisenbarth in 1986 and updated in 2001 with further modifications (Atkinson and 
Eisenbarth 2001). 
Polymorphisms in genes that are the major risk factors for Type 1 Diabetes predispose 
individuals to failures on their tolerance mechanisms. As described above, the mutations 
alter the way insulin is presented in the thymus during negative selection, allowing 
autoreactive T cells to escape deletion (Ridgway et al. 1999). However, as demonstrated 
in congenic mice carrying the NOD MHC genes, the polymorphisms are necessary, but 
not sufficient for diabetes development by themselves (Yui et al. 1996).  
Many theories about what triggers diabetes in the pancreas have been investigated. 
Although immune homeostasis in the pancreatic islets is damaged and the immune 
system attacks beta cells, leading to its destruction and compromised production of 
insulin, the role of each cell and what alters this homeostasis is still under investigation. 
The association between virus infection and type 1 diabetes has been investigated since 
the late 1960’s-early 1970’s. Studies with Coxsackie B virus in mice demonstrated 
tropism of this virus for beta cells. They infect pancreatic islets, causing lysis of beta 
cells, infiltration of immune cells and transient hyperglycaemia (Yoon et al. 1978). In 
humans, this association is mostly based on epidemiological data (Laitinen et al. 2014). 
Other viruses, such as rubella virus and retroviruses, are also linked to T1D and their 
mechanisms of action could vary between direct destruction of beta cells or alterations 
in the immune system (for example, release of autoantigens, upregulation of MHC class 
I and II, activation of autoantibodies producer B cells and production of pro-
inflammatory cytokines) (Jun and Yoon 2003; Richardson et al. 2011).  
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The importance of immune system cells in the development of type 1 diabetes is 
incontestable and both CD4 and CD8 T cells play the main roles in beta-cell 
destruction, which precedes clinical signs of diabetes in humans and rodent models. 
Murine models naturally deficient in T cells, as NOD.scid and athymic NOD mice, do 
not develop diabetes. This protection is lost when T cells from diabetic mice are 
transferred (Christianson et al. 1993; Matsumoto et al. 1993). On this note, one of the 
most efficient treatments tested so far in clinical trials has been the administration of 
anti-CD3 monoclonal antibodies to patients, especially newly diagnosed young patients 
(Daifotis et al. 2013), although the effects are not maintained. 
The major role of CD4 T cells is highlighted by the predisposition to T1D lying mainly 
in the MHC/HLA class II genes. CD4 T cells with affinity for islet autoantigens (such 
as insulin, GAD and chromogranin A) have been used to investigate the role of these 
cells in diabetes pathogenesis. Lennon and colleagues demonstrated that the majority of 
T cells homing to the pancreas are islet-specific and the trafficking is mediated by 
chemokines (Lennon et al. 2009). These autoreactive CD4 T cells, that escaped deletion 
in the thymus and are later found in the pancreas, travel from the pancreatic lymph 
nodes to the pancreas attracted by autoantigens bound to antigen presenting cells 
(APCs). 
One subpopulation of CD4 T cells that is very important for the fate of individuals that 
are susceptible to type 1 diabetes (and other autoimmune diseases) is the regulatory T 
cells (Tregs). These cells, with the phenotype CD4
+
CD25
+
Foxp3
+
, are key factors for 
peripheral tolerance, keeping anergic cells in check and suppressing inflammatory 
responses. Indeed, although the number of Treg cells in healthy controls and patients 
with T1D is similar, they do not work as effectively in the case of type 1 diabetes and 
effector T cells are resistant to their suppression (Kuhn et al. 2016; Visperas and Vignali 
2016). Indeed, in the islet infiltration of NOD mice, although the number of regulatory 
T cells was not altered, the expression of CD25 on these Treg cells significantly 
decreased as infiltration and disease progressed. CD25 is the α-chain of IL-2 receptor, 
responsible for providing survival signals for the cells (Tang et al. 2008).  
In addition to CD4 T cells, studies showed that IFN-γ-producing CD8 T cells, with 
affinity for the B:15-23 portion of insulin, are present in the islet of 4 week old NOD 
mice (Wong et al. 1999). Moreover, β2-microglobulin-deficient NOD mice (deficient in 
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MHC class I molecules) presented no signs of insulitis or diabetes (Serreze et al. 1994; 
Wicker et al. 1994) and adoptive transfer of these islet-specific CD8 T cell clones, 
isolated from 7-week old. NOD mice, was sufficient to cause diabetes in irradiated 
NOD and NOD-SCID mice (Wong et al. 1996). CD8 T cells are responsible for the 
cytolysis of beta cells, by the release of perforins and granzymes (Amrani et al. 1999; 
Estella et al. 2006), and also causing death of beta cells through Fas-FasL interactions 
(Savinov et al. 2003).  
Macrophages and DCs are seen circulating in the pancreatic islets of neonatal NOD 
mice and a higher frequency of these cells by the third, fourth week of life precedes the 
infiltration of lymphocytes. Temporary depletion on both macrophages and DCs when 
mice were 8 weeks old delayed the disease and, although by the end of the experiment 
(35 weeks old) insulitis was present in all NOD mice, treated and non-treated, during 
the period these cells were depleted in the pancreas, lymphocyte infiltration was 
reduced and reappeared when macrophages and DCs returned (Nikolic et al. 2005). 
One theory proposing that a physiological mechanism is the key to understanding the 
role of phagocytes in diabetes onset is being investigated. Studies have demonstrated 
that, as a natural phenomenon that also occurs in mouse strains not prone to diabetes, 
beta cells transfer vesicles containing insulin and insulin peptides to local macrophages 
and dendritic cells. Anti-insulin CD4 T cells are then activated when they interact with 
these APCs (Vomund et al. 2015). This model, however, does not include the role of 
environmental factors and other cells of the immune system. 
 
The time between pancreatic infiltration and clinical signs varies from one individual to 
another. In humans, it takes years and in mice it could take months. This time gap 
suggests that some kind of suppression or regulation is taking place to contain the beta-
cell destruction. In the original Eisenbarth proposition for the pathogenesis of diabetes, 
after the beginning of insulitis there was no turning back in beta cell loss and their mass 
would only decrease, until there was no beta cells left (Eisenbarth 1986). However, it is 
believed now that T1D could present relapsing-remitting phases depending on the 
efficacy of beta-cells to proliferate when attacked, how fast autoantigens are released 
and how efficient regulatory cells are in the individual (von Herrath et al. 2007). All 
these factors could delay or accelerate the progression of type 1 diabetes and, in some 
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cases, regulatory cells may be able to stop destructive beta cell loss before the onset of 
type 1 diabetes (Figure 1.4).  
 
 
 
Figure 1.4 Theories correlating beta cell mass loss and the beginning of type 1 
diabetes clinical signs.  The first theory about how the loss of beta cells correlates 
with the detection of type 1 diabetes signs was suggested by Eisenbarth in 1986 
who postulated that after the beta cell mass started to decrease, there was no way 
back (red line). However new theories incorporated the i dea that regulatory cells 
balance the damage to the beta cells caused by effector cells, leading to a 
relapsing-remitting curve (green line). The blue line indicates cases where 
genetically predisposed individuals present some beta cell mass loss; however,  
regulatory mechanisms are sufficient to suppress them or an appropriate 
environmental factor never triggers the disease onset (van Belle et al. 2011).  
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A diagram explaining the theory for the immunopathogenesis of Type 1 diabetes is 
shown in Figure 1.5: 
 
 
Figure 1.5 Immunopathogenesis of type 1 diabetes . The process that leads to 
type 1 diabetes begins in the thymus of genetically susceptible individuals (a) , 
where islet-specific autoreactive T cells (purple circles) escape from negative 
selection. These cells exit the thymus and are found in the pancreatic lymph 
nodes. Meanwhile, in the pancreas (b), environment factors (like virus infection, 
for example – here represented by the lightning bolt) may disturb the homeostasis 
and beta cells, responsible for the production of insulin, start to release self -
antigens. These autoantigens are captured by phagocytes (yellow cells) and 
presented to those autoreactive T  cells in the pancreatic lymph nodes (c). 
Attracted by chemokines, the autoreactive T cells travel to the pancreatic islets 
and, with the help of B cells (green cells), start to destroy the beta cells (d). As 
the infiltration progresses, the production of insulin becomes insufficient and the 
first signs of type 1 diabetes are detected.  
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Although T cells are believed to be the main cells that actually damage the beta cells, B 
lymphocytes have multiple functions and influence the onset and progression of Type 1 
Diabetes, which will be discussed in the next section. 
 
1.5 B cells and Type 1 Diabetes – What is known so far? 
1.5.1 Islet cell antibodies (ICAs) 
Although type 1 diabetes is characterized as a disease caused by T cell-mediated beta 
cell destruction, several other cells of the immune system are involved in this process. 
The first abnormality associated with B cells in type 1 diabetes was the production of 
islet cell antibodies (ICAs).  
In earlier years when type 1 diabetes was not so clearly defined as an autoimmune 
disease, ICAs started to be detected in patient blood samples. Palmer and colleagues 
showed that insulin bound to proteins that were present in the blood of newly-diagnosed 
patients and those proteins were insulin antibodies. The experiments were performed 
before the beginning of insulin treatment, so the insulin antibodies were not produced 
against exogenous insulin (Palmer et al. 1983). GAD, an enzyme responsible for 
synthesizing γ-Amino Butyric Acid (GABA) from glutamic acid, was first found in the 
Central Nervous System (CNS) and antibodies against this enzyme were detected in 
patients with stiff-man syndrome. Interestingly, there was a high incidence of T1D in 
these patients. In 1990, anti-GAD obtained from patients who had this neurological 
condition and antibodies against a 64K protein from diabetic patient’s sera were tested 
together. It was demonstrated that they behaved very similarly and both GAD and the 
64K protein exhibited the same activity, proving they were the same enzyme, produced 
not only in the brain, but also in the pancreas and related to type 1 diabetes (Baekkeskov 
et al. 1990). Insulinoma Antigen-2 (IA-2), designated ICA152 before recognition as the 
tyrosine phosphatase IA-2, is also found in brain cells as well as in the pancreas. 
ICA512 was the first membrane protein identified as a target for autoantibodies in type 
1 diabetes (Solimena et al. 1996). Recently, another autoantigen has been characterized. 
Zinc Transporter, ZnT8 – which controls the intracellular concentration of zinc in the 
insulin granule, was scanned from a list of 300 genes of autoantibodies candidates and 
showed to be highly expressed in the islets (Wenzlau et al. 2007). 
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ICAs can be detected in the serum, years before the disease diagnosis, and are still used 
as a marker for the development of the disease in humans. Even though the production 
of autoantibodies in type 1 diabetes prediction is well established, the role of 
autoantibodies in the development of the disease is still uncertain and studies show 
controversial results. It is proposed that autoantibodies could promote tissue damage or 
help DCs in antigen presentation and cross presentation to CD4 and CD8 T cells, 
respectively (Harbers et al. 2007; Silva et al. 2011). However, it is known that they are 
not themselves pathogenic, at least in mice, as they did not cause disease when 
antibodies from diabetic mice were transferred to NOD.IgM
null
 (B cell depleted) mice 
(Serreze et al. 1998). 
 
1.5.2 B cell depletion and type 1 diabetes 
Experiments using depletion to study B cell function in type 1 diabetes have been 
performed by different research groups in many different ways. Noorchashm and 
colleagues administered μ-chain antibody (anti-IgM) 3 times weekly to NOD mice, 
initiating the treatment 24h after birth and lasting for 30 weeks. Compared to controls, 
these mice did not develop insulitis or diabetes. A group of mice received antibody 
injections for only 8 weeks; in this case, B cell population was reconstituted 10 weeks 
after the end of treatment, insulitis was detected, but no diabetes was observed. These 
results showed that B cells are necessary for the development of type 1 diabetes, and 
although the role of B cells was suggested to be as antigen-presenting cells, 
autoantibody production as a pathogenic mechanism was not discarded at this point 
(Noorchashm et al. 1997). For this reason, transgenic NOD mice which only expressed 
the membrane-bound form of IgM (and therefore did not secrete antibodies) were used 
to study the effect on diabetes development in the absence of autoantibodies. mIgM 
transgenic mice had more insulitis and a higher incidence of diabetes compared to the 
NOD mice completely depleted of B cells. These findings demonstrated that the B cell 
role in type 1 diabetes is mainly autoantibody-independent (Wong et al. 2004). 
Moving from the use of depleting B cells as a mechanism to study the B cell role in 
disease towards possible treatments, the use of monoclonal antibodies for short-term B 
cell depletion was first investigated in lymphomas. A chimeric antibody anti-CD20, 
Rituximab, was efficient when used to treat these B-cell malignancies, and there were 
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few side effects. There was also interest in this treatment for autoimmune diseases 
(Johnson and Glennie 2001). In type 1 diabetes, murine studies using rituximab were 
possible by the generation of transgenic NOD mice expressing human CD20 (Hu et al. 
2007). These mice received a cycle of 4 injections of anti-CD20 (2H7 clone) while they 
were young (4 or 9 weeks old – before hyperglycaemia). In treated mice, diabetes was 
delayed and the incidence was lower, compared to mice that received control IgG. 
These findings confirmed the role for B cells in the onset and progression of type 1 
diabetes. Moreover, when injected in diabetic mice, 36% of newly-diagnosed mice had 
decreased blood glucose and sustained this euglycaemia for a long period, although the 
degree of insulitis was similar to that found in control mice. Because the protection 
lasted longer than the treatment, the mechanisms proposed for these results involved 
more than just depletion of pathogenic B cells: increased CD4
+
CD25
+
Foxp3
+
 (Treg 
cells) and less effective macrophages and DCs, for example. Also after repopulation, an 
increased frequency of transitional B cells was observed in treated mice (Hu et al. 
2007). 
Anti-CD20 was also tested in a clinical trial. Newly-diagnosed patients with type 1 
diabetes received one cycle of the treatment and were followed for one year. Patients 
receiving rituximab needed less daily insulin administration than controls, presented 
higher levels of C-peptide (i.e., more insulin being produced) and had reduced levels of 
glycated haemoglobin. However after one year, the results started to diminish, 
suggesting that the effects of rituximab were transient (Pescovitz et al. 2009). More 
detailed studies to understand the mechanisms by which depletion has the protective 
effect could improve the treatment. 
B cell depletion with rituximab does not optimize the mechanisms of central tolerance 
in treated patients, as shown by Chamberlain and colleagues. After treatment with anti-
CD20, the number of new autoreactive B cells repopulating the periphery were similar 
to non-treated patients (Chamberlain et al. 2016). Thus, the effect of B cell depletion 
lasting longer than the period when B cells are absent could be due to a correction in the 
individuals’ immune regulatory system. Based on these interesting findings, the effects 
of B cell depletion and repopulation on regulatory B cells in transgenic NOD mice were 
investigated in this thesis. 
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Other antibodies have also been targeted to promote B cell depletion in type 1 diabetes: 
Treatment with anti-CD22 conjugated with calicheamicin also led to delayed diabetes, 
decreased insulitis and a reprogramed/more regulatory immune system (Fiorina et al. 
2008). Another approach to deplete B cells in NOD mice consisted of eliminating 
survival signals by neutralizing BLyS/BAFF (B Lymphocyte Stimulator). One dose of 
this antibody delayed diabetes development, reduced insulitis and decreased the 
incidence of diabetes during the first weeks; however, by the end of the experiment, the 
diabetes incidence in treated and control mice was the same (Zekavat et al. 2008). 
The results of the depletion experiments, the finding that the production of 
autoantibodies from islet autoantigen-specific B cells is not important, together with 
their expression of MHC class II, all suggest that B cells can play an important antigen-
presenting role in type 1 diabetes. As APCs, although B cells are not as efficient as 
dendritic cells, they can bind specifically to soluble autoantigens through their B cell 
receptor and this antigen specificity means that B cells are potentially very powerful 
antigen-specific antigen presenting cells. The role of B cells as APCs over other APCs 
in NOD mice is intensified by the fact that DCs are defective in NOD mice, with 
impaired development and altered co-stimulatory signals (Vasquez et al. 2004). 
 
1.5.3 B cells as APCs 
Insulin-specific B cells, have been shown to be anergic and were able to internalize and 
process insulin, presenting the antigen to CD4 T cells that were activated in vitro 
(Kendall et al. 2013). Transgenic NOD mice with B cells lacking the I-A
g7 
(NOD-
specific) form of MHC class II (other APCs were normal) had decreased incidence of 
diabetes and had only peri-insulitis but no invasive infiltration. These results showed 
that although B cells do not participate in the initial priming of T cells by islet 
autoantigens, they are important for the break in tolerance that leads T cells from benign 
infiltration to beta-cell destruction (Noorchashm et al. 1999). B cells with APC function 
are believed to be located in the marginal zone in the spleen. MZ B cells have a superior 
capacity to activate CD4 T cells (induce proliferation and cytokine secretion) in an 
antigen-specific manner, when compared to FO B cells. Marginal zone B cells also have 
higher levels of CD86 than follicular B cells (Attanavanich and Kearney 2004).  
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1.5.4 B cell infiltrating the pancreas 
B cells are found among the cells infiltrating the pancreatic islets, being the most 
abundant immune cell in the infiltrate of NOD mice (around 48% in 10-week-old mice). 
These B cells produce TNF-α, similar to macrophages and DCs; islet B cells also had a 
higher frequency of CD80 and CD86 – co-stimulatory molecules that promote 
interaction between APCs and T cells (Hussain and Delovitch 2005).  
B cells have also been detected infiltrating islets of human patients. They were observed 
in early periods of insulitis and their number increased four-fold in advanced stages (In't 
Veld 2014). Their disposition in the islets, analysed by immunohistochemistry, also 
showed evidence for interaction between B cells and CD8 T cells (Willcox et al. 2009). 
Variable expression of CD20 in infiltrating B cells (CD20HI and CD20Lo) was also 
observed and, in general, children diagnosed before 7 years old had more CD20HI B 
cells; while expression of CD20Lo B cells was found in patients diagnosed after 13 
years old. At both ages, in the patients that had high frequencies of infiltrating CD8 T 
cells. The CD20HI phenotype was also linked to a more aggressive and rapid onset of 
type 1 diabetes (Leete et al. 2016). 
In NOD mice, the interaction between B cells and CD8 T cells was studied in a NOD  
mouse model of accelerated diabetes (100% incidence by the 15
th
 week of age) where 
RIP-TNF mice were crossed with the NOD-μMT-/- mice (B cell absence from birth). 
In these new transgenic mice, the disease was delayed. No difference was observed in 
the number of CD4
+
CD25
+
Foxp3
+
 cells in the islet infiltration and pancreatic lymph 
nodes (PLNs) and this suggested that the effect was not Treg-dependent. However, the 
delay in the disease was attributed to the interaction between B cells and CD8 T cells, as 
there was a decreased frequency of these T cells in 8-week-old B-cell depleted mice, 
when compared to non-depleted mice. B cells are believed to be important also in the 
second phase of islet infiltration, helping CD8 T cells in their differentiation into 
cytotoxic cells and providing survival signals to these cells. This was confirmed in the 
study, as the decrease in the percentage of CD8 T cells in the infiltrate was not observed 
in 4-6 week old transgenic mice (Brodie et al. 2008). Mariño and colleagues also 
demonstrated that B cells were responsible for the proliferation and activation of islet 
specific CD8 T cells in the pancreatic lymph nodes in a MHC class I-dependent manner 
(Marino et al. 2012). 
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Besides their help in maintaining CD8 T cells in the pancreatic islets, B cells have also 
been associated with infiltrating CD4 T cells. The role of B-1 cells in the establishment 
of destructive insulitis was studied in the DO11 3 RIP-mOVA mouse model, where B 
cell-depleted mice (by using an anti-CD22-calicheamicin treatment) had decreased 
incidence of type 1 diabetes. This protective effect was attributed to the lack of 
CD19
+
CD5
+
 B cells in the early phases of disease development and when they were 
absent, T cell infiltration was not observed. The deficiency of B-1 cells did not prevent 
T cell-priming in the pancreatic lymph nodes, but rather the signals facilitating access of 
these cells into the islets were not provided. The number of B-1 B cells decreased in the 
infiltration as the disease progressed and they were substituted by B-2 B cells (Ryan et 
al. 2010). 
 
1.5.5 Regulatory B cells and Type 1 Diabetes 
As discussed previously, cytokine-producing B cells are found among the cells 
infiltrating the islets, secreting TNF-α and interacting with the T cells. However, 
observations that B cells were able to suppress responses by producing regulatory 
cytokines in other autoimmune diseases raised the questions about the association 
between Bregs and type 1 diabetes. 
One of the earliest reports demonstrating the role of regulatory B cells in type 1 diabetes 
focused on TGF-β-producing B cells. In 2001, Tian and colleagues showed that B cells 
activated with LPS expressed more FasL, produced higher frequencies of TGF-β than 
unstimulated B cells and caused apoptosis of diabetogenic T cells, decreasing the 
incidence of the disease in NOD mice. In this case, the protection was IL-10 
independent (Tian et al. 2001). 
The role of IL-10-producing B cells in T1D was partially elucidated by Kleffel and 
colleagues. When compared with diabetic mice, normoglycemic NOD mice (those that 
reach 35 weeks old with no signs of type 1 diabetes) had lower percentages of B cells 
infiltrating the pancreas. Moreover, more of these B cells that were seen in the insulitis 
of protected NOD mice were anergic and produced more IL-10 than the infiltrating B 
cells in diabetic mice. The comparisons between the spleen B cells of young, protected 
and diabetic NOD mice did not show any statistically significant difference in the 
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production of IL-10. However, the B cells were not cultured in the presence of 
stimulants, such as LPS or anti-CD40 (Kleffel et al. 2014).  
Considering what is known about Bregs in other autoimmune diseases and the relatively 
little knowledge of their role and whether they are defective in the NOD model of type 1 
diabetes, a broad study of their phenotype and the differences NOD mice might present 
while aging was warranted. 
 
1.6 Aims and Hypothesis 
Based on the information derived from earlier investigations discussed in this chapter, 
our hypothesis was that regulatory B cells, especially IL-10-producing B cells, could be 
impaired in NOD mice, an experimental model to study type 1 diabetes. 
Our aims were to investigate the association between regulatory B cells and NODs in 
the following studies: 
1) Compare the ability of B cells to produce inflammatory and regulatory cytokines in 
NOD and control mice at different ages (Chapter 3); 
2) Analyse the expression of regulatory markers in B cells producing IL-10 in protected 
and diabetic NOD mice (Chapter 3); 
3) Study the ability of B cells to regulate immune responses by CD8 T cells and DCs, 
specific to insulin (Chapter 4); 
4) Investigate the importance of regulatory B cells in the protection against type 1 
diabetes conferred by B cell depletion (Chapter 5).
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2. Methods 
 
Information and details on reagent manufacturers, catalogue numbers and recipes for 
solutions described in these sections can be found in 2.17 in Tables 2.2-2.4. 
 
2.1 Mice 
The following strains of female and/or male mice were used in these studies:  
The NOD/Caj (Non-Obese Diabetes) is the main murine model used to study type 1 
diabetes. This strain was first developed in Japan, while Makino and colleagues worked 
on the refinement of a cataract-prone strain. NOD mice should be kept in specific 
pathogen-free environments to ensure high incidence of diabetes in female mice; male 
NOD mice generally present a lower incidence (Anderson and Bluestone 2005). Our 
colony has been inbred in Cardiff University for the last 6 years. During the period 
while these studies were performed (2013-2016), the incidence of diabetes for the 
female NOD colony varied around 70%. 
B6.H-2
g7
 (B6
g7
) mice were used as a non-diabetes prone control strain. This congenic 
strain has all the genes from a C57BL/6 mouse, except for the MHC genes (Major 
Histocompatibility Complex class I and II), which is the NOD MHC H-2
g7
.  
G9Cα-/-.NOD (G9) mice were genetically modified to express the T cell receptor 
derived from the CD8 T cell clone G9C8, reactive to amino acids 15-23 of the insulin 
B-chain (Wong et al. 2009).  
NOD.MHCII-Ins2 (PI homo) mice have a transgene that encodes proinsulin 2 
expressed in antigen presenting cells, as the construct is directed by the MHC Class II 
promoter I-Eα. This strain does not develop diabetes spontaneously (French et al. 1997).  
hCD20/NOD mice were originally developed on the C57BL/6 background (Ahuja et al. 
2007) and were backcrossed to the NOD genetic background, more than 10 generations. 
B cell surface markers, antibody production and diabetes incidence were not affected by 
the expression of human CD20 (Hu et al. 2007). 
Mice were generated and maintained in Joint Biological Services (JBIOS), located in 
Heath Park – Cardiff University. All animals received water and food ad libitum and 
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were housed in a 12h dark/light cycle and specific pathogen-free conditions in isolators 
or scantainers. All experiments were conducted according to United Kingdom Home 
Office guidelines. 
 
2.2 Mouse strain genotyping  
 
2.2.1 PCR genotyping of transgenic mice 
Mouse genotyping to confirm the presence of the transgenes were performed by the 
Diabetes Research Group’s technician Joanne Davies, following these protocols: 
 
2.2.1.1 DNA extraction from mouse tissue 
Murine tissue obtained from ear coding was collected for DNA extraction at day 1. 
Each ear sample was added to 250μL of tail digest solution (Table 2.3) and 1μL of 
pronase. Samples were left overnight in a water bath, pre-heated to 55ºC. 
At day 2, samples were removed from the water bath and placed in the fridge, at 4ºC, 
for 5 minutes. A hundred microliters of saturated salt solution was then added to the 
samples, which were centrifuged (16200g, 4ºC) for 20 minutes. After centrifugation, the 
supernatants were collected, transferred to new tubes with 1 μL of RNAase and 
incubated at 37ºC for 20 minutes. Samples were cooled for 5 minutes in the fridge and 
500μL of 100% cold ethanol was added to the samples and vortexed, before 
centrifugation (20 minutes, 16200g, 4ºC). A hundred percent ethanol was poured off the 
samples and replaced by 70% cold ethanol. After being centrifuged (20 minutes, 
16200g, 4ºC), the tubes were inverted, to remove the excess ethanol and the remaining 
ethanol was left to evaporate at room temperature for 3 hours. When the samples were 
dry, 50μL of water for PCR was added to them. DNA samples were stored at 4ºC. 
 
2.2.1.2 PCR protocol and Gel Electrophoresis 
A master mix was prepared with 1.5μL 10x PCR buffer, 0.3μL of each primer (20 
pmol/µl working solution), 0.6µl dNTP, 0.1µl Taq Polymerase and enough water for 
PCR to make up to a final volume of 13µl, per sample (for more information on 
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reagents and how solutions were prepared, please see Tables 2.2 and 2.3). Each 13µl 
aliquot of the mastermix was then added to one well and 2µl of the DNA extracted from 
the mouse tissues were added to it. The wells were closed, centrifuged at 300g for 30s 
and placed in the PCR thermocycler. 
The PCR program used was: 1) 94°C for 3 min; 2) 94°C for 1 min; 3) 55°C for 1 min; 
4) 72°C for 1 min; 5) Repeat steps 2-4 34 times; 6) 72°C for 5 min and 7) 8°C for 10 
min. 
One percent agarose gel was prepared, by adding agarose to TAE buffer and boiling the 
solution in the microwave until the gel powder was dissolved and the solution was clear. 
After cooling, 5µl of Ethidium bromide was added while stirring for 2 minutes. 
The agarose gel was placed in the gel tank, with combs to produce the wells into which 
the samples were loaded for electrophoresis, and allowed to set for 30 minutes. After 
setting, the electrophoresis tank was filled with TAE buffer, to cover the agarose gel. 
Following completion of the PCR program, 3µl of orange G was added to the samples 
and 10µl of each sample was loaded into the wells in the agarose gel. A DNA ladder 
(1000-100bp) was used as a size marker. Gel electrophoresis was performed for 50 
minutes at 100V. The gel was then photographed on Gel Doc system. Figure 2.1 shows 
an example of a PCR gel for NOD.MHCII-Ins2 mice studied. 
Primers used for the genotyping of mice cited in this chapter: 
 
NOD.MHCII-Ins2 mice: 5’ CCA CTG CCA AGG TCT GAA GGT CAC C 3’ 
     5’ TTG TTA ATT CTG CCT CAG TCT GCG 3’ 
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Figure 2.1: Photograph of genotyping of PI homo mice. DNA was extracted 
from mouse ear tissues and PCRs with primers for the homozygous proinsulin, 
band size: ~950bp, were performed. After the electrophoresis, the gels were 
photographed; positive bands are shown as light bars. The first row contains a 
control 100bp ladder for PCR product band sizes. 
 
2.2.2 Blood test for genotyping 
To confirm that every hCD20 NOD mouse expressed human CD20, and the G9Cα-/-
.NOD mice were all Vβ6 positive, 50-100 μL of blood were collected from the mouse 
tail vein into 1ml Blood buffer (Table 2.2) and stained for flow cytometry. 
After collection, the samples were centrifuged for 5 minutes (400g, at 4ºC), resuspended 
and the antibody was added to the cells. Samples were incubated for 30 minutes at 4ºC, 
and then 1ml of FACS (Fluorescence-Activated Cell Sorting) lysis buffer (diluted 1:10 
with dH20) was added to the cells at room temperature and further incubated for 10 
minutes in the dark, to remove erythrocytes. After 10 minutes, the samples were washed 
with 2ml of FACS buffer and centrifuged (5 minutes, 400g, 4C) one last time. Cells 
were then resuspended in 100μL of FACS buffer and analysed by flow cytometry 
(FACS Canto II) for positivity or negativity. Figure 2.2 presents flow cytometric plots 
showing samples that were positive for the markers studied. 
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Figure 2.2 Flow cytometry plots exemplifying the presence of the markers 
studied. 50-100 μL of blood were collected from the tail vein. hCD20 NOD mouse 
samples were stained with PE human CD20 (a) and samples from G9Cα-/-.NOD 
mice were stained with APC CD8 and PE Vβ6 (b). After incubation, erythrocytes 
were lysed and the samples were then ready to be analysed by the flow cytometer. 
The plots above show positive examples of mice for both strains.  
 
2.3 Detection of diabetes 
To diagnose diabetes, NOD mice older than 12 weeks old were tested weekly for 
glycosuria with Diastix strips (Bayer). If glycosuria was confirmed after two urine 
positive tests on consecutive weeks, the blood glucose was tested and blood glucose 
concentration over 13.9mmol/L was diagnostic for diabetes (Wong et al. 2009). Table 
2.1 presents the age and last blood glucose level measured in female diabetic NOD 
mice, which were included in the studies discussed in this thesis.  
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Table 2.1 Age and blood glucose levels for the diabetic mice included in the 
studies discussed in this thesis 
Age (weeks) Blood glucose (mmol/L) 
Cytokine-production Experiments (Chapter 3) 
24 High (>33) 
11.9 29 
24 25.8 
15.6 21.8 
31.0 25.6 
19.7 33 
22.0 18.3 
Functional experiments (Chapter 4) 
16.9 High (>33) 
16.9 21.4 
13.7 25.8 
13.4 21.3 
16.6 21.2 
17.4 27.1 
17.6 15.2 
19.4 14.9 
18.6 19.4 
18.4 19.8 
17.9 25.1 
14.6 24.5 
 
 
2.4 Dendritic cells – Culture and stimulation 
Dendritic cells (DCs) were obtained from the bone marrow of the posterior legs of 
experimental mice. The legs were removed and the muscles were cleaned from the 
bones. They were then placed in 30ml of RPMI complete medium. In a sterile 
environment, the bones were placed in a Petri dish and, using a 5ml syringe (with a 27G 
needle), filled with RPMI complete medium. The needle was inserted into the bone 
marrow cavity and the bone marrow cells were flushed into the Petri dish. After 
repeating this procedure for all the bones, the suspension was collected from the Petri 
dish into the 50ml tube, to be centrifuged (10 minutes, 400g, room temperature). The 
cells were resuspended in 20ml of complete medium, passed through the cell strainer 
and transferred into a 75cm
3
 flask. Cells were incubated in the flask for 2h at 37°C, 
5%CO2. This step aimed to remove macrophages from the cell suspension, which got 
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attached to the plastic during the incubation, while the immature dendritic cells 
remained in the suspension. 
After incubation, the cell culture was collected into a 50ml tube (avoiding the adherent 
macrophages) and the cells were counted with Trypan Blue (dilution 1:10), while cells 
were centrifuged once again (10 minutes, 400g, room temperature). They were then 
resuspended in RPMI complete medium, to which 1.5ng/ml of GM-CSF was added to a 
final concentration of 2x10
6
 cells/ml. Cells were then placed in 6-well plates (5x10
6
 
cells/well), with an addition of 4ml of RPMI complete medium + GM-CSF and 
incubated (37°C, 5%CO2) for 8 days. Medium changes were performed on day 3 or 4. 
On day 7, in addition to medium change, DCs received 5μl of 1mg/ml LPS. 
 
2.5 CD8 T cells from G9Cα-/-.NOD mice and B cells – Enrichment and stimulation 
Spleens were collected in IMDM complete medium, homogenized and centrifuged at 
400g, 4ºC for 5 minutes. The erythrocytes were lysed by the addition of 900µl of 
deionised water (dH20) and 100µl of sterile 10X PBS, after quickly flicking the tube to 
separate the lymphocytes and the debris. To remove dead erythrocytes from the 
samples, the suspension was passed through a 40µm cell strainer and the cells were 
centrifuged once again (5 minutes, 400g, 4ᵒC). After being resuspended in 10ml of 
medium, cells were counted with Trypan blue, in a 1:10 dilution, and followed to a 
magnetic sorting (following the manufacturer’s instructions – explained below). 
After enrichment, B cells were counted with Trypan Blue (1:10 dilution), their 
concentrations were adjusted to 5x10
6
 cells/ml and cells were then plated in a 6-well 
plate. Half of the wells were left for 24h without any further stimulation and half of 
them were stimulated with LPS (5 µg/ml). All plates were incubated (37°C, 5%CO2) for 
24h. 
CD8 T cells were counted with Trypan Blue (1:10 dilution). Cells were divided in two 
portions and half were labelled with CFSE for the proliferation assay. CD8 T cells 
which were not stained, were centrifuged (5 minutes, 400g, 4ᵒC), resuspended in IMDM 
medium and the concentration was adjusted to 4x10
5
 cells/ml. 
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2.6 Magnetic-activated cell sorting (MACS) of B cells and CD8 T cells 
After preparing spleens into cell suspensions, the cells were centrifuged and 
resuspended in 40µl of MACS buffer (Table 2.2) per 10
7
 cells and 10µl of biotinylated 
antibody beads per 10
7
 cells. In both cases (B and CD8 T cells), negative selection kits 
were used for cell separation. The cells were incubated with the appropriate biotinylated 
antibody mix for 5 minutes at 2-8ºC and then another 30µl of MACS buffer per 10
7
 
cells was added, along with 20 µl of Anti-biotin Microbeads per 10
7
 cells. Cells were 
incubated once again for 10 minutes at 2-8ºC. 
Before the separation, the magnetic columns were prepared by washing them once with 
3ml of MACS buffer. After the incubation with the microbeads, cells were applied to 
the column, passing through a cell strainer to avoid bubbles. The column was then 
washed once with 3ml of MACS buffer. The suspension obtained after passing the cells 
through the column contained the cells of interest. 
Purity for B cell sorting: 94-97%. Purity for CD8 T cell sorting: 95%. 
 
2.7 CFSE (Carboxyfluorescein succinimidyl ester) labelling of cells 
For proliferation assays, MACs sorted CD8 T cells were labelled with CFSE dye. To 
prepare the 10mM stock solution, CFSE was diluted in 90μL of the high-quality DMSO 
(Dimethyl sulfoxide) – as suggested by the manufacturer. Samples were aliquoted in 
5μL and stored at -20ºC. 
The CD8 T cells were centrifuged after magnetic sorting and resuspended in warm PBS 
at a concentration of 2x10
6
cells/ml. A sample of the stock solution was diluted in warm 
PBS to achieve 0.5μM/L – the ideal concentration for G9Cα-/-.NOD mice, as titrated 
previously in our laboratory (Thayer et al. 2016) – and added to the cells, which were 
incubated for 15 minutes (37°C, 5%CO2).  
After incubation, cells were centrifuged (5 minutes, 400g, room temperature) and 
resuspended in warm IMDM medium to wash off any non-attached dye. Cells were 
incubated again for 30 minutes (37°C, 5%CO2). Labelled CD8 T cells were then 
centrifuged for the last time (5 minutes, 400g, room temperature) and resuspended in 
IMDM medium at a concentration of 4x10
5
 cells/ml. 
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2.8 Cell interaction experiment set-up for Chapter 4 
On day 0, B cells (LPS-stimulated and unstimulated cells) and LPS-stimulated DCs 
were harvested, centrifuged once (5 minutes, 400g, room temperature) and counted with 
Trypan Blue (dilution 1:2). The numbers of DCs and B cells were adjusted to 1.6x10
6
 
cells/ml and 5.6x10
6
 cells/ml, respectively. The cells were incubated in a 48-well plate, 
in a proportion of 1:2:7 (2x10
5
 CD8 T cells; 4x10
5
 DCs; 1.4x10
6
 B cells) and a final 
volume of 1ml.  
For the NOD or B6
g7
 controls, a positive control was achieved by the addition of the 
nonamer 15-23 peptide from the insulin B-chain (designated G9 peptide) at 1 μg/ml to 
specified wells. 
Experimental cells were set up such that one set was harvested after 1 day, for 
intracellular cytokine staining. The other set was incubated for 3 days, for analysis of 
proliferation and surface markers. More details about this experiment set-up are 
provided in chapter 4. 
 
2.9 Cell collection and stimulation 
Pancreatic and mesenteric lymph nodes, Peyer’s patches, bone marrow and spleen were 
collected from NOD, B6
g7
 and hCD20 NOD mice, depending on the investigation. 
Lymph nodes and Peyer’s patches were placed in Petri dishes containing IMDM and the 
lymphocytes were released, using needles and forceps. The suspension was divided into 
FACS tubes, using a cell strainer to avoid collection of debris. 
For the B cell depletion experiments, described in chapter 5, bone marrow was collected 
to study B cells. After taking the posterior legs of hCD20 NOD mice, the bones were 
cleaned from the muscles and placed in 10ml IMDM medium. In a Petri dish, using a 
5ml syringe and a 27G needle, the bone marrow cavity was flushed with media and the 
bone marrow cells were collected, centrifuged (5 minutes, 400g, 4ᵒC), resuspended in 
10ml and passed through a cell strainer.  
Spleens were processed as explained in section 2.5 and, after adjusting the cell number, 
they were ready for surface marker flow cytometric staining. For in vitro experiments 
and analysis of cytokine expression, spleen cells were placed in a 24-well plate and 
stimulated with: LPS (5 µg/ml), anti-CD40 (5 µg/ml), CpG (0.5 µg/ml) and anti-CD40 
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with CpG (5 µg/ml and 0.5 µg/ml, respectively) or left unstimulated during incubation 
(37°C, 5%CO2) for 24h. 
After the stimulation and prior to staining, 10 μL per well of a mix containing monensin 
(1:1500), Phorbol 12-myristate 13-acetate – PMA (50ng/ml) and ionomycin (500ng/ml) 
were added to the cells, to activate and prevent cells from releasing the cytokines. 
Three hours after the addition of monensin, PMA and ionomycin the cells were 
harvested and transferred to FACS tubes.  
 
2.10 Surface monoclonal antibody staining for flow cytometry 
Cells were harvested and transferred to FACS tubes for antibody staining. 2ml of FACS 
buffer were added into the FACS tubes containing the cells and then, centrifuged once 
(5 minutes, 400g, 4ᵒC). Fc receptors were blocked with TruStain diluted in FACS buffer 
(1:12.5). The cells were incubated for 5-10 minutes at 4ºC and then 50 µl of a master 
mix containing the determined antibodies for each panel was added to each sample (see 
Table 2.3) and incubated for 30 minutes at 4ºC.  Following this, cells were washed in 
FACS buffer and then resuspended and stored in 100µl FACS buffer at 4ºC until they 
were analysed in the cytometer. 
Initially, the samples were analysed in an 8-colour-FACS Canto II (BD Biosciences). 
However, the facility was upgraded with a 16-colour-LSR Fortessa (BD Biosciences) 
and this then increased the number of fluorochromes that could be analysed 
simultaneously.  
 
2.11 Intracellular cytokine staining for flow cytometry 
For intracellular cytokine staining, the cells were resuspended, vortexed and 200µl of 
fixation/permeabilisation buffer were added to each sample and incubated for 20 
minutes at 4ºC and then washed with 1ml of Fixation/Permeabilisation Buffer (diluted 
1:10 in dH2O). After centrifugation, TruStain was added once again (1:5). 25 µl of each 
sample was transferred to a new tube for the intracellular cytokine or isotype control 
staining and cells were kept on ice. Then another master mix, containing the antibodies 
against the cytokines or the isotype controls, was added to each tube. Cells were 
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incubated for 30 minutes at 4ºC. After incubation, cells were washed with 
Fixation/Permeabilisation buffer and centrifuged for the last time. Then they were 
resuspended in 200µl of FACS buffer and stored at 4ºC to be analysed in a flow 
cytometer. 
For CD107a staining, in chapter 4, the antibody was added to the cell culture half an 
hour before monensin was added to the wells. As explained, monensin was then left for 
3h before harvesting. 
 
2.12 Meso Scale Discovery assay 
The cytokines released in the culture supernatants were measured by the Meso Scale 
Discovery (MSD) assay, according to the manufacturer’s (Meso Scale Diagnostics, 
LLC.) instructions. This multiplex technique followed the same concept of ELISAs 
(Enzyme-Linked Immunosorbent Assay); however, it allowed the simultaneous 
measurement of 5-10 cytokines in the same sample. 
The cytokines evaluated for these studies were: IFN-γ, IL-6, IL-10, IL-12p and TNF-α, 
and the plates came pre-coated with the capture antibodies. At room temperature, 50μL 
of each sample (diluted 1:2 in Diluent 41) was added to the wells. For the standard 
curve, the highest concentration was prepared by the dilution of lyophilized Calibrator 
in 1000μL of Diluent 41 (a solution containing serum, blockers and preservatives). The 
next 6 points were obtained by a 4-fold dilution and the last well was filled with Diluent 
41 alone (blank well). The plates were, then, sealed with the adhesive plate seal. 
Samples and standard curves were incubated for 2h at room temperature, with 
continuous shaking. 
After 2h, the plates were washed 3 times with 150μL/well of Wash Buffer (provided by 
the kit as a 20X solution, to be diluted in deionized water). To prepare the detection 
antibody mix, 60μL of each antibody used in the assay was added to Diluent 45 (the 
final volume for each plate was 3000μL). Plates were sealed again and incubated for 2h 
at room temperature, while shaking. After incubation, the plates were washed a further 3 
times. 
For the detection in the MSD instrument (MSD Sector Imager 6000), 150μL of Read 
Buffer (4X stock solution, to be diluted in deionized water as 2X working solution) 
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were added to every well. There was no incubation prior to detection and the software 
used to analyse the plates was MSD Workbench, 2006. 
 
2.13 B cell depletion protocol 
Human CD20 NOD mice, received one cycle of treatment with anti-hCD20 antibody 
(clone 2H7) or control IgG2b antibody (clone MPC-11) when they were 6-8 weeks old. 
One cycle consisted of 4 injections, with a 3-day-interval between them: the first 
injection was intravenous, delivering 500µg of antibody diluted in 200µl of saline. The 
next 3 injections were via the intraperitoneal route and delivered 200µg of antibody 
diluted in 200µl of saline. 
 
2.14 Preparation of tissue and frozen sectioning for Germinal centre staining 
For the preparation of histological slides, spleens from hCD20 mice were collected 
during experiments. Spleens did not require fixation, so they were collected in media or 
PBS. To freeze the organs, a bath of isopentane (2-methyl-butane) was prepared and 
placed over a tray of dry ice. The organs were placed in a mould, with a thin layer of 
OCT compound applied on the bottom of the mould. After placing the pancreas or 
spleen, the mould was filled with OCT and transferred to the isopentane bath, to freeze. 
Moulds were stored at -80ºC until being sectioned in a cryostat machine. Each slide had 
three 5μm spleen sections and was stored at -20ºC, until use. 
 
2.15 Germinal centre staining for histological sections 
Slides stored at -20ºC were left at room temperature for 10 minutes to defrost. A circle 
was drawn around the sections with PAP pen, a film-like water repellent to contain the 
liquids over the sections during staining. 
Sections were fixed in cold acetone for 20 minutes and incubated for 20 minutes 
subsequently in PBS, for hydration. After this period, 1ml of PBS/H202 (0.5ml of 30% 
H202/100ml PBS) was added over the sections for 10 minutes to inhibit endogenous 
peroxidase. Slides were then washed with PBS once. To block non-specific reactions, 
1ml of PBS + 3% BSA was added for 30 minutes. Samples were washed with PBS, 3% 
BSA and 0.1% Tween 20. 
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The slides were then divided in two groups: Half of the slides were stained with 
biotinylated B220 (B cells) and the other half with biotinylated Thy 1.2 (T cells). The 
slides were incubated with the antibodies for one hour and, after this period, washed 
three times with PBS/BSA/Tween. 
B cells and T cells inside germinal centres are activated and, for this reason, express L-
galactose residues on their surface. These residues bind to peanut agglutinin, a reagent 
that was labelled with horseradish peroxidase and added to the slides concomitantly 
with streptavidin + alkaline phosphatase. The mix was left incubating for 1h and the 
sections were then washed with PBS/BSA/Tween. 
For the development of the colours (B and T cells in blue and PNA+ cells in brown), 
alkaline phosphatase substrate (1:1 solution of nitroblue tetrazolium and 5-brom-4-
chloro-3-indolyl phosphate) and DAB (3-3’ diaminobenzidine – prepared according to 
the manufacturer’s instruction) were added to the slides, consecutively, and left for 20 
minutes. Sections were checked regularly under the microscope for the optimal staining. 
When ready, the slides were washed one last time with PBS and immuno-mount was 
used to seal the slides. 
* One of the initial aims of chapter 5 was to determine how the generation of germinal 
centres in the spleen would be affected by B cell depletion and repopulation. However, 
on staining the spleen sections for immunohistochemistry, no germinal centres were 
detected even in the spleen of control hCD20 NOD mice. Therefore, images of the 
slides for the different time points after depletion are not shown in this thesis. 
 
2.16 Data analysis 
Flow cytometry percentages were obtained by analysis on FlowJo V10 (Tree Star). Data 
analysis was performed using GraphPad Prism 4.02 and R 3.2.0. 
Parametric data was analysed with t-test or one-way ANOVA, followed by Tukey 
Honest Significant Difference, carried out post-hoc. Graphs present the data as means 
and standard error of the mean (SEM). When non-parametric, the data was analysed by 
Mann-Whitney test or Kruskal-Wallis test, followed by Dunn Test and corrected with 
Bonferroni test. In these cases, graphs present the data as medians. 
The significance level adopted was p < 0.05. 
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2.17 Reagents 
 
Table 2.2 Reagents 
Reagent 
Dilution/ 
Concentration 
Supplier Catalogue nº 
0.5μg/ml CpG (ODN 1826 sequence: 5’-TCCATGACGTTCCTGACGTT-3’) 
10x PCR buffer  Sigma P2192 
2-MercaptoEthanol 55mM Gibco 31350-010 
30% H2O2  Sigma 216763 
Absolute Ethanol  Sigma E7023 
Acetic acid  Sigma 320099 
Acetone  
Fisher 
scientific 
A18-4 
Agarose powder 1% 
AGTC 
Bioproducts 
AGD1 
Alkaline phosphatase substrate  Sigma AB0300 
Anti-CD40 monoclonal antibody 
(Clone FGK45) 
5μg/ml Bio X-cell BE0016-2 
Anti-human CD20 
Clone 2H7 
Stock 
concentration: 
9.99mg/ml 
BioXCell 
Produced as 
requested 
B cell MACS Isolation kit  
Miltenyi 
Biotec 
130-090-86 
Bovine Serum Albumin (BSA) 0.5% 
Fisher 
Scientific 
BP1600-100 
CD8a
+
 T cell MACS Isolation kit  
Miltenyi 
Biotec 
130-104-075 
CFSE – Vybrant® CFDA SE Cell 
Tracer 
1 kit Invitrogen V12883 
Cytofix/Cytoperm 
Fixation/Permeabilization 
Solution Kit 
 
BD 
Biosciences 
554714 
DAB kit  Vector SK4100 
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dNTP set, containing dATP, 
dCTP, dGTP and dTTP 
5mM working 
solution 
Fisher 
Bioreagents 
10234683 
EDTA 0.5M Ambion AM9261 
Ethidium bromide  Sigma E-2515 
FACS lysing buffer for blood 
samples 
10x concentrated 
BD 
Biosciences 
349202 
Fetal Bovine Serum 5% Sigma F7524 
GeneRuler™ 100 bp 
DNA ladder, 100-1000 bp 
0.5µg/µl 
Fisher 
Bioreagents 
11873953 
GM-CSF (Granulocyte-macrophage colony-stimulating factor) 
Derived from X63-GM-CSF cells 
HRP-PNA  
EY 
Laboratories 
H-2301-2 
IMDM 
(Iscove’s Modified Dulbecco’s 
Medium) 
 Gibco 12440-053 
Insulin B chain 15-23 peptide 
[G9 peptide – LYLVCGERG] 
5mg/ml 
GL Biochem 
(Shanghai) 
068592 
Insulin-Transferrin-Selenium 0.1% Gibco 41400-045 
Ionomycin calcium salt from 
Streptomyces conglobatus 
500ng/ml Sigma I0634 
Isopentane  
Fisher 
scientific 
P/1030/21 
L-Glutamine 1% Gibco 25030-081 
LPS from Escherichia coli 
026:B6 
5μg/ml Sigma L2654 
Monensin 1:1500 Sigma M5273 
Mouse IgG2b Isotype control 
Clone MPC-11 
Stock 
concentration: 
11.68mg/ml 
BioXCell BE0086 
MSD Multi-spot Assay System 1 V-plex  kit MSD K15048D-1 
OCT compound  Cell Path KMA-0100-00A 
Orange G  Sigma O-3756 
Pap pen  Vector H-4000 
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PBS tablets 
1 tablet/100ml 
dH2O 
Thermo 
Scientific 
BR0014G 
Penicillin-Streptomycin 1% Gibco 15070-063 
PMA 50ng/ml Sigma P8139 
Pronase (from Streptomyces 
griseus) 
1g Pronase 
dissolved in 4.4ml 
water for PCR 
Sigma P6911 
RNAase  Sigma R4642 
RPMI-1640 
(Roswell Park Memorial Institute 
Medium) 
 Gibco 31870-025 
Sodium Azide 0.1% 
BDH 
Laboratory 
Supplies 
30111 
Sodium chloride  
Acrós 
organic 
327300010 
Sodium dodecyl sulfate 10% Sigma 11667289001 
Sterile PBS  Sigma D8662 
Streptavidin-alkaline phosphatase  
Southern 
Biotech 
7100-04 
Taq DNA Polymerase from 
Thermus aquaticus 
5U/µl Sigma D1806 
Tris base pH 8.0 
Fisher 
Bioreagents 
BP152 
TruStain fcX (anti-mouse 
CD16/32) Antibody 
1:12.5 
(Extracellular) 
Biolegend 101320 
Trypan Blue Stain  
Thermo 
Scientific 
SV30084.01 
Tween 20  
Thermo 
Scientific 
85114 
VectaMount Permanent Mounting 
Medium 
 Vector H5000 
Water, molecular biology grade, 
Rnase, Dnase and Protease free 
 
Fisher 
Bioreagents 
10192813 
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Table 2.3 Preparation of solutions cited in the Methods  
Solution Volume/Concentration 
50x TAE buffer 
121g Tris base, 50ml 0.5M EDTA pH 8.0, 25ml Acetic Acid. 
Make up to 500ml with distilled water. For use, dilute it to 1x 
with dH20. Stored at room temperature. 
Blood buffer 
PBS, 0.5% BSA; 4% 0.1M EDTA and 0.2% Sodium Azide. 
Stored at 4ºC 
FACS buffer PBS; 0.5% BSA and 0.1 % Sodium Azide. Stored at 4ºC 
IMDM complete 
medium 
IMDM medium; 1% Glutamine; 1% Penicillin-Streptomycin; 
5% Fetal Bovine Serum; 55mM 2-MercaptoEthanol and 0.1% 
Insulin-Transferrin-Selenium. Stored at 4ºC 
MACS buffer PBS, 5% BSA and 2mM EDTA. Stored at 4ºC 
RPMI complete 
medium 
RPMI medium; 1% Glutamine; 1% Penicillin-Streptomycin; 5% 
Fetal Bovine Serum and 55mM 2-MercaptoEthanol. Stored at 
4ºC 
Saturated salt 
solution  
Sodium chloride has a solubility of 35.7 grams in 100ml of cold 
dH20 
Tail digest buffer 
5% 1M Tris pH 8; 4% 0.5M EDTA; 20% Sodium dodecyl 
sulfate; dH2O 
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Table 2.4 Antibodies used for flow cytometry 
Antibody Fluorochrome Dilution Supplier Catalogue 
no. 
Clone 
B220 Biotin 1:200 Biolegend 103204 RA3-6B2 
CD107 PeCy7 1:200 Biolegend 121620 1D4B 
CD11b APC 1:200 Biolegend 101212 M1/70 
CD11b BV650 1:400 Biolegend 101239 M1/70 
CD11c PerCP Cy5.5 1:400 eBioscience 45-0114-82 N418 
CD11c BV650 1:400 Biolegend 117339 N418 
CD138 BV510 1:100 Biolegend 142521 281-2 
CD19 APC e780 1:800 eBioscience 47-0193-80 eBio1D3 
CD19 AF700 1:100 Biolegend 115528 6D5 
CD1d PE 1:400 
BD 
Biosciences 
553846 1B1 
CD1d FITC 1:100 Biolegend 123507 1B1 
CD1d APC 1:200 Biolegend 123512 1B1 
CD1d BV510 1:200 
BD 
Biosciences 
563189 1B1 
CD21 FITC 1:400 eBioscience 11-0212-81 eBio4E3 
CD21 PE CF594 1:1000 
BD 
Biosciences 
563959 7G6 
CD23 PE 1:800 eBioscience 12-0232-81 B3B4 
CD23 PeCy7 1:200 eBioscience 25-0232-81 B3B4 
CD23 BV711 1:800 
BD 
Biosciences 
563987 B3B4 
CD24 BV421 1:800 Biolegend 101825 M1/69 
CD24 FITC 1:400 
BD 
Biosciences 
553261 M1/69 
CD24 BV650 1:400 
BD 
Biosciences 
563545 M1/69 
CD25 PE 1:200 
BD 
Biosciences 
533866 PC61 
CD27 APC 1:200 eBioscience 17-0271-81 LG7F9 
CD27 PeCy7 1:400 Biolegend 124216 LG.3A10 
CD279 BV786 1:200 Biolegend 135225 29F.1A12 
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CD3 PerCP Cy 5.5 1:200 
BD 
Biosciences 
551163 145-2C11 
CD3 PE 1:100 Biolegend 100307 145-2C11 
CD3 AF700 1:100 Biolegend 100216 17A2 
CD3 FITC 1:100 Biolegend 100306 145-2C11 
CD3 BV786 1:100 
BD 
Biosciences 
564379 145-2C11 
CD3 BV605 1:100 Biolegend 100351 145-2C11 
CD38 PeCy7 1:800 Biolegend 102717 90 
CD38 FITC 1:200 Biolegend 102705 90 
CD4 BV421 1:800 Biolegend 100443 GK1.5 
CD4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         BV650 1:400 Biolegend 100555 RM4-5 
CD4 FITC 1:400 
BD 
Biosciences 
553729 GK1.5 
CD40 PE CF594 1:400 
BD 
Biosciences 
562847 3/23 
CD43 FITC 1:400 eBioscience 11-0431-82 eBioR2/60 
CD43 AF700 1:200 
BD 
Biosciences 
565532 S7 
CD44 PerCP Cy5.5 1:1600 eBiosciences 45-0441-82 IM7 
CD5 FITC 1:200 eBioscience 11-0051-82 53-7.3 
CD5 PeCy7 1:200 eBioscience 25-0051-81 53-7.3 
CD5 BV421 1:100 Biolegend 100617 53-7.3 
CD5 AF700 1:200 
BD 
Biosciences 
565505 53-7.3 
CD62L PeCy7 1:800 Biolegend 104417 MEL-14 
CD69 BV786 1:200 
BD 
Biosciences  
564683 H1.2F3 
CD8 PE CF594 1:800 Biolegend 100762 53-6.7 
CD8 APC e780 1:200 eBiosciences 47-0081-82 53-6.7 
CD80 BV650 1:100 
BD 
Biosciences 
563687 16-10A1 
CD86 PeCy7 1:200 Biolegend 105116 PO3 
CTLA-4 BV421 1:200 Biolegend 106311 UC10-4B9 
Fas-L PeCy7 1:100 eBiosciences 25-5911-82 MFL3 
Foxp3 eF660 1:200 eBiosciences 50-5773-82 FJK-16s 
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Human 
CD20 
PE 1:50 Biolegend 302306 2H7 
IFN-γ BV711 1:100 Biolegend 505835 XMG1.2 
IgD APC 1:800 eBioscience 17-5993-80 11-26c 
IgD PE 1:400 eBioscience 12-5993-83 11-26c 
IgD BV786 1:200 
BD 
Biosciences 
563618 11-26c.2a 
IgM BV421 1:200 Biolegend 406517 RMM-1 
IgM PerCP Cy5.5 1:200 Biolegend 406512 RMM-1 
IgM BV650 1:400 
BD 
Biosciences 
564027 R6-60.2 
IL-10 PerCP Cy 5.5 1:200 eBioscience 45-7101-80 JES5-16E3 
IL-10 APC 1:200 
BD 
Biosciences 
554468 JES5-16E3 
IL-6 APC 1:200 Biolegend 504507 MP5-20F3 
IL-6 PerCP efluor710 1:200 eBioscience 46-7061-80 MP5-20F3 
Live/Dead 
dye 
eF506 1:500 eBioscience 65-0866-14  
Live/Dead 
dye 
APC e780 1:500 eBioscience 65-0865-14  
Live/Dead 
dye 
BV605 1:500 Invitrogen L-34959  
MHC I 
(H-2D
b
) 
PE 1:1000 Biolegend 111507 KH95 
MHC II  
I-A
k
 (Aβk) 
FITC 1:400 Biolegend 109905 10-3.6 
MHC II 
I-A
k
 (Aβk) 
PE 1:400 Biolegend 109908 10-3.6 
Mouse IgG1, 
κ 
Isotype 
Control 
BV421 1:200 Biolegend 400157 MOPC-21 
Rat IgG1, κ 
Isotype 
Control 
APC 1:200 Biolegend 400411 RTK2071 
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Rat IgG1, κ 
Isotype 
Control 
BV711 1:100 Biolegend 400441 RTK2071 
Rat IgG2b, κ 
Isotype 
Control 
PerCP Cy5.5 1:200 eBioscience 45-4031-80 
eB149/10H
5 
TCR Vβ6 PE 1:1000 Biolegend 140004 RR4-7 
TGF-β BV421 1:200 Biolegend 141407 TW7-16B4 
Thy 1.2 Biotin 1:50 Biolegend 140314 53-2.1 
TIM-1 PE 1:200 Biolegend 119505 RMT1-4 
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3. Cytokine production and the expression of regulatory markers in 
IL-10-producing B cells in NOD mice 
 
3.1 Introduction and Objectives 
3.1.1 Cytokines 
Although B cells have a major function as antibody producers, they also exert a role as 
APCs (antigen presenting cells). In addition, they communicate with T cells and 
produce cytokines. 
Cytokines are proteins secreted mainly by leukocytes as a way to establish 
communication between cells (Akdis et al. 2016). Studies have shown that they were 
able, for example, to polarize lymphocytes to differentiate into the various 
subpopulations of effector cells, such as Th1, Th2, Th17, Be1, Be2 (Harris et al. 2000). 
Cytokines can modulate immune responses as well and, therefore, they are also 
categorised into pro- and anti-inflammatory and their balance is vital for the 
maintenance of a healthy individual. 
The pro-inflammatory cytokine examined in this study, IL-6, is mainly produced by B 
cells and is important in germinal centres, as enhancers of antibody production. IL-6 is 
also important in the maintenance of Th17 cells (Bao and Cao 2014). 
TGF-β is a regulatory cytokine secreted not only by leukocytes, but also fibroblasts and 
epithelial cells. TGF-β is very important as a mechanism of action for regulatory T cells 
and it is also important for the differentiation of Th17 cells, along with IL-6 (Gutcher et 
al. 2011). 
IL-10 is considered the most important regulatory cytokine due to its powerful 
suppressive effects. When binding to IL-10R in APCs, for example, IL-10 reduces the 
expression of MHC II and co-stimulatory molecules and, in T and B cells, decreases the 
secretion of proinflammatory cytokines (Hofmann et al. 2012). 
The importance of IL-10-producing B cells and TGF-β-producing B cells in 
autoimmune diseases and what is known so far about their relevance in type 1 diabetes 
have already been discussed in chapter 1. This chapter aims to further this investigation. 
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3.1.2 B cell surface markers – Regulatory B cell markers 
As explained in chapter 1, regulatory B cells are not yet determined by one unified 
phenotype and they are currently characterized by the production of regulatory 
cytokines, such as IL-10, TGF-β and IL-35. A number of surface markers, however, are 
associated with the enhanced production of these cytokines by B cells. 
As a summary, Table 3.1 presents the phenotypes for the different levels of maturation 
and subsets of B cells in rodents and humans (Pillai and Cariappa 2009; Blair et al. 
2010). Regulatory B cells described in the literature commonly exhibit T2 and Marginal 
zone (MZ) phenotypes. In addition to markers that distinguish T2 and MZ B cells, 
regulatory B cells in rodents are also characterized by the markers CD1d and CD5. 
Yanaba and colleagues described this phenotype for the first time and they observed 
that CD19
+
CD1d
hi
CD5
+
 spleen B cells comprised most of the IL-10-producing B cells 
and these cells were able to inhibit ear swelling after adoptive transfer (Yanaba et al. 
2008). 
In humans, immature B cells expressing high levels of CD24 and CD38 are also linked 
with IL-10 production (Blair et al. 2010). 
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Table 3.1 B cell subsets based on the expression of surface markers, in 
rodents and humans (information from (Pillai and Cariappa 2009; Blair et al. 
2010) 
 Level of maturation/Subsets B cell Phenotype 
Rodents 
Immature B cells (T2) CD19
+
IgD
–
IgM
+
CD21
high
CD23
+
 
Mature Marginal B cells CD19
+
IgD
low
IgM
hi
CD21
hi
CD23
-
CD1d
hi
 
Mature Follicular B cells CD19
+
IgD
hi
IgM
low
CD21
int
CD23
+
 
Humans 
Immature B cells 
CD19
+
CD24
hi
CD38
hi 
 
(IgM
hi
IgD
hi
CD5
+
CD20
+
CD27
-
CD1d
hi
) 
Mature B cells 
CD19
+
CD24
int
CD38
int
 
(IgM
int
IgD
+
CD5
-
CD20
+
CD27
-
CD1d
+
) 
Memory Cells 
CD19
+
CD24
hi
CD38
-
 
(IgM
+ 
or IgM
- 
IgD
+
 or IgD
- 
CD5
-
CD20
+
CD27
+
CD1d
+
) 
 
 
3.1.3 Objectives 
In depth studies about regulatory B cells in Type 1 Diabetes are still limited. Our 
general hypothesis was that B cells in the NOD mice are deficient in regulatory 
functions, which could be one of the factors leading to spontaneous development of 
autoimmune diabetes. 
Therefore the first aim was to study cytokine production in CD19
+
 B cells in the non-
obese diabetic (NOD) mouse model, discussed in detail previously, in Chapter 1, 
specifically comparing age and gender with a mouse strain that is not prone to diabetes. 
The second aim of this chapter was to evaluate the variance of the regulatory markers in 
IL-10-producing B cells in male and female NOD and B6
g7
 mice. We focused on 30-35 
weeks old (w.o.) and diabetic mice, as these were the groups showing the most 
interesting results for cytokine-producing B cells. 
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3.2 Evaluation of cytokine production by B cells from NOD mice, compared to a 
non-diabetic prone mouse strain 
The aim of this first study was to evaluate the cytokine production by the whole B cell 
population after a 24h cell culture. For this analysis, NOD splenic B cells, from male 
and female mice, were compared to a strain that does not develop autoimmune diabetes 
(B6
g7
). Congenic B6
g7
 mice share the same genetic background with C57BL/6 mice, 
with one exception: the MHC, H-2
g7
, is derived from NOD mice. This strain does not 
develop type 1 diabetes. 
The time points for the investigations were chosen, based on the natural history of type 
1 diabetes for this mouse model: young (5-8-week-old) NOD mice, which had just 
passed the first checkpoint in the pathway to the development of autoimmune diabetes 
and started to develop infiltration of lymphocytes in their pancreatic islets (insulitis), 
though there was no sign of hyperglycaemia. Intermediate (13-17-week-old) is the age 
when NOD mice reach the second checkpoint and begin to develop diabetes; NOD mice 
that were tested positive for glycosuria for two consecutive weeks and blood glucose 
over 13.9mmol/L were diagnosed with type 1 diabetes and constituted the diabetic 
group (see Table 2.1, Chapter 2 for blood glucose levels). These mice have a severe 
destruction of pancreatic islets and almost no production of insulin; another group of 
NOD mice > 35 weeks of age with no signs of diabetes were considered to be protected 
from the disease [The checkpoints of type 1 diabetes in NOD mice were reviewed in 
(Andre et al. 1996)].  
For this set of experiments, spleens were collected and processed into a single cell 
suspension (Section 2.5) and 2x10
6
 cells were cultured for 24h with different stimulants: 
Lipopolysaccharide (LPS) activates cells through Toll-like Receptor (TLR) 4 and is the 
main stimulant described in the literature to enrich for IL-10-producing B cells (Yanaba 
et al. 2009); CpG are oligonucleotides, non-methylated DNA common in bacteria, 
which act via TLR-9 and have previously been studied for their ability to induce B cells 
to produce IL-10 (Mion et al. 2014). Here, CpG was studied alone or associated with 
anti-CD40 (anti-CD40); CD40 is a co-stimulatory receptor in B cells, activated by 
CD40L, which is found on T cells, and can enhance the production of cytokines (Mauri 
et al. 2003). Spleen cells were also cultured with no addition of stimulant 
(unstimulated). All cells in culture received PMA, ionomycin and monensin 3h prior to 
the staining: the first two to boost cell activation and the latter to avoid cytokine release 
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into the supernatant. The choice of the stimulants was based on previous B cell studies 
and the concentrations were chosen after preliminary titration experiments, performed 
previously in the lab. To study both inflammatory and anti-inflammatory effects, the 
cytokines selected were IL-6 (inflammatory) and IL-10, TGF-β (both regulatory). 
The putative regulatory subsets were divided into panels, as described in Table 3.2. 
Each group displayed in the graphs in chapter 3 consisted of 5-10 mice pooled of at 
least two independent observations (two repetitions). 
 
Table 3.2 Division of antibodies in 3 panels for cytokine production 
evaluation in B cells  
 
  
Panel 1 Panel 2 Panel 3 
Live-Dead Dye (LD): 
eF506 
Live-Dead Dye (LD): 
eF506 
Live-Dead Dye (LD): 
eF506 
CD3: PE CD3: PE CD3: PE 
CD19: APC e780 CD19: APC e780 CD19: APC e780 
IL-10 PerCP Cy5.5 IL-10 PerCP Cy5.5 IL-10 PerCP Cy5.5 
TGF-β: BV421 TGF-β: BV421 TGF-β: BV421 
IL-6: APC IL-6: APC IL-6: APC 
CD21: FITC CD1d: FITC CD24: FITC 
CD23: PeCy7 CD5: PeCy7 CD38: PeCy7 
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Figure 3.1 provides a schematic view of the complex and layered set of data presented 
next, to clarify the groups and conditions used.  
 
 
Figure 3.1 Schematic representation of the experimental design for the 
cytokine production evaluation . NOD mice were compared to a non-diabetes 
prone mouse strain called B6
g7
. Variations in B cells with gender were also 
evaluated, as well as the influence of the age of the mice, considering the kinetics 
of the disease in NOD mice. Spleen cells were cultured for 24h with different 
stimulants and examined for IL-10, TGF-β and IL-6 production by CD19 positive 
cells. Finally, the contribution of regulatory B cell subsets to cytokine production 
by the whole B cell population was investigated.  
 
The gating strategy for this section is illustrated in Figure 3.2. The production of 
cytokines was determined as the percentage of CD19
+
 B cell population that was also 
positive for intracellular IL-6, TGF-β or IL-10 (Figure 3.2e). As the cytokines were 
present in the three panels (Table 3.2), each individual point shown in the graphs were 
calculated as an average of these 3 technical replicates. 
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Figure 3.2 Example of gating of flow cytometric plots used for the cytokine 
production analysis . Spleens from NOD and B6
g7
 mice were collected, 
erythrocytes were lysed, cells were counted and left in culture with or without 
stimulants for 24h. Surface markers and intracellular cytokines were examined by 
flow cytometry. All analysis presented in this and the next chapters proceeded, as 
follows: (a) determination of lymphocytes by size and granulation, (b) exclusion 
of doublets and (c) exclusion of dead cells, which were positive for the live/dead 
dye, and (d) finally discrimination between T cells (CD3) and B cells ( CD19). For 
every sample, 30,000 CD19
+
 cells were acquired. In (e) one example of how the 
IL-10-producing-B cells were gated can be observed. TGF-β and IL-6 followed 
this same analysis and the gates were established based on isotype controls – 
Figure A1, in the appendix.  
 
 
3.2.1 IL-6-producing B cells 
3.2.1.1 Unstimulated, LPS and anti-CD40-stimulated B cells 
IL-6 was the pro-inflammatory cytokine examined in this study. However the 
percentage of IL-6-producing B cells was very low or undetectable in all groups for 
unstimulated cell cultures (Figures 3.3a and b) and when cells were stimulated with LPS 
(Figures 3.3 c and d) and anti-CD40 (Figures 3.3 e and f). 
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3.2.1.2 CpG-stimulated B cells 
Stimulation with CpG activated B cells to produce IL-6. Female mice, both NOD and 
B6
g7
, had increasing percentages of IL-6-producing B cells over time (NOD mice: 
young 9.4%; intermediate 12%; protected 15.5% and diabetic 19.3%. B6
g7
 mice: young 
14.9%; intermediate 23.6% and 30-35 w.o. 17.6%), as observed in Figure 3.4a. B cells 
from male mice behaved differently when compared between themselves or with female 
mice. The production of IL-6 by B cells from NOD male mice showed a significant 
increase from young to intermediate groups, 11.6% to 19.3% respectively, and returned 
to 12.6% in older NOD mice (Figure 3.4b). On the other hand, the frequency of 
CD19
+
IL-6
+
 cells significantly decreased in male B6
g7
 mice over time (24.5% in young 
mice to 8.4% in 30-35 week old mice). 
 
3.2.1.3 anti-CD40/CpG-stimulated B cells 
The combination of CpG and anti-CD40 produced an interesting synergistic effect in 
the stimulation of B cells to produce IL-6. Although anti-CD40 alone did not induce 
CD19
+
IL-6
+
 cells, when added in culture with CpG, IL-6-producing B cells were 
increased compared to CpG alone, a result not seen for the anti-inflammatory cytokines 
(described next). 
In both female mouse strains (Figure 3.5a), the frequency of IL-6 producing B cells 
increased with age (NOD young: 16.4%; NOD protected: 32% and diabetic: 35%) 
although the percentages were higher in female B6
g7
 mice (young: 34%; 30-35 week 
old: 46.5%). The percentage of CD19
+
IL-6
+
 cells in young male mice was significantly 
higher in B6
g7
 mice, when compared to NOD mice (29% versus 19%, respectively), this 
observation was reversed when mice were 30-35 weeks old and the frequency of IL-6 
producing B cells in male NOD mice (31%) was higher than the frequency in male B6
g7
 
mice (22.9%), as illustrated in Figure 3.5b.  
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Figure 3.4Frequency of IL-6-producing B cells stimulated with CpG. Spleens 
from male and female NOD and B6
g7 
mice were collected, erythrocytes were lysed 
and removed and spleen cells were cultured for 24h with CpG; PMA, ionomycin 
and monensin were added for the last 3 hours and then cells were stained for 
extracellular markers and intracellular IL-6. Samples were examined by flow 
cytometry and tested with Kruskal -Wallis, followed by Dunn’s post hoc test and 
Bonferroni correction. Filled symbols represent female mice of both strains (a) 
and open symbols represent male mice (b). Each symbol represents an individual 
mouse and a median bar is shown.  
n = 5-10 and at least 2 repetitions for each group . 
* p < 0.05; ** p < 0.01 and *** p < 0.001  
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Figure 3.5 Frequency of IL-6-producing B cells stimulated with anti-CD40 
and CpG. Spleens from male and female, NOD and B6
g7
 mice were collected, 
erythrocytes were lysed and removed and spleen cells were cultured for 24h with 
anti-CD40 and CpG; PMA, ionomycin and monensin were added for the last 3 
hours and then cells were stained for extracellular markers and intracellular IL-6. 
Samples were examined by flow cytometry and tested with Kruskal -Wallis, 
followed by Dunn’s post hoc test and Bonferroni correction. Filled symbols 
represent female mice of both strains (b). Each symbol represent s an individual 
mouse and a median bar is shown.  
n = 5-10 and at least 2 repetitions for each group . 
* p < 0.05; ** p < 0.01 and *** p < 0.001   
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3.2.1.4 Summary 
In summary, the production of IL-6 by B cells is highly determined by the nature of the 
stimulants added to the cell culture. B cells do not produce IL-6 when the cells are 
unstimulated or stimulated with LPS or anti-CD40 alone. However, when anti-CD40 is 
added in combination with CpG, a synergistic effect is observed. The percentages of B 
cells producing IL-6 in female mice increased with age and were higher in B6
g7
 mice 
when compared to NOD mice. Results in male mice were more heterogeneous, but in 
general, the frequency peaked in intermediate NOD male mice and decreased with age 
in male B6
g7
 mice. 
There were no significant differences in the percentages of IL-6-producing B cells in 
30-35 w.o. and diabetic NOD mice, which suggests the protection seen in these mice 
was not due to impairment in the production of this inflammatory cytokine. 
 
3.2.2 TGF-β-producing B cells 
3.2.2.1 Unstimulated B cells 
The next cytokine studied was TGF-β. Frequency of TGF-β-producing B cells was less 
than 1.5% for all the groups in unstimulated cell cultures, as presented in Figures 3.6a 
and 3.6b. Although there were some statistically significant differences, the percentages 
were very small and the biological impact is questionable. 
 
3.2.2.2. LPS-stimulated B cells 
The increased percentage of CD19
+
TGF-β+ cells in female NOD mice was related to 
diabetes, but also with age (intermediate: 0.5%; protected: 4.2% and diabetic: 5.6%) and 
age-related increase was also seen in female B6
g7
 mice, from young (1.8%) to 30-35 
week old mice (3.9%, Figure 3.7a). Male B6
g7
 mice had the same increasing percentage 
of TGF-β-producing B cells seen in female mice, increasing from 5% in young to 8.6% 
in 30-35 w.o. male mice. On the other hand, as presented in Figure 3.7b, TGF-β-
producing B cells in male NOD mice reduced with age, from 9.8% in young mice to 
2.6% in protected male NOD mice. 
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Figure 3.6 Frequency of TGF-β production in unstimulated B cells. Spleens 
from male and female NOD and B6
g7
 mice were collected, erythrocytes were lysed 
and removed and spleen cells were cultured for 24h with no stimulants; PMA, 
ionomycin and monensin were added for the last 3 hours and then cells were 
stained for extracellular markers and intracellular TGF-β. Samples were examined 
by flow cytometry and tested with Kruskal -Wallis, followed by Dunn’s post hoc 
test and Bonferroni correction. Filled symbols represent female mice of both 
strains (a) and open symbols represent male mice (b). Each symbol represents an  
individual mouse and a median bar is shown.  
n = 5-10 and at least 2 repetitions for each group . 
* p < 0.05; ** p < 0.01 and *** p < 0.001  
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Figure 3.7 Frequency of TGF-β-producing B cells stimulated with LPS . 
Spleens from male and female NOD and B6
g7
 mice were collected, erythrocytes 
were lysed and removed and spleen cells were cultured for 24h with LPS; PMA, 
ionomycin and monensin were added for the last 3 hours and then cells were 
stained for extracellular markers and intracellular TGF-β. Samples were examined 
by flow cytometry and tested with Kruskal -Wallis, followed by Dunn’s post hoc 
test and Bonferroni correction. Filled symbols represent female mice of both 
strains (a) and open symbols represent male mice (b) . Each symbol represents an 
individual mouse and a median bar is shown.  
n = 5-10 and at least 2 repetitions for each group . 
* p < 0.05; ** p < 0.01 and *** p < 0.001 
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3.2.2.3 anti-CD40-stimulated B cells 
Results for B cells cultured with anti-CD40 were consistent with those seen with LPS 
stimulation. In both female strains (Figure 3.8a), the frequencies of CD19
+
TGF-β+ cells 
increased with age and this trend was also followed by diabetic NOD mice (NOD mice: 
young 1.3%; intermediate 0.9%; protected 4.4% and diabetic 5.9%. B6
g7
: young 1.7%; 
intermediate 6% and 30-35 weeks old 5.1%). Again, similar to LPS stimulation, B cells 
from young male NOD mice were able to produce TGF-β (7.6%) and this percentage 
decreased (2.5%) in old male NOD mice (Figure 3.8b). In contrast, male B6
g7
 mice 
presented an increased frequency of TGF-β-producing B cells, increasing from 3.4% in 
young to 6.5% in 30-35 week old mice. 
 
3.2.2.4 CpG-stimulated B cells 
Figure 3.9a illustrates the variations in CD19
+
TGF-β+ cells from female mice, when cell 
cultures were stimulated with CpG. One interesting finding was that B6
g7
 mice 
responded better to CpG than NOD mice. However, both strains showed increased 
percentages of TGF-β-producing B cells with age, in response to CpG. The percentages 
in female NOD mice varied less (young: 0.8%; protected: 2.3% and diabetic: 2.9%) 
than B6
g7
 mice (young: 1.5%; 30-35 w.o: 6%). The strain difference was more 
pronounced in older male mice (Figure 3.9b). Although both male NOD and B6
g7
 mice 
had decreased percentages of TGF-β-producing B cells with age in response to CpG, 
male B6
g7
 mice started higher and were more variable than male NOD mice (11.6% 
versus 4.1%, respectively) and were still higher when mice were 30-35 weeks old (B6
g7
: 
7.6%; NOD: 1.1%). 
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Figure 3.8 Frequency of TGF-β-producing B cells stimulated with anti-CD40. 
Spleens from male and female, NOD and B6
g7
 mice were collected, erythrocytes 
were lysed and removed and spleen cells were cultured for 24h with anti-CD40; 
PMA, ionomycin and monensin were added for the last 3 hours and then cells 
were stained for extracellular markers and intracellular TGF-β . Samples were 
examined by flow cytometry and tested with Kruskal -Wallis, followed by Dunn’s 
post hoc test and Bonferroni correction. Filled symbols represent female mice of 
both strains (a) and open symbols represent male mice (b). Each symbol 
represents an individual mouse and a median bar is shown.  
n = 5-10 and at least 2 repetitions for each group . 
* p < 0.05; ** p < 0.01 and *** p < 0.001  
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Figure 3.9 Frequency of TGF-β-producing B cells stimulated with CpG.  
Spleens from male and female NOD and B6
g7
 mice were collected, erythrocytes 
were lysed and removed and spleen cells were cultured for 24h with CpG; PMA, 
ionomycin and monensin were added for the last 3 hours and then cells were 
stained for extracellular markers and intracellular TGF-β. Samples were examined 
by flow cytometry and tested with Kruskal -Wallis, followed by Dunn’s post hoc 
test and Bonferroni correction. Filled symbols represent female mice of both 
strains (a) and open symbols represent male mice (b). Each symbol represents an 
individual mouse and a median bar shown.   n = 5-10 and at least 2 repetitions for 
each group. 
* p < 0.05; ** p < 0.01 and *** p < 0.001 
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3.2.2.5 anti-CD40/CpG-stimulated B cells 
Cell culture stimulation with both anti-CD40 and CpG did not further increase TGF-β 
production by B cells. The frequencies were, in fact, similar to CpG alone. Again, B6
g7
 
mice had higher percentages of CD19
+
TGF-β+ cells compared to NOD mice in both 
genders. In female mice, as seen in Figure 3.10a, the frequency of TGF-β production by 
B cells increased with age, being less in female NOD mice (young: 0.9%; protected: 
1.4% and diabetic: 2.8%) compared with female B6
g7
 mice (young: 0.9%; intermediate: 
11.2% and 30-35w.o: 4%). In male NOD mice, a decrease in the frequency from young 
(3%) to protected mice (1%) was observed. Male B6
g7
 mice did not have variation in the 
percentage of CD19
+
TGF-β+ cells over time (young: 4.3%; intermediate: 5.7% and 30-
35 weeks old: 3.6%), as observed in Figure 3.10b. 
 
3.2.2.6 Summary 
In summary, TGF-β production was low in unstimulated B cells and cultures stimulated 
with LPS and anti-CD40 exhibited similar frequencies of CD19
+
TGF-β+ cells. There 
was no difference in the percentages of TGF-β-producing B cells between diabetic mice 
and protected female NOD mice. The difference between diabetic mice and the other 
healthy NOD groups is probably more associated with age than with the development of 
the disease. Male NOD mice presented a different dynamic and the percentages of 
CD19
+
TGF-β+ cells decreased with age. 
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Figure 3.10 Frequency of TGF-β-producing B cells stimulated with anti-CD40 
and CpG. Spleens from male and female NOD and B6
g7
 mice were collected, 
erythrocytes were lysed and removed and spleen cells were cultured for 24h with 
anti-CD40 and CpG; PMA, ionomycin and monensin were added for the last 3 
hours and then cells were stained for extracellular markers and intracellular TGF-
β. Samples were examined by flow cytometry and tested with Kruskal -Wallis, 
followed by Dunn’s post hoc test and Bonferroni correction. Filled symbols 
represent female mice of both strains (a) and open symbols represent male mice 
(b). Each symbol represents an individual mouse and a median bar is shown.  
n = 5-10 and at least 2 repetitions for each group . 
* p < 0.05; ** p < 0.01 and *** p < 0.001  
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3.2.3 IL-10-producing B cells 
3.2.3.1 Unstimulated B cells 
Unstimulated B cells from the NOD mouse had more IL-10
+
 B cells compared to B6
g7
 
B cells. There was a significant difference when female mice from both strains were 
compared at 30-35 weeks old (p < 0.01). Unstimulated B cells from diabetic NOD mice 
did not produce IL-10 and this was significantly different from other mice at all ages, as 
seen in Figure 3.11a. A significantly increased percentage of IL-10-producing B cells 
was found in NOD male mice and decreased percentage was seen in B6
g7
 mice with age 
(0.7%; 4.6% and 4.5% in young, intermediate and protected NOD mice, respectively, 
compared to 1.9%, 0.06% and 0.9% in B6
g7 
mice), in Figure 3.11b.  
 
3.2.3.2 LPS-stimulated B cells 
When the cells were stimulated with LPS, they showed a different pattern from TGF-β-
producing B cells. Here, the percentage of IL-10
+ 
B cells from female protected NOD 
mice (11%) was significantly increased compared to NOD diabetic mice (5.8%; p < 
0.001), as demonstrated in Figure 3.12a. The percentage of IL-10-producing B cells in 
female B6
g7 
mice decreased with age (7.5% to 2.4%, from young to old, respectively). 
In male NOD mice (Figure 3.12b) the increase in the percentage of IL-10-producing B 
cells with age was even more accentuated (young: 4.9%; intermediate: 5.4% and 
protected: 12.4%). Male B6
g7
 mice maintained the frequency of CD19
+
IL-10
+
 cells 
around 2-4%. 
 
3.2.3.3 anti-CD40-stimulated B cells 
As observed in Figure 3.13a, B cells from diabetic NOD mice, when stimulated with 
anti-CD40, had few IL-10-B cell producers (<1%). This frequency was significantly 
lower than the CD19
+
IL10
+
 cells at all other time-points in non-diabetic mice (young: p 
< 0.01; intermediate: p < 0.01 and protected mice: p < 0.001). A significant decrease of 
IL-10 producing B cells was found between young and 30-35 week old B6
g7
 mice (7.7% 
versus 1.4%, respectively). Furthermore, a significant difference was found between 
protected/old female NOD mice and old B6
g7
 mice. Figure 3.13b shows that B cells 
from male mice stimulated with anti-CD40 behaved very similarly as when they were 
stimulated with LPS. Once again, the frequency of CD19
+
IL-10
+
 cells significantly 
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increased with age in male NOD mice (young: 1.7%; intermediate: 4.6% and protected 
mice: 7.5%), while the frequency of CD19
+
IL-10
+
 cells in male B6
g7
 mice remained low 
through young and intermediate groups, with a higher percentage in the 30-35 w.o. 
(young: 1.9%; intermediate: 0.6% and 30-35 w.o: 3.1%). 
 
3.2.3.4 CpG-stimulated B cells 
The next stimulant analysed was CpG (Figure 3.14). Interestingly, unlike LPS and anti-
CD40, B cells from young female B6
g7
 mice had a higher percentage of IL-10-
producing B cells compared with young female NOD mice (16% versus 10.6%, 
respectively). When female mice were 13-17 weeks old, this frequency decreased in 
both strains (11.6%: 4.9%, B6
g7
: NOD mice). However, at 30-35 weeks old, female 
NOD mice had a significantly higher percentage of IL-10 producing B cells (10.3%), 
when compared to female B6
g7
 mice (1.4%). The percentage of CD19
+
IL-10
+
 cells in 
diabetic mice in response to CpG was 4.7%, similar to the intermediate group (Figure 
3.14a). These differences were not seen in males, which had a similar percentage of IL-
10-producing B cells between strains in young (NOD: 5.3%; B6
g7
:
 
5.4%) and 
intermediate groups (NOD: 3.9%; B6
g7
: 5.5%). However, in mice 30-35 weeks old, the 
percentage of CD19
+
IL-10
+
 was significantly higher (p < 0.01) in NOD mice (8.7%) 
than in male B6
g7
 mice (2.8%). These results are shown in Figure 3.14b. 
 
3.2.3.5 anti-CD40/CpG-stimulated B cells 
Lastly, combining CpG and anti-CD40 only produces an additive effect in the 
production of IL-10 by B cells in female B6
g7
 mice. For both genders of NOD and male 
B6
g7
 mice, the trend was similar to when cells were stimulated with CpG alone. Figure 
3.15a illustrates the significantly decreasing frequency of CD19
+
IL-10
+
 cells in female 
young B6
g7
 mice over time (young: 21.2%; intermediate: 14.9% and 30-35 w.o. mice: 
1.5%). Female NOD mice, on the other hand, had an increased frequency of IL-10-
producing B cells in protected mice, unless they were diabetic (young: 6.1%; protected: 
8% and diabetic: 3.2%). In male NOD mice, the percentage of CD19IL-10
+
 cells 
increased with age (young: 2.9%; protected: 5.2%), while CD19
+
IL-10
+
 cells from male 
young B6
g7
 increased (1.7%) compared to mice that were 13-17 weeks old (5.6%) and 
decreased again (1.6%) in 30-35 week old B6
g7
 mice (Figure 3.15b). 
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Figure 3.11 Frequency of IL-10 production in unstimulated B cells.  Spleens 
from male and female NOD and B6
g7
 mice were collected, erythrocytes were lysed 
and removed and spleen cells were  cultured for 24h with no stimulant; PMA, 
ionomycin and monensin were added for the last 3 hours and then cells were 
stained for extracellular markers and intracellular IL-10. Samples were examined 
by flow cytometry and tested with Kruskal -Wallis, followed by Dunn’s post hoc 
test and Bonferroni correction. Filled symbols represent female mice of both 
strains (a) and open symbols represent  male mice (b). Each symbol represents an 
individual mouse and a median bar is shown.  
n = 5-10 and at least 2 repetitions for each group . 
* p < 0.05; ** p < 0.01 and *** p < 0.001   
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Figure 3.12 Frequency of IL-10-producing B cells stimulated with LPS. 
Spleens from male and female NOD and B6
g7
 mice were collected, erythrocytes 
were lysed and removed and spleen cells were cultured for 24h with LPS; PMA, 
ionomycin and monensin were added for the las t 3 hours and then cells were 
stained for extracellular markers and intracellular IL -10. Samples were examined 
by flow cytometry and tested with Kruskal -Wallis, followed by Dunn’s post hoc 
test and Bonferroni correction. Filled symbols represent female mic e of both 
strains (a) and open symbols represent male mice (b). Each symbol represents an 
individual mouse and a median bar is shown.  
n = 5-10 and at least 2 repetitions for each group . 
* p < 0.05; ** p < 0.01 and *** p < 0.001  
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Figure 3.13 Frequency of IL-10-producing B cells stimulated with anti-CD40.  
Spleens from male and female NOD and B6
g7
 mice were collected, erythrocytes 
were lysed and removed and spleen cells were cultured for 24h with anti-CD40; 
PMA, ionomycin and monensin were added for the last 3 hours and then cells 
were stained for extracellular markers and intracellular IL -10. Samples were 
examined by flow cytometry and tested with Kruskal -Wallis, followed by Dunn’s 
post hoc test and Bonferroni correction. Filled symbols represent female mice of 
both strains (a) and open symbols represent male mice (b). Each symbol 
represents an individual mouse and a median bar is shown.  
n = 5-10 and at least 2 repetitions for each group . 
* p < 0.05; ** p < 0.01 and *** p < 0.001  
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Figure 3.14 Frequency of IL-10-producing B cells stimulated with CpG.  
Spleens from male and female NOD and B6
g7
 mice were collected, erythrocytes 
were lysed and removed and spleen cells were cultured for 24h with CpG; PMA, 
ionomycin and monensin were added for the last 3 hours and then cells were 
stained for extracellular markers and intracellular IL -10. Samples were examined 
by flow cytometry and tested with Kruskal -Wallis, followed by Dunn’s post hoc 
test and Bonferroni correction. Filled symbols represent female mice of both 
strains (a) and open symbols represent male mice (b). Each symbol represents an 
individual mouse and a median bar is shown.  
n = 5-10 and at least 2 repetitions for each group . 
* p < 0.05; ** p < 0.01 and *** p < 0.001  
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Figure 3.15 Frequency of IL-10-producing B cells stimulated with anti-CD40 
and CpG. Spleens from male and female NOD and B6
g7
 mice were collected, 
erythrocytes were lysed and removed and spleen cells were cultured for 24h with 
anti-CD40 and CpG; PMA, ionomycin and monensin were added for the last 3 
hours and then cells were stained for extracellular markers and intracellular IL-
10. Samples were examined by flow cytometry and tested with Kruskal -Wallis, 
followed by Dunn’s post hoc test and Bonferroni correction. Filled symbols 
represent female mice of both strains (a) and open symbols rep resent male mice 
(b). Each symbol represents an individual mouse and a median bar is shown.  
n = 5-10 and at least 2 repetitions for each group . 
* p < 0.05; ** p < 0.01 and *** p < 0.001   
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3.2.3.6 Summary 
In summary, B cells responded differently to various stimulants and showed an age 
variation, associated with strain and whether they developed diabetes or not. While B 
cells from both male and female B6
g7
 mice had a decreasing frequency of IL-10-
producing B cells over time, the B cells from NOD mice had the opposite trend and 
showed higher percentages of CD19
+
IL-10
+
 cells in protected mice. The diabetic NOD 
mouse group comprised female NOD mice with an age-range that varied between 11.9 
and 31 weeks old. Therefore, if female NOD mouse results are analysed without the 
protected groups, they follow the trend seen in B6
g7
 mice. The results suggested that 
protected NOD mice had a clear increase in frequency of IL-10-producing B cells, 
which may contribute to the protection against diabetes. 
The expression of regulatory markers on these IL-10-producing B cells will be 
discussed in the next section.  
 
 
3.3 Expression of regulatory B cell subpopulation markers in the IL-10-producing 
B cells  
Considering the results for the production of IL-10 by B cells and the differences 
observed between diabetic, 30-35 w.o. NOD and B6
g7
 mice, we decided to focus on 
these groups to study the cell-surface markers associated with the IL-10-producing B 
cells.   
There were two possible gating strategies to analyse the frequency of IL-10-producing 
Breg subpopulations: 1) Gating the putative regulatory subpopulations, using cell 
surface markers previously identified to be expressed in Bregs, in the whole CD19
+
 B 
cell population and then gate the positive cells for the cytokine of interest in this 
population. However, as discussed previously, the subpopulations needed to be divided 
into 3 different panels. As B cells could express all the surface markers concomitantly, 
this division would represent a misleading result. Therefore, the strategy adopted was 2) 
Gating the IL-10-producing cells within the total B cells (results shown in section 3.2.3) 
and then study how each of the regulatory markers were expressed in these B cells. 
Examples of both gating strategies are illustrated in Figure 3.16. 
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Thus, the following graphs represent the percentage of the markers CD21
+
CD23
+
 
(transitional cells), CD21
+
CD23
-
 (marginal zone), CD1d
hi
CD5
+
 and CD24
hi
CD38
hi
, 
taking the percentage of CD19
+
IL-10
+
 cells of each group as 100%.  
 
 
Figure 3.16 Example of the two possible flow cytometric gating strategies for 
the cytokine-producing regulatory B cell subpopulation analysis. Spleens from 
NOD and B6
g7
 mice were collected, erythrocytes were lysed, cells were counted 
and left in culture with or without stimulants fo r 24h. Surface markers and 
intracellular cytokines were examined by flow cytometry. For every sample, 
30,000 CD19
+
 cells were acquired. In the first strategy, the three putative 
regulatory subsets (CD1d
hi
CD5
+
 in (a); CD21 and CD23 in (b) and CD24
hi
CD38
hi
 
in (c)) were gated first and then, the frequency of IL -10-producing B cells was 
analysed. In the second strategy (d), chosen for this thesis, the IL -10-producing B 
cells were gated first and the expression of regulatory surface markers in these 
cells was analysed subsequently. In both cases, the markers are not all in the same 
panel, but they are not exclusive. Gates were set, based on FMOs and isotype 
controls – Figure A1, in the appendix.  
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3.3.1 Regulatory markers in unstimulated IL-10–producing B cells 
When B cells were unstimulated, there were no differences in the T2 phenotype markers 
(CD21
hi
CD23
hi
 – Figures 3.17a and b) in CD19+IL-10+ cells between the 3 groups. 
There were also no statistically significant differences observed between the groups in 
female or male mice. For IL-10-producing B cells expressing the Marginal zone 
phenotype (CD21
hi
CD23
-
 – Figures 3.17c and d), the same pattern was observed. 
When the expression of CD1d
hi
CD5
+
 was examined in unstimulated IL-10-producing B 
cells, statistically significant strain differences were observed in both female (p < 0.05 – 
Figure 3.17e) and male mice (p < 0.001 – Figure 3.17f). The strain difference was also 
observed for the expression of CD24
hi
CD38
hi
; however the CD24
hi
CD38
hi
 population 
was only higher in NOD male mice, when compared to B6g7 mice (Figures 3.17g and 
h). The frequencies of CD1d
hi
CD5
+ 
and CD24
hi
CD38
hi
 increased in diabetic mice, 
compared with protected NOD mice, but the difference was not statistically significant. 
 
3.3.2 Regulatory markers in IL-10–producing B cells stimulated with LPS 
Compared to unstimulated cells, IL-10-producing B cells stimulated with LPS had an 
increase in the expression of regulatory markers. 
Although there was no significant difference, it is interesting to note that, for this 
stimulant, the expression of T2 markers was higher in 30-35 w.o. B6
g7
 mice, compared 
to NOD mice (mainly in male mice – Figures 3.18a and b). Nevertheless, the expression 
of marginal zone markers was still higher (though not significant) in NOD mice. The 
percentage of CD19
+
IL-10
+
 cells from diabetic mice expressing CD21
hi
CD23
- 
was even 
higher. This could suggest that IL-10 is being produced by different populations of B 
cells depending on the strain (Figures 3.18c and d). 
As described previously in the literature (Yanaba et al. 2008), the majority of the B cells 
stimulated with LPS and producing IL-10 expressed CD1d
hi
CD5
+
, as illustrated in 
Figures 3.18e and f. The expression was higher in NOD mice, when compared to B6
g7
 
mice. This difference was statistically significant in male mice (p < 0.05). 
When stimulated with LPS, more than 80% of the B cells producing IL-10 expressed 
CD24
hi
CD38
hi
 in all strains and genders and there was no significant difference between 
the groups (Figures 3.18g and h). 
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3.3.3 Regulatory markers in IL-10–producing B cells stimulated with anti-CD40 
When B cells were stimulated with anti-CD40, there was an upregulation of the surface 
markers CD21
hi
CD23
hi
 and it was independent of the gender or strain being analysed. 
As a counterbalance to this upregulation, the expression of MZ phenotype in B cells 
producing IL-10 was very low (Figures 3.19a-d). This observation could suggest a 
downregulation or upregulation of markers dependent on stimulation and/or that IL-10 
production varies on B cell subpopulations depending on the stimulant used. 
Despite the difference in T2 and MZ markers, the expression of CD1d
hi
CD5
+
 in cells 
stimulated with anti-CD40 was still higher than 50% in all the groups (Figures 3.19e 
and f). Male NOD mice had a statistically higher percentage of IL-10-producing B cells 
expressing CD1d
hi
CD5
+
, in comparison to B6
g7
 mice (p <0.05). 
As observed in Figures 3.19g and h, the expression of CD24
hi
CD38
hi
 in CD19
+
IL-10
+
 
cells stimulated with anti-CD40 was strikingly higher in NOD mice, compared to B6
g7
 
mice; however, there were no statistically significant differences. As observed for LPS-
stimulated cells, the anti-CD40 stimulated cells from diabetic mice expressed more 
putative regulatory markers than protected mice. 
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Figure 3.17 Frequency of regulatory markers expression in unstimulated IL-
10-producing B cells. Spleens from 30-35 w.o. male and female NOD and B6
g7
 
mice, as well as diabetic female NOD mice,  were collected, erythrocytes were 
lysed and removed and spleen cells were cultured for 24h with no stimulant 
added; PMA, ionomycin and monensin were added for the last 3 hours and then 
cells were stained for extracellular markers and intracellular cytokin es. Samples 
were examined by flow cytometry and tested with Kruskal -Wallis, followed by 
Dunn’s post hoc test and Bonferroni correction. Filled symbols represent female 
mice of both strains and open symbols represent male mice. Frequency of 
CD21
hi
CD23
hi
 expression in CD19
+
IL-10
+
 cells is shown in (a) female mice and in 
(b) male mice; frequency of CD21
hi
CD23
-
 expression in CD19
+
IL-10
+
 cells is 
shown in (c) female mice and in (d) male mice ; the frequency of CD1d
hi
CD5
+
 
expression in CD19
+
IL-10
+
 cells is shown in (e) female mice and in (f) male mice 
and, lastly, frequency of CD24
hi
CD38
hi
 expression in CD19
+
IL-10
+
 cells is shown 
in (g) female mice and in (h) male mice. Each symbol represents an individual 
mouse and a median bar is shown.  
n = 5-10 and at least 2 repetitions for each group. * p < 0.05; ** p < 0.01 and *** 
p < 0.001   
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Figure 3.18 Frequency of regulatory markers expression in IL-10-producing B 
cells stimulated with LPS. Spleens from 30-35 w.o. male and female NOD and 
B6
g7
 mice, as well as diabetic female NOD mice, were collected, erythrocytes 
were lysed and removed and spleen cells were cultured for 24h with LPS; PMA, 
ionomycin and monensin were added for the last 3 hours and then cells were 
stained for extracellular markers and intracellular cytokin es. Samples were 
examined by flow cytometry and tested with Kruskal -Wallis, followed by Dunn’s 
post hoc test and Bonferroni correction. Filled symbols represent female mice of 
both strains and open symbols represent male mice. Frequency of CD21
hi
CD23
hi
 
expression in CD19
+
IL-10
+
 cells is shown in (a) female mice and in (b) male 
mice; frequency of CD21
hi
CD23
-
 expression in CD19
+
IL-10
+
 cells is shown in (c) 
female mice and in (d) male mice; the frequency of CD1d
hi
CD5
+
 expression in 
CD19
+
IL-10
+
 cells is shown in (e) female mice and in (f) male mice and, lastly, 
frequency of CD24
hi
CD38
hi
 expression in CD19
+
IL-10
+
 cells is shown in (g) 
female mice and in (h) male mice. Each symbol represents an individual mouse 
and a median bar is shown.  
n = 5-10 and at least 2 repetitions for each group. * p < 0.05; ** p < 0.01 and *** 
p < 0.001  
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Figure 3.19 Frequency of regulatory markers expression in IL-10-producing B 
cells stimulated with anti-CD40. Spleens from 30-35 w.o. male and female NOD 
and B6
g7
 mice, as well as diabetic female NOD mice, were collected, erythrocytes 
were lysed and removed and spleen cells were cultured for 24h with anti-CD40; 
PMA, ionomycin and monensin were added for the last 3 hours and then cells 
were stained for extracellular markers and intracellular cytokines. Samples were 
examined by flow cytometry and tested with Kruskal -Wallis, followed by Dunn’s 
post hoc test and Bonferroni correction . Filled symbols represent female mice of 
both strains and open symbols represent male mice. Frequency of CD21
hi
CD23
hi
 
expression in CD19
+
IL-10
+
 cells is shown in (a) female mice and in (b) male 
mice; frequency of CD21
hi
CD23
-
 expression in CD19
+
IL-10
+
 cells is shown in (c) 
female mice and in (d) male mice; the frequency of CD1d
hi
CD5
+
 expression in 
CD19
+
IL-10
+
 cells is shown in (e) female mice and in (f) male mice and, lastly, 
frequency of CD24
hi
CD38
hi
 expression in CD19
+
IL-10
+
 cells is shown in (g) 
female mice and in (h) male mice. Each symbol represents an individual mouse 
and a median bar is shown.  
n = 5-10 and at least 2 repetitions for each group. * p < 0.05; ** p < 0.01 and *** 
p < 0.001 
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3.3.4 Regulatory markers in IL-10–producing B cells stimulated with CpG 
As observed with LPS-stimulated B cells, when stimulated with CpG, the frequency of 
CD19
+
IL-10
+
 cells expressing the T2 phenotype was higher in B6
g7
 mice (however the 
difference was not statistically significant – Figures 3.20a and b). The expression of 
CD21
hi
CD23
-
, CD1d
hi
CD5
+
 and CD24
hi
CD38
hi 
on IL-10-producing B cells stimulated 
with CpG was similar between 30-35 w.o. NOD and B6
g7
 mice, from both genders 
(Figures 3.20c-h). Diabetic mice expressed the highest frequencies of regulatory 
markers (non-significant - ns). 
 
3.3.5 Regulatory markers in IL-10–producing B cells stimulated with anti-CD40/ 
CpG 
The combination of anti-CD40 and CpG did not show a synergistic effect for the 
expression of regulatory markers and the frequencies were very similar to the cells 
stimulated with CpG only. The expression of regulatory markers on IL-10-producing B 
cells was not as high as in LPS-stimulated B cells and was heterogeneous between the 
individual mice. 
The expression of the T2 phenotype (CD21
hi
CD23
hi
 – Figures 3.21a and b) in IL-10-
producing B cells was higher in B6
g7
 mice (ns). The expression of MZ phenotype 
markers and CD1d
hi
CD5
+
, on the other hand, was similar in all groups, with non-
significant higher frequencies in NOD mice (Figures 3.21c-f).  
The expression of CD24
hi
CD38
hi
 on IL-10-producing B cells stimulated with anti-CD40 
and CpG was significantly higher in diabetic mice, when compared to 30-35 w.o. mice 
(p < 0.05 – Figure 3.20g). 
 
3.3.6 Summary 
Although there was a statistically significant difference between protected and diabetic 
NOD mice in the percentage of total B cells producing IL-10, the expression of 
regulatory markers on these cells was generally very similar in both groups, with a non-
significant upregulation in diabetic mice. NOD mice, both male and female, had overall 
higher frequencies of regulatory markers when compared to B6
g7
 mice. Different 
86 
 
stimulants stimulated different phenotypes of IL-10-producing B cells (LPS stimulated 
MZ B cells and anti-CD40 stimulated T2 B cells). 
 
Figure 3.20 Frequency of regulatory markers expression in IL-10-producing B 
cells stimulated with CpG.  Spleens from 30-35 w.o. male and female NOD and 
B6
g7
 mice, as well as diabetic female NOD mice,  were collected, erythrocytes 
were lysed and removed and spleen cells were cultured for 24h with CpG; PMA, 
ionomycin and monensin were added for the last 3 hours and then cells were 
stained for extracellular markers and intracellular cytokines. Samples were 
examined by flow cytometry and tested with Kruskal -Wallis, followed by Dunn’s 
post hoc test and Bonferroni correction. Filled symbols represent female mice of 
both strains and open symbols represent male mice. Frequency of CD21
hi
CD23
hi
 
expression in CD19
+
IL-10
+
 cells is shown in (a) female mice and in (b) male 
mice; frequency of CD21
hi
CD23
-
 expression in CD19
+
IL-10
+
 cells is shown in (c) 
female mice and in (d) male mice; the frequency of CD1d
hi
CD5
+
 expression in 
CD19
+
IL-10
+
 cells is shown in (e) female mice and in (f) male mice and, lastly, 
frequency of CD24
hi
CD38
hi
 expression in CD19
+
IL-10
+
 cells is shown in (g) 
female mice and in (h) male mice. Each symbol represents an individual mouse 
and a median bar is shown. n = 5-10 and at least 2 repetitions for each group . 
* p < 0.05; ** p < 0.01 and *** p < 0.001  
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Figure 3.21 Frequency of regulatory markers expression in IL-10-producing B 
cells stimulated with anti-CD40 and CpG. Spleens from 30-35 w.o. male and 
female NOD and B6
g7
 mice, as well as diabetic female NOD mice,  were collected, 
erythrocytes were lysed and removed and spleen cells were cultured for 24h with 
anti-CD40 and CpG; PMA, ionomycin and monensin were added for the last 3 
hours and then cells were stained for extracellular markers and intracellular 
cytokines. Samples were examined by flow cytometry and tested with Kruskal-
Wallis, followed by Dunn’s post hoc test and Bonferroni correction. Filled 
symbols represent female mice of both strains and open symbols represent male 
mice. Frequency of CD21
hi
CD23
hi
 expression in CD19
+
IL-10
+
 cells is shown in (a) 
female mice and in (b) male mice; frequency of CD21
hi
CD23
-
 expression in 
CD19
+
IL-10
+
 cells is shown in (c) female mice and in (d) male mice ; the 
frequency of CD1d
hi
CD5
+
 expression in CD19
+
IL-10
+
 cells is shown in (e) female 
mice and in (f) male mice and, lastly, frequency of CD24
hi
CD38
hi
 expression in 
CD19
+
IL-10
+
 cells is shown in (g) female mice and in (h) male mice. Each symbol 
represents an individual mouse and a median bar is shown.  
n = 5-10 and at least 2 repetitions for each group . 
* p < 0.05; ** p < 0.01 and *** p < 0.001 
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3.4 Discussion 
For a long time it was believed that the role of B cells was restricted to pathogenic 
effects in type 1 diabetes. However, although not new, the concept of regulatory B cells 
(Bregs) has previously been studied mainly in other autoimmune diseases, such as 
arthritis (Mauri et al. 2003), Systemic Lupus Erythematosus – SLE (Blair et al. 2009) 
and Experimental Autoimmune Encephalomyelitis – EAE (Fillatreau et al. 2002), but 
not in great detail in type 1 diabetes. Therefore, our aim in this investigation was to 
characterize cytokine-producing B cells and the expression of regulatory markers in 
NOD mice, compared with a non-diabetes-prone congenic strain, the B6
g7
 mice. 
The first cytokine evaluated was IL-6, a pro-inflammatory cytokine. We observed that 
unstimulated, LPS- and anti-CD40-stimulated spleen B cells do not produce IL-6, which 
supports the idea of these stimulants (alone) shifting B cells to a regulatory profile. On 
the other hand, the combination of CpG and anti-CD40 increased the frequency of 
CD19
+
IL-6
+
 cells in comparison to CPG and anti-CD40 alone and the effect was 
synergistic. 
A study that determined the role of IL-6 produced by B cells in EAE supports our 
findings. In their investigation, spleen cells stimulated with anti-CD40 combined with 
CpG produced more IL-6 than cells stimulated with LPS or anti-CD40 or CpG alone 
(Barr et al. 2012). The study also showed that the combination of LPS and anti-CD40 
produced the same effect as CpG and anti-CD40, proving to be a result of dual 
stimulation of different types of receptors. A study in humans demonstrated that 
stimulating B cells with CpG upregulates the expression of CD40. They also observed 
the synergistic effect of combining CpG and a CD40-CD40L stimulation in B cells, 
with increased expression of IL-6 and IL-10, although IL-6 production occurred faster 
than IL-10 (Gantner et al. 2003). This could suggest that even if anti-CD40 by itself 
does not stimulate the cells to produce IL-6, it could bring B cells to a state of activation 
where the effect of CpG stimulation is optimised, as a second signal. The mechanism, 
however, is still unclear. 
We then moved on to the regulatory cytokines, starting with TGF-β. Although TGF-β-
producing B cells have not been studied as much as IL-10-producing B cells, the role of 
this cytokine in type 1 diabetes, in lymphoid organs and inside the islet, has been 
broadly discussed in the literature (Peng et al. 2004; Tai et al. 2013). 
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Our results show that the frequencies of CD19
+
TGF-β+ cells were more heterogeneous 
than observed for IL-10 and the main finding was the increased frequency of TGF-β-
producing B cells associated with age. 
As discussed in the introduction to this chapter, Tian and colleagues studied the relation 
between TGF-β production by B cells and NOD mice. According to their studies, B 
cells from young mice stimulated with LPS express more FasL and release TGF-β, and 
this induces apoptosis in diabetogenic T cells. Also in concordance with our results, 
they showed that unstimulated B cells do not produce TGF-β (Tian et al. 2001). Our 
results, however, show that diabetic mice have a similar percentage of CD19
+
TGF-β+ 
cells when compared to protected mice; this may bring into question the importance of 
TGF-β produced by B cells as contributing to natural protection against autoimmune 
diabetes. Nevertheless as protected mice have more B cells producing IL-10, B cells 
that produce TGF-β could be relevant in synergy. Another point to be made and 
possibly investigated in the future is whether effector cells in protected NOD mice are 
as resistant to regulation as in younger NOD mice (D'Alise et al. 2008). If they are not 
as resistant, the same percentage of TGF-β-producing B cells would be able to regulate 
the system more efficiently. 
Lastly, we evaluated IL-10, a major factor determining regulatory B cell function. Our 
main findings were 1) Increased baseline frequency in IL-10-producing B cells in 
protected NOD mice in comparison to diabetic mice; 2) Different stimulants affect the 
production of IL-10 in diabetic NOD mice. Upon LPS and CpG stimulation, B cells 
from diabetic mice produced IL-10, but not after anti-CD40 stimulation; 3) NOD mice 
in general had higher frequencies of CD19
+
IL-10
+
 cells when compared to B6
g7
 mice 
and 4) The expression of regulatory markers was non-significantly higher in diabetic 
mice, when compared to protected mice, although both groups had higher frequencies of 
these B cells than B6
g7
 mice. 
There are not many studies in the literature aiming to investigate >35 week old 
protected NOD mice and the regulatory role of B cells. Kleffel and colleagues compared 
these older mice to young and hyperglycaemic NOD mice. In the pancreatic islets, 
similar to young (4 weeks old) mice, they found that protected mice had preserved 
insulin production and reduced insulitis in comparison to diabetic mice. Moreover, it 
was observed that, compared to other groups, protected NOD mice (denominated Long-
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term Normoglycaemic mice in the paper) had a higher frequency of IL-10
+
 B cells 
infiltrating the pancreatic islets. Similar to our investigation, they also examined the 
production of IL-10 by spleen B cells over time and observed a higher percentage of IL-
10
+
 B cells in young mice, although it was non-significant, and they found no difference 
between diabetic and protected mice. The discrepancy between their and our results 
could be due to differences in the cell stimulation methods. Here, the stimulants were 
added for 24h, with a 3h boost of PMA, ionomycin and monensin, while in their paper, 
they added PMA, ionomycin and monensin for 5h, which is comparable only to our 
unstimulated cell cultures (Kleffel et al. 2014). 
Although IL-10-producing B cells from diabetic mice were capable of responding to 
LPS stimulation, the frequency of CD19
+
IL-10
+
 cells was higher in older, protected 
female NOD mice. Diabetic mouse splenocytes presented an interesting variation in the 
frequency of CD19
+
IL10
+
 cells depending on the stimulant. Unstimulated and anti-
CD40 stimulation did not increase the percentage of B cells producing IL-10. Mion and 
colleagues observed that, in C57BL/6 mice, B cells stimulated with anti-CD40 antibody 
took longer to produce IL-10 than cells stimulated with LPS and CpG. This was thought 
to be due to anti-CD40 mimicking a cellular interaction compared to stimulation by 
exogenous stimulants (Mion et al. 2014). That does not explain, however, why diabetic 
mice are less responsive when stimulated with anti-CD40 than other mice. One possible 
explanation for this could be the downregulation of CD40 receptors on the surface of B 
cells from diabetic mice. A study using chimeric mice, where the B cells were CD40-/-, 
resulted in the mice having non-remitting severe EAE when compared to control mice, 
supporting the idea of an association between autoimmune disease and the lack of CD40 
receptors (Fillatreau et al. 2002). However, to confirm this hypothesis, a study focusing 
on expression of CD40 on B cells in NOD mice during aging and after diabetes onset 
would be necessary. Another study in patients with SLE demonstrated that 
CD19
+
CD24
hi
CD38
hi
 B cells, a key human Breg population, derived from peripheral 
blood were refractory to CD40 stimulation and would not produce IL-10, as opposed to 
B cells collected from healthy donors. This difference, however, was not related to the 
expression of CD40 receptors, but to the STAT3 signalling pathway that is activated 
when CD40-CD40L bind and is impaired in Breg cells from SLE patients (Blair et al. 
2010). These observations could suggest an association between the B cell 
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unresponsiveness to CD40 stimulation and autoimmune diabetes in NOD mice and 
needs further investigation.  
The expression of CD1d
hi
CD5
+
 in IL-10-producing B cells of diabetic mice was not 
significantly higher, when compared to protected NOD mice and B6
g7
 mice; these 
results were seen independent of the stimulant. The study by Mizoguchi and colleagues 
demonstrated an increase in the expression of CD1d and IgM in a model of intestinal 
inflammation. Increased expression was shown in the MLNs of diseased mice when 
compared to wild-type mice (mice that do not have the knock out gene and, therefore, 
are not prone to develop the intestinal inflammation) and healthy mice prone to 
development of the disease. However, in agreement with our findings, they did not 
observe statistically significant differences in the spleen (Mizoguchi et al. 2002). 
The higher frequency of IL-10 producing B cells in NOD compared to B6
g7 
mice, when 
spleen cells were stimulated with LPS, was also described by Yanaba and colleagues. 
They demonstrated that NOD mice and a lupus-prone strain had higher frequencies of 
CD1d
hi
CD5
+
 and IL-10-producing B cells, when compared to B6 mice (Yanaba et al. 
2009). Our results for the expression of regulatory markers in IL-10-producing B cells 
also showed that more than 50% of CD19
+
IL-10
+
 cells from NOD mice expressed 
CD1d
hi
CD5
+
, when cells were unstimulated or stimulated with LPS, anti-CD40 alone or 
CpG alone. It was higher than 40% for cells stimulated with anti-CD40 and CpG 
together. For B6
g7
 mice, the percentages varied more depending on the stimulant: LPS 
was best able to upregulate these markers, but the percentages were always lower than 
in NOD mice. 
This observation could be explained by a higher frequency of CD1d
hi
 B cells, the 
subpopulation believed to comprise the regulatory B cells, and marginal zone B cells in 
NOD mice when compared to C57BL/6 mice (Rolf et al. 2005). Mariño and colleagues 
demonstrated that the number of cells in the marginal zone increased with time (and, 
hence, with the development of insulitis) in female NOD mice.  They also revealed the 
mechanism for this finding: marginal zone B cells from NOD mice have more S1P3 
receptors and, therefore, are hyperresponsive to the chemokine (S1P) responsible for 
retention of cells in the marginal zone in the spleen (Marino et al. 2008).  
Although CD1d
hi
 cells are mainly concentrated in marginal zone, we also investigated 
the transitional B cells (T2), following previous studies in the literature (Evans et al. 
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2007). Blair and colleagues investigated regulatory B cells in a murine model for lupus 
erythematous and demonstrated that anti-CD40 amplified the production of IL-10 by 
purified T2-like B cells, in comparison to LPS and CpG. These two stimulants, when 
investigated in the whole B cell population, stimulated IL-10 production in marginal 
zone and T2-like B cells (not as abundant as anti-CD40) in the same proportion (Blair et 
al. 2009). Indeed our results showed that cytokine-producing B cells stimulated with 
anti-CD40 expressed the T2 phenotype in a higher proportion. However, when the 
stimulants had a bacterial origin (LPS and CpG), B cells from NOD mice producing the 
cytokines analysed had higher frequencies of CD21
+
CD23
-
, the marginal zone markers. 
These findings raise questions about the real location of regulatory B cells in the spleen 
in vivo, before the tissue is disrupted and stimulants are added for cell culture. A 
histological study identifying IL-10 producing B cells in situ in the spleen of NOD mice 
would have to be conducted to clarify this matter. Nevertheless, the stimulation to 
induce regulatory B cells might be necessary and negative results should be analysed 
very carefully. 
In summary, this was the first time differences between the frequency of CD19
+
IL-10
+
 
spleen cells upon stimulation with LPS, anti-CD40 and CpG were demonstrated in 
protected and diabetic NOD mice.  Functional experiments to analyse the regulatory 
effect of B cells from >35 week old protected NOD mice when cultured with dendritic 
cells and CD8 T cells from G9Cα-/-.NOD mice are described in chapter 4. 
Although there were interesting findings, our studies were limited by the number of 
fluorochromes that could be analysed simultaneously in the flow cytometer available at 
the time of this study. IL-10 production is associated with a number of B cell 
phenotypes as delineated by cell surface markers. The analysis of all these surface 
markers together on these putative regulatory cells would facilitate our understanding of 
the regulatory B cells in NOD mice as a whole and answer some questions, which 
include: How many regulatory B cell phenotypes exist? How do the stimulants modify 
these phenotypes?  
In conclusion, this chapter highlighted the differences in cytokine production, mainly 
regulatory cytokines, and the expression of regulatory markers related to type 1 
diabetes, age of NOD mice and the stimulants used to trigger this production. The main 
result was that 30-35 week old protected female NOD mice had a higher frequency of 
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IL-10-producing B cells when compared to diabetic mice. An examination of whether 
the cells have in vitro protective effects will be examined in Chapter 4. 
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4. Effect of B cells on the interaction between antigen-specific CD8 T 
cells and dendritic cells 
 
4.1 Introduction and Objectives 
 
4.1.1 Introduction 
After analysing the results in chapter 3 and observing the increased percentage of IL-10-
producing B cells in protected NOD mice, the next step was to carry out functional 
experiments to test whether B cells from these mice were better at suppressing immune 
responses. 
The regulatory function of B cells could have been assessed in many different assays, 
aiming to understand their effects on various types of cells. The cooperative effects of 
CD4 T cells and B cells are well known. However, for our first experiments, we chose 
to investigate the effect of B cells on the activation of insulin-specific CD8 T cells, 
derived from a transgenic NOD mice (G9Cα -/-) developed by Professor Susan Wong 
(Wong et al. 2009). These experiments were to test not only direct effects on CD8 T 
cells but also effects through dendritic cells (DCs) as antigen presenting cells. 
The importance of CD8 T cells in type 1 diabetes is now well-documented. An early 
study highlighted the observation that knockout NOD mice lacking β2-microglobulin 
(essential component of the MHC I molecule) were not able to activate cytotoxic T cells 
and did not develop disease (Serreze et al. 1994). 
The study of islet antigen-specific CD8 T cells have given further clues for the role of 
these T cells on the onset of the disease: CD8 T cells with TCR specificity for a peptide 
of the β-chain of insulin (B:15-23) are found in the islets of NOD mice as early as 4 
weeks after birth. IFN-γ producing CD8 T cells are essential for the inflammation 
observed in pancreatic islets of NOD mice and the damage caused by them might “open 
the door” for other lymphocytes, with specificity for other islet antigens (Wong et al. 
1996; Wong et al. 1999). CD8 T cells recognising the autoantigen islet-specific glucose-
6-phosphatase catalytic subunit related protein (IGRP) have also been shown to play an 
important role (Nagata et al. 1994; Verdaguer et al. 1997; Lieberman et al. 2003). 
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Although initially associated with the priming of CD4 T cells, DCs are essential for 
cross-presentation of antigens to CD8 T cells (Joffre et al. 2012). This is important for 
the presentation of tissue-associated antigens to CD8 T cells via MHC class I (Kurts et 
al. 1996). DCs play a role in the activation of antigen-specific CD8 T cells to cause type 
1 diabetes: Professional antigen presenting cells presenting antigens to CD8 T cells via 
MHC I, rather than direct presentation of islet specific antigens by beta cells, has been 
shown to be essential for invasive infiltration of pancreatic islets (de Jersey et al. 2007).  
As discussed in chapter 1, CD8 T cells have been shown to interact with B cells in type 
1 diabetes. B cells contribute to disease by providing the signals for CD8 T cell 
survival, especially in late islet infiltration (Brodie et al. 2008). B cells can also cross-
present autoantigens to CD8 T cells, via MHC class I, which was demonstrated by 
studying NOD mice lacking B cells (NOD.μMT) or B cells from transgenic β2m-/- NOD 
mice (not expressing MHC I). In these mice, IGRP-CD8 T cells were not able to 
proliferate in the PLNs and diabetes was prevented (Marino et al. 2012). On the other 
hand, in the lymphoid organs, a regulatory effect of B cells on CD8 T cells was also 
described by Parekh and colleagues. When stimulated with LPS, B cells induced anergy 
in CD8 T cells in a membrane bound TGF-β1-dependent way (Parekh et al. 2003). 
B cells and dendritic cells are also known to interact. B cells suppress dendritic cell IL-
12 production in response to a number of different types of stimulation.  For example, B 
cells activated to produce IL-10 by Leishmania major infection induced suppression of 
IL-12 production by DCs (Ronet et al. 2010). This mechanism of action has also been 
demonstrated by CpG-activated neonatal B cells, which were able to suppress IL-12 
production by neonatal dendritic cells (Sun et al. 2005). Regulatory effects of B cells on 
DCs were described previously in the autoimmune model of multiple sclerosis EAE. In 
this model, when DCs were co-cultured with B10 cells (CD1d
hi
CD5
+
 B cells, producing 
IL-10) prior to interaction with antigen specific CD4 T cells, they were less efficient in 
inducing T cell proliferation, compared to DCs co-cultured with CD1d
low
CD5
-
 B cells 
or IL-10
-
/
-
 B cells (Matsushita et al. 2010). 
Thus, in the context of studying the role of regulatory B cells in a model of diabetes, we 
were interested in investigating B cell interactions with CD8 T cells, which could 
interact directly by cytokine production or cell-cell contact, but also indirectly, by 
modulating the dendritic cell function.  
96 
 
4.1.2 Objectives 
Based on previous findings from chapter 3 and the studies described above, we aimed to 
study how B cells from older NOD and B6
g7
 mice (> 35 w.o.) and diabetic NOD mice 
may affect the activation of CD8 T cells (specific for an insulin peptide) by DCs. Our 
hypothesis was that B cells from protected NOD mice could potentially have more 
accentuated regulatory properties and be more efficient than B cells from diabetic NOD 
mice or B6
g7
 mice in suppressing the cytotoxic function of CD8 T cells. 
 
4.2 Experimental Design 
To investigate the interaction between B cells, dendritic cells and CD8 T cells, a number 
of mouse strains were used. A diagram of the interactions studied and the timeline for 
the experimental set-up is shown in Figure 4.1. 
To make it possible to study interactions between B cells and dendritic cells in culture 
with CD8 T cells, without the addition of exogenous peptide in the cell culture, we 
utilized dendritic cells from transgenic mice that express proinsulin 2 (PI2) under the 
promoter of MHC class II I-E
k 
(French et al. 1997), here designated PI homo mice.  
DCs from 6-12 week-old PI homo mice (4 mice pooled for each experiment) were 
processed as described in the Methods chapter (section 2.4) and were activated with 
LPS one day before the set-up. 
B cells from the spleen of  > 35 weeks old NOD (protected) and B6
g7
 mice and diabetic 
NOD mice (3-4 mice pooled for each group) were magnetically separated, stimulated 
with LPS or left unstimulated for 24h prior to the set-up. In addition to LPS being the 
main stimulant used to generate regulatory B cells in the literature, the choice of LPS as 
the stimulant for the B cells was based on the results seen in chapter 3. 
We studied a number of CD8 T cell functions including activation, proliferation and 
degranulation as a surrogate measure of cytotoxicity, as well as cytokine production. 
CFSE was used to measure proliferation, CD69 was used as a marker for early 
activation and CD107a is found on the membrane of granzyme/perforin granules, and so 
measurement of CD107a gave an induction of degranulating cytotoxic CD8 T cells 
(Betts et al. 2003). In addition to the anti-inflammatory (IL-10) and inflammatory (IL-6, 
IFN-γ and TNF-α) cytokines, we also evaluated the production of MIP1-β. This 
97 
 
chemokine is secreted by various cells, like lymphocytes, macrophages and DCs and is 
responsible for the attraction of T cells to the site of inflammation (Maurer and von 
Stebut 2004). 
On day 0, insulin-specific CD8 T cells were collected from the spleen of 6-12 week-old 
G9Cα-/- mice and labelled with CFSE on the day of the set-up (methods described in 
section 2.7). Cells were added to the wells of a 24-well culture plate at a ratio of 1 CD8 
T cell : 2 DCs : 7 B cells, a proportion determined previously by titration. The total 
number of cells was: 2x10
5
 CD8 T cells : 4x10
5
 DCs : 1.4x10
6
 B cells. The 3 types of 
individual cells cultured alone and controls were set-up with wells containing CD8 T 
cells + DCs, but without B cells. One day after the set-up, half of the plates were 
harvested for the analysis of the expression of CD69 and CD107a by flow cytometry; 
from the remaining plates, supernatants were collected 2 days after the set-up (for 
multiplex cytokine assay). Finally, CFSE and CD69 were assessed by flow cytometry 3 
days after the set-up. Experiments were performed at least 3 times for all the groups. 
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Figure 4.1 Experimental design for chapter 4 – the effect of B cells, as 
bystanders, on the activation of CD8 T cells. To evaluate B cell potential to 
regulate responses, unstimulated and LPS-stimulated B cells were cultured with 
CD8 T cells and PI homo DCs (endogenously expressing PI2). These B cells were 
from NOD and B6
g7
 mice, older than 35 weeks of age and also diabetic NOD mice 
(hyperglycaemic mice aged between 12-30 w.o.). In this system, B cells would not 
act as APCs to the CD8 T cells, as there was no exogenous antigen present. The 
read-outs for CD8 T cells and B cells are listed. The experimental timeline was as 
following: Dendritic cells were prepared from the bone marrow of PI homo m ice 
on day -8 and were activated with LPS on day -1. Also on day -1, spleens from 
NOD or B6
g7
 mice were collected, processed, and the B cells were magnetically 
sorted and incubated for 24h with LPS or left unstimulated. On day 0, CD8 T cells 
from G9 mice were collected, processed, magnetically sorted, CFSE labelled and 
the three types of cells were incubated together. On day 1, cells were harvested 
for the analysis of CD107a and CD69 by flow cytometry. On day 2, supernatants 
were collected for cytokine mult iplex assay. Finally on day 3, cells were 
harvested for proliferation, determination of viable cells and CD69.   
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4.3 The effect of B cells as bystanders in the activation of CD8 T cells by DCs 
 
4.3.1 Proliferation, viable CD8 T cells and activation  
To evaluate the effect of B cells on the activation of insulin-specific CD8 T cells, we 
analysed T cell proliferation, percentage of viable cells and activation (1 and 3 days 
after set-up). 
Proliferation was determined by CFSE labelling 72h after the set-up (Day 0) and the 
gating strategy is explained in Figure 4.2a. Because the experiments were repeated at 
least 3 times and the staining for CFSE may vary, data shown in Figure 4.3a was 
normalized: Wells where B cells were not added (DCs and CD8 T cells only – a 
positive control) were taken as 100% for each experiment (represented by the dashed 
line in the graph). The percentages represent the increase or decrease from this control 
parameter, with the addition of unstimulated or LPS-stimulated B cells. 
In all groups, the addition of unstimulated B cells to CD8 T cells + DCs led to T cell 
proliferation similar to or more than the proliferation seen in the control, implying they 
did not affect proliferation. However, when LPS-stimulated B cells were added to the 
system, the percentage of proliferation decreased from the control level in all groups. 
This difference was statistically significant when stimulated B cells were derived from 
NOD mice (protected and diabetic – p < 0.01 and p <0.05, respectively), but was not as 
remarkable with B6
g7
 B cells. 
It is important to note that the analysis of proliferation as the percentage of dividing 
cells (decreasing signal for CFSE), as shown in this chapter, is incomplete and does not 
discriminate the nature of the dividing cells. It is not possible to determine, for example, 
if it is a case of few CD8 T cells dividing many times or many CD8 T cells dividing 
less. To complement the data shown here, an index of division should be performed and 
the graphs should be represented as histograms. 
To evaluate whether this decreased proliferation was due to cell death, the percentage of 
live T cells was analysed. The gating strategy here was different (Figure 4.2b), to focus 
on the percentage of viable CD8 T cells, 72h after the set-up. Compared to the 
percentage of live T cells in the control well (black bar), the addition of unstimulated B 
cells or LPS-stimulated B cells from B6
g7
 mice did not cause more CD8 T cell death. 
However, when activated B cells from NOD mice (protected and diabetic) were added 
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to the system, the percentage of viable T cells significantly decreased, compared to the 
system containing unstimulated NOD B cells, as illustrated in Figure 4.3b.  
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Figure 4.2 Example of the gating of flow cytometric plots used for the 
determination of CD8 T cell proliferation (CFSE), activation (CD69), 
degranulation (CD107a) and percentage of live CD8 T cells . After one week of 
culture, bone marrow DCs of PI homo mice were sti mulated with LPS for 18h. 
Splenic B cells purified from NOD or B6
g7
 mice were stimulated with LPS for 24h 
or left unstimulated. Splenic CD8 T cells (from G9 mice) were purified on the day 
of the set-up of the experiment and then labelled with CFSE for the evaluation of 
CD8 T cell proliferation. The experimental procedure was as follows: 2x10
5
 CD8 
T cells, 4x10
5
 stimulated DCs and 1.4x10
6
 stimulated or unstimulated B cells were 
added to each well. After 24h and 72h of incubation, cells were harvested for 
antibody-staining and flow cytometric analysis. One example of the gating 
strategy for these experiments is found in (a): Lymphocytes Single cells 
Exclusion of any CD4 T cells in the culture Viable cells  Exclusion of DCs 
(CD11b
-
CD11c
-
) Distinction between CD8 T cells and B cells (CD19). In the 
CD8 T cell pool, proliferation (CFSE dilution), activation (CD69
+
) and 
degranulation (CD107a
+
) were assessed. For the analysis of live CD8 T cells (b), 
the order of gating was Lymphocytes Single cells Exclusion of any CD4 T 
cells in the culture  Exclusion of DCs (CD11b -CD11c -)  Distinction between 
CD8 T cells and B cells (CD19)  Viable cells. 
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Figure 4.3 Decreased antigen-specific CD8 T cell proliferation and percentage 
of viable cells in the presence of LPS-stimulated NOD B cells.  After culture for 
one week, bone marrow DCs from PI homo mice were stimulated with LPS for 
18h. Splenic B cells from NOD or B6
g7
 mice were stimulated with LPS for 24h or 
left unstimulated. Splenic CD8 T cells (from G9 mice ) were purified on the day of 
the set-up of the experiment and labelled with CFSE for the evaluation of CD8 
proliferation (a). The experimental procedure was as follows: 2x10
5
 CD8 T cells, 
4x10
5
 stimulated DCs and 1.4x10
6
 stimulated or unstimulated B cells  were added 
to each well. After 72h of incubation, cultures were harvested for flow cytometric 
staining – Live cells were gated as described previously and the percentages are 
shown in (b). The data are represented as mean and standard error and were 
analysed by Two-way ANOVA. n=3-4 individual experiments, each experiment 
using pooled spleen cells from 3-4 mice. 
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The percentages of CD8 T cells expressing CD69 were analysed 24h (Figure 4.4a) and 
72h (Figure 4.4b) after the set-up. 
Twenty-four hours after the set-up, CD8 T cells cultured with DCs alone had the highest 
frequencies of CD69, followed closely by CD8 T cells cultured with DCs and 
unstimulated B cells from NOD mice. The other groups had lower percentages of 
CD8
+
CD69
+ 
T
 
cells. 
On the next time point, 72h after the set-up, most of the frequencies of CD8
+
CD69
+
 
cells had increased when compared to the results seen at 24h. T cells cultured with DCs 
alone still had the highest frequencies of CD69 expression, but the percentages 
increased to almost the same level when B cells from B6
g7
 mice were added. When 
LPS-stimulated B cells from NOD mice (protected and diabetic) were added to the 
system, the percentage of T cells expressing CD69 was the lowest and did not vary 
between the time points. 
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Figure 4.4 Activation of CD8 T cells cultured with B cells and DCs 
(percentage of CD8
+
CD69
+
 T cells). After culture for one week, bone marrow 
DCs from PI homo mice were stimulated with LPS for 18h. Splenic B cells from 
NOD or B6
g7
 mice were stimulated with LPS for 24h or left unstimulated. Splenic 
CD8 T cells (from G9 mice) were purified on the day of the set -up of the 
experiment and labelled with CFSE for the evaluation of CD8 proliferation. The 
experimental procedure was as follows: 2x10
5
 CD8 T cells, 4x10
5
 stimulated DCs 
and 1.4x10
6
 stimulated or unstimulated B cells were added to each culture. After 
24h (a) or 72h (b) of incubation, cultures were harvested for flow cytometric 
staining. The data are represented as mean and standa rd error and were analysed 
by Two-way ANOVA. n=3-4 individual experiments, each experiment using 
pooled spleen cells from 3-4 mice. 
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4.3.2 Markers of cytotoxicity (MIP1-β and CD107a) 
Although proliferation and activation of T cells are essential parameters to study, the 
most important read-outs for CD8 T cells are those involved with inflammation and 
cytotoxic function. Hence, we analysed the concentration of MIP1-β, a chemokine that 
attracts cells to the site of inflammation, in the supernatants, together with the 
expression of CD107a, marker of degranulation, on CD8 T cells. 
As illustrated in Figure 4.5a, all three types of cells (DCs, B and T cells) were able to 
secrete MIP1-β when cultured alone. Curiously, LPS-stimulated B cells from protected 
mice cultured alone secreted the highest concentration of this chemokine, followed by 
diabetic mice and then B6
g7
 mice. Adding CD8 T cells and DCs together only resulted 
in an additive amount of MIP1-β secreted in the supernatant. The addition of 
unstimulated B cells to the system increased the concentration of this chemokine for all 
groups. This increase was seen on adding stimulated B6
g7
 B cells. Although the high 
concentrations of MIP1-β secreted by LPS-stimulated B cells from protected mice 
cultured alone (indicating they were able to produce this chemokine), when cultured 
with CD8 T cells and DCs, the concentration was lower than for T cells + DCs alone. 
The same was observed for stimulated B cells from diabetic mice. In summary, the 
addition of LPS-stimulated B cells from NOD mice reduced the levels of MIP1-β in the 
supernatant, while unstimulated B cells had the opposite effect. However, as the assay 
was based on cytokines in the supernatants, it was not possible to determine which 
cell/cell groups was/were producing less MIP1-β in this system. 
The next parameter analysed was the percentage of CD8 T cells expressing CD107a, a 
marker for degranulating cytotoxic cells (Figure 4.5b). While the percentage was around 
15% for CD8 T cells cultured with DCs alone, when unstimulated B cells from diabetic 
mice were added to the system, this percentage increased. For all other culture 
conditions, the percentage of CD8
+
CD69
+
CD107a
+
 T cells was lower; however, when 
LPS-stimulated B cells from diabetic mice were added the frequency was similar to the 
control cultures with CD8 T cells and DCs alone. Interestingly, addition of either 
stimulated or unstimulated B cells from protected mice and > 35 w.o. B6
g7
 mice 
inhibited the expression of CD107a. 
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Figure 4.5 Concentration of MIP1-β in the supernatants of B cells cultured 
with CD8 T cells and DCs and percentage of T cell degranulation (percentage 
of CD8
+
CD69
+
CD107a
+
). After culture for one week, bone marrow DCs from PI 
homo mice were stimulated with LPS for 18h. Splenic B cells were collected from 
NOD or B6
g7
 mice and were left unstimulated or stimulated with LPS for 24h. 
Splenic CD8 T cells (from G9 mice) were purified on the day of the set -up of the 
experiment and labelled with CFSE for the evaluation of CD8 proliferation. The 
experimental procedure was as follows: 2x10
5
 CD8 T cells, 4x10
5
 stimulated DCs 
and 1.4x10
6 
stimulated or unstimulated B cells were added to each well. After 24h 
of incubation, wells were harvested for flow cytometric staining a nd after 48 
hours the supernatants were collected for chemokine analysis. (a) MIP1 -β was 
measured in the supernatant after 48 hours. The dashed line indicates the levels of 
MIP1-β produced by CD8 T cells + DCs cultured together. (b) For CD107a 
staining, the antibody was added to the wells 3h before harvesting. The dashed 
line indicates the percentage of cells expressing CD107a when CD8 T cells were 
cultured together with DC in the absence of B cells. The data are represented as 
mean and standard error and were analysed by Two-way ANOVA. n=3-4 
individual experiments, each experiment using pooled spleen cells from 3 -4 mice.  
* p < 0.05 
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4.3.3 Secretion of inflammatory cytokines 
The analysis of the results so far showed greater suppression of CD8
 
T cell activity by B 
cells stimulated with LPS when compared to unstimulated B cells. The results also 
showed that these findings were more accentuated when B cells were from NOD mice, 
especially protected NOD mice. 
To better understand the effect of LPS stimulation on B cells, we also analysed the 
secretion of cytokines, starting with pro-inflammatory cytokines. 
IFN-γ was undetectable from all of the cell types when cultured by themselves (B cells 
alone not shown). As observed in Figure 4.6a, when CD8 T cells were cultured with 
DCs, IFN-γ was secreted. The addition of unstimulated B cells from all groups resulted 
in no difference compared to positive control. LPS-stimulated B cells from protected 
mice and > 35 w.o. B6
g7
 mice did not contribute or inhibit the concentration shown in 
the control well (similar values for the 3 groups). The addition of stimulated B cells 
from diabetic mice to the system inhibited the secretion of IFN-γ. 
For TNF-α (Figure 4.6b), CD8 T cells and DCs, but not B cells produced the cytokine 
when cultured by themselves, (B cells not shown). TNF-α was considerably increased 
when DCs were cultured with CD8 T cells and the addition of unstimulated B cells did 
not affect this secretion. The addition of LPS-stimulated B cells of all three groups 
decreased the levels of TNF-α in the cultures, especially when B cells were from 
diabetic mice, which was statistically different from unstimulated B cells. 
The IL-6 found in the supernatants (Figure 4.6c), appeared to be mostly secreted by 
DCs, as the levels in the cultures of DCs alone was similar to the levels when CD8 T 
cells and DCs were cultured together. The addition of B cells (stimulated or 
unstimulated) from diabetic mice did not alter these levels, while the addition of B cells 
from protected or > 35 w.o. B6
g7
 mice decreased the concentration of IL-6, especially 
B6
g7
 B cells. 
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Figure 4.6 Concentration of IFN-γ, TNF-α and IL-6 in the supernatants of B 
cells cultured with CD8 T cells and DCs. After culture for one week, bone 
marrow DCs from PI homo mice were stimulated with LPS for 18h. Splenic B 
cells from NOD or B6
g7
 mice were stimulated with LPS for 24h or left 
unstimulated. Splenic CD8 T cells (from G9 mice) were purif ied on the day of the 
set-up of the experiment and labelled with CFSE for the evaluation of CD8 
proliferation. The experimental procedure was as follows: 2x10
5
 CD8 T cells, 
4x10
5
 stimulated DCs and 1.4x10
6 
stimulated or unstimulated B cells were added 
to each well. After 48h, supernatants were collected and IFN-γ (a), TNF-α (b) and 
IL-6(c) were measured. The dashed line indicates the levels of the cytokines 
produced by CD8 T + DCs cells alone (no B cells added). The data are represented 
as mean and standard error and were analysed by Two-way ANOVA. n=3-4 
individual experiments, each experiment using pooled spleen cells from 3 -4 mice.  
* p < 0.05 
[One single outlying value was excluded from the IFN-γ results from the “> 35 
w.o. NOD/Act B cells” group as the level far exceeded values obtained from these 
types of cultures (4650 pg/ml), compared to all other repetitions].  
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4.3.4 Secretion of IL-12p70 
IL-12p70 is a cytokine produced mainly by DCs to induce Th1 responses. As illustrated 
in Figure 4.7, DCs cultured with CD8 T cells had higher levels than DCs cultured alone. 
The addition of B cells only altered IL-12p70 levels when B cells (stimulated and 
unstimulated) were from diabetic mice, inducing more secretion of IL-12p70. B cells 
from protected mice did not alter the levels and cultures with B cells from B6
g7
 mice 
had lower concentrations of this cytokine. 
 
 
Figure 4.7 Concentration of IL-12p70 in the supernatants of B cells cultured 
with CD8 T cells and DCs. After culture for one week, bone marrow DCs from PI 
homo mice were stimulated with LPS for 18h. Splenic B cells from NOD or B6
g7
 
mice were stimulated with LPS for 24h or left unstimulated. Splenic CD8 T cells 
(from G9 mice) were purified on the day of the set -up of the experiment and 
labelled with CFSE for the evaluation of CD8 proliferation. The experimental 
procedure was as follows: 2x10
5
 CD8 T cells, 4x10
5
 stimulated DCs and 1.4x10
6  
stimulated or unstimulated B cells were added to each well. Forty -eight hours 
after the set-up, supernatants were collected and IL-12p70 was measured. The 
dashed line indicates the levels of the cytokines produced by CD8 T cells + DCs 
alone (no B cells added). The data are represented as mean and standard error and 
were analysed by Two-way ANOVA. n=3-4 individual experiments, each 
experiment using pooled spleen cells from 3 -4 mice.  
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4.3.5 Secretion of regulatory cytokines 
Ideally, IL-10 and TGF-β would be analysed by intracellular cytokine staining and 
analysed by flow cytometry as well as in the supernatants, to make this data comparable 
to the data in chapter 3. However, here, the percentages of B cells producing regulatory 
cytokines, as measured by intracellular cytoplasmic staining, were very low for all 
groups in this set of experiments. TGF-β was also undetectable by ELISA. Thus, the 
results shown here are only for the secretion of IL-10 in the supernatants. 
The levels of IL-10 from the cultures of CD8 T cells alone, DCs alone or T cells and 
DCs together were also very low, indicating that it is likely that the IL-10 detected after 
the addition of B cells was secreted by the B cells. 
As expected, based on the results of chapter 3, the levels of IL-10 were higher when B 
cells alone were stimulated with LPS, compared to unstimulated B cells (Figure 4.8). 
The difference between the groups was also in agreement with the data from the 
previous chapter. LPS-stimulated B cells from protected NOD mice produced more IL-
10 than B cells from diabetic and B6
g7
 mice. 
When all cell types were cultured together, the secretion of IL-10 was boosted. 
Compared to CD8 T cells + DCs, the addition of unstimulated B cells increased the 
levels of IL-10; however, the increase was less in comparison to the addition of 
activated B cells. LPS-stimulated B cells, especially when B cells were derived from 
NOD mice, secreted high levels of IL-10 when in culture with T cells and DCs. The IL-
10 level reached its highest (and was significantly different from control) when B cells 
were from protected mice. 
 
4.3.6 Summary 
The most important finding determined by the analysis of these results was the 
suppressive effect of activated B cells on antigen-specific CD8 T cells when in the 
presence of an antigen presenting cell (DC). Compared to cultures where B cells were 
not added or to cultures with unstimulated B cells, LPS-stimulated B cells reduced 
proliferation, activation (percentage of CD69
+
 cells), degranulation (frequency of 
CD69CD107a
+
 cells) and secretion of MIP1-β, IFN-γ, TNF-α and IL-6. On the other 
hand, activated B cells also increased CD8 T cell death and the secretion of IL-10. This 
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effect was more accentuated in B cells from NOD mice, especially protected NOD 
mice, when compared to B cells from B6
g7
 mice. 
 
 
 
Figure 4.8 Concentration of IL-10 in the supernatants of B cells cultured with 
CD8 T cells and DCs. After culture for one week, bone marrow DCs from PI 
homo mice were stimulated with LPS for 18h. Splenic B cells from NOD or B6
g7
 
mice were stimulated with LPS for 24h or left unstimulated. Splenic CD8 T cells 
(from G9 mice) were purified on the day of the set -up of the experiment and 
labelled with CFSE for the evaluation of CD8 proliferation. The experimental 
procedure was as follows: 2x10
5
 CD8 T cells, 4x10
5
 stimulated DCs and 1.4x10
6  
stimulated or unstimulated B cells were added to each well. Forty -eight hours 
after the set-up, supernatants were collected and IL-10 was measured. The data 
are represented as mean and standard error and were analysed by Two -way 
ANOVA. n=3-4 individual experiments, each experiment using pooled spleen cells 
from 3-4 mice.  
* p < 0.05 
[One single outlying value was excluded from the “Diabetic NOD/Act B cells” 
group as the level far exceeded values obtained from these types of cultures 
(23700 pg/ml), compared to all other repetitions].  
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4.4 Discussion 
After demonstrating that protected NOD mice had more baseline IL-10 producing B 
cells than diabetic mice and age-matched B6
g7
 mice which increased more on 
stimulation, it was of importance to test whether these B cells would also be able to 
suppress inflammatory responses in a more efficient manner. 
To analyse the suppressive effect of B cells, we used a system where dendritic cells 
present proinsulin to insulin-specific CD8 T cells without the addition of exogenous 
peptide in the culture. In this system, the B cells added in culture would only modulate 
the response by interacting with one or both of the cells, in a non-antigen-specific 
manner. B cells from all three groups (protected and diabetic NOD mice and > 35 w.o. 
B6
g7
 mice) were left unstimulated or cultured with LPS for 24h prior to the set-up of 
cultures with CD8 T cells and the dendritic cells. 
We investigated the role of B cells in influencing proliferation, the cytotoxic activity of 
CD8 T cells and chemokine and cytokine production. As discussed previously, in type 1 
diabetes the interaction between B and CD8 T cells has been shown to induce 
pathogenic activity (Brodie et al. 2008). Indeed, here we showed that unstimulated B 
cells increased markers of degranulation and the levels of inflammatory cytokines. 
Interestingly, when LPS-stimulated B cells were added to the wells with DCs and CD8 
T cells, the effect was the opposite. Activated B cells inhibited the activation of CD8 T 
cells and suppressed inflammatory cytokine production, surprisingly mostly by the 
stimulated B cells from the diabetic mice.  Conversely, the levels of IL-10 increased to 
their highest with the stimulated B cells. Once again, the outcomes were more 
noticeable with B cells from NOD mice, compared with B cells from B6
g7
 mice.  
Although B cells from protected mice added to the system caused less degranulation of 
CD8 T cells, the reduced percentage of live T cells was observed when these cells were 
cultured with B cells from both protected and diabetic mice. The ability of LPS-
stimulated B cells from NOD mice to cause apoptosis of diabetogenic T cells has been 
described in the literature and was TGF-β-dependent (Tian et al. 2001). As shown in 
chapter 3, B cells from protected and diabetic NOD mice had similar percentages of B 
cells producing this cytokine; therefore, our new observations agree with previous 
findings. One limitation of this investigation was not having data for TGF-β being 
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released by B cells, as there are also studies in the literature associating B cell regulation 
of CD8 T cells to this cytokine (Parekh et al. 2003). 
Oncogenic viruses designated Py can induce two different fates, depending on the strain 
of mice into which they are inoculated. In some mice, showing a predominant 
production of IL-12 in the spleen, the cytotoxic response was optimal and tumours were 
controlled; however, in another strain, IL-10 was the dominant cytokine and CD8 T 
cells did not exert optimal cytotoxicity. They observed that the main cells producing 
this IL-10 were B cells and the main difference between both strains was the expression 
of TLR-4 (Velupillai et al. 2006). Although TLR-4 is associated with development of 
diabetes (inducing the secretion of inflammatory cytokines when activated in 
monocytes), TLR-4
-
/
-
 transgenic NOD mice have accelerated diabetes (Gulden et al. 
2013). Therefore, the difference between the expression of TLR-4 on B cells of 
protected and diabetic NOD mice (which has already been raised as a question arising 
from the results presented in chapter 3) might be the key to understanding these results. 
One interesting finding here was that B cells from diabetic NOD mice helped DCs to 
increase their production of IL-12p70, while in protected NOD mice the levels were 
similar to DCs cultured with CD8 T cells alone. These observations were similar for 
stimulated and unstimulated B cells. It is already known that DCs tend to shift from the 
Th1 path and have reduced secretion of IL-12 when cultured in the presence of IL-10 
(De Smedt et al. 1997). In our system, however, the reduction of DC activity might have 
not been completely dependent on IL-10, as the effect was also seen with unstimulated 
B cells from protected mice (less IL-10 in the supernatant than cultures with activated B 
cells from diabetic NOD mice). Experiments utilising the addition of anti-IL-10 to the 
system might give us an insight of how much of this effect was IL-10-dependent. 
The addition of LPS-stimulated B cells from protected mice did not change or in fact 
increased the secretion of IFN-γ, TNF-α and IL-6 (in comparison to control CD8 T cells 
+ DCs and to stimulated B cells from the other groups). These results indicate that the 
pool of B cells was heterogenous, containing not only regulatory B cells. They also 
suggest that protected mice are as able to generate inflammatory responses as are 
diabetic mice, but they may also have more capacity to regulate this response. 
Furthermore, IL-10 production from B cells cultured alone was less than when B cells 
were cultured with CD8 T cells and DCs which suggests that regulatory B cells need 
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some inflammatory signals to produce increased concentrations of IL-10. This 
observation confirms findings of others as discussed before in the literature (Rosser et 
al. 2014). 
As explained in the section 4.3.5, ideally both intracellular cytoplasmic cytokine (ICC) 
staining as well as concentration of cytokines in the supernatant would be analysed. 
Each provides different information that would help us better understand the interaction 
between the cells: ICC gives valuable information about which cell is producing the 
cytokine, while with MSD data, this is not possible. On the other hand, cytoplasmic 
cytokine is not necessarily cytokine that will be secreted; and that is where MSD is also 
important. 
These findings propose a regulatory function of LPS-stimulated B cells when cultured 
with CD8 T cells and DCs, but there are many questions raised from these results. The 
direction these experiments could take for further investigations will be discussed in 
more detail in chapter 6. 
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5. Effect of depletion and repopulation in regulatory B cell subsets in 
Type 1 Diabetes 
 
5.1 Introduction and Objectives 
 
CD20 is a molecule expressed by B cells from early stages (late pre-B cells) until 
plasma cells and is well conserved in mice and humans (73% homologous). It is 
involved in the regulation of calcium influx, being important for the initiation of the 
transition from the G0 phase to G1 in the cell cycle (Golay et al. 1985; Tedder and Engel 
1994). CD20 is considered to be a good target for depletion strategies as it is expressed 
in the majority of B cells and is not internalized or solubilized (Reff et al. 1994). 
 
5.1.1 Anti-CD20-mediated B cell depletion in humans 
Monoclonal antibodies targeting CD20 were first used as a treatment for non-Hodgkin’s 
lymphomas. A chimeric anti-CD20 (murine variable regions and human Fc) called 
C2B8 (now known as Rituximab) was designed by Reff and colleagues and proved to 
be more effective than murine anti-CD20 in killing neoplastic B cells, with just mild 
adverse effects. As CD20 is not expressed by fully differentiated plasma cells (hence 
they are not depleted), antibody serum levels were not altered and susceptibility to 
infections was not increased (Reff et al. 1994; Maloney et al. 1997). 
The main mechanism of action of the CD20 antibody is antibody-dependent cellular 
cytotoxicity, transforming B cells to be targets for macrophages. Binding to CD20 
antibodies can also induce apoptosis and complement-mediated lysis (Gopal and Press 
1999). It is important to note, however, that in NOD mice this last mechanism might not 
be as relevant, as they are not able to produce the C5 factor of complement (Baxter and 
Cooke 1993). 
Having been approved for treatment of patients with lymphomas, the use of anti-CD20 
mAbs in clinical trials was expanded to autoimmune diseases. Clinical trials in patients 
with systemic lupus erythematous (Leandro et al. 2002), and even diseases that are more 
T-cell related, such as rheumatoid arthritis (Edwards and Cambridge 2001) and multiple 
sclerosis (Cross et al. 2006) resulted in reduced symptoms, lasting longer than the 
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treatment. As seen in lymphomas, they had good efficacy and no severe adverse events 
were reported. 
In Type 1 Diabetes, as discussed in chapter 1, patients who received rituximab needed 
less daily insulin and had better preserved beta-cell function. Compared to placebo, the 
treatment delayed C-peptide fall by 8.2 months. The effects, however, were temporary 
(Pescovitz et al. 2009; Pescovitz et al. 2014).  
 
5.1.2 Anti-CD20-mediated B cell depletion in mice 
Monoclonal anti-CD20 antibodies are already used therapeutically in humans. A full 
understanding of the mechanisms and the degree of B depletion in lymphoid organs in 
different diseases has been obtained by a number of complementary studies in animal 
models. 
To mimic the treatment in humans as closely as possible, Gong and colleagues created 
C57BL/6 mice carrying genes encoding human CD20. As seen in humans, peripheral B 
cells were completely depleted after treatment. In lymphoid organs, the efficiency of B 
cell depletion was dependent on the cell flux: B cells in lymph nodes, with high 
circulation of cells, were depleted more quickly than peritoneal B cells (B cells 
recirculate more slowly). Depletion of macrophages impaired anti-CD20 action, 
indicating that they are the major cell type involved in killing the B cells (Gong et al. 
2005). 
Mark Shlomchik’s group, almost at the same time, crossed a SLE-prone mouse strain 
(MRL/lpr) with transgenic mice expressing human CD20 (hCD20), initiating the 
investigation of B cell depletion in autoimmune diseases (Ahuja et al. 2007). They 
observed that, independent of the anti-CD20 used (they tested rituximab, 2H7, 8B9 and 
anti-mCD20 antibodies), the depletion of B cells was always better in BALB/c 
transgenic mice than in the autoimmune models. For all antibodies tested, lymph node B 
cells were more susceptible to depletion than splenic and peritoneal cavity B cells. 
Murine anti-human CD20 clone 2H7 binds to the same peptide targeted by rituximab 
(Du et al. 2008) and was chosen for subsequent experiments. 
After dose adjustments for better results, the effect of B cell depletion in SLE was 
investigated. The treatment decreased the percentage of memory T cells, the infiltration 
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in the kidneys and the serum levels of IgG1 and IgG2a (but not IgM and IgG2b). 
Although CD20 molecules are known to not be expressed in plasma cells, around 20% 
of CD138
+
 plasmablasts expressed the molecule in these experiments, which probably 
contributed to decreased antibody levels in the blood (Ahuja et al. 2007). The rationale 
for the use of B cell depletion as a treatment in SLE is clear, as autoantibodies have a 
major role in SLE. 
As discussed previously, T cells are the main type of lymphocytes linked to type 1 
diabetes. Despite the measurement of autoantibodies to insulin and other islet proteins 
as markers for the development of the disease, they have not been shown to be major 
contributors in the pathogenesis of T1D. However, B cells can exert a role as APC and 
modulate T cell responses by producing cytokines, and clinical trials of anti-B cell 
therapy have shown some promising results, although the effects were transient. 
Therefore, to investigate the mechanisms behind the efficacy of B cell depletion in type 
1 diabetes, NOD mice were crossed with transgenic mice expressing human CD20 to 
generate hCD20/NOD mice (Hu et al. 2007).  
The hCD20/NOD mice were evaluated and compared to NOD mice and there were no 
significant differences between the strains for number and function of cells, expression 
of surface markers and incidence of diabetes (Hu et al. 2007).  These mice then received 
4 intravenous (i.v.) injections of 2H7 or control IgG in 9 days (one every 3 days). 
Depletion could be detected in peripheral blood as early as 1 hour after the first 
injection, repopulation started 3 weeks after last injection and B cell populations were 
fully recovered after 12 weeks. The cycle of injections was given at different ages (pre-
insulitis, pre-diabetes and after the diagnosis of diabetes), to study the role of B cells in 
different phases of type 1 diabetes development. 
Mice injected at pre-insulitis and pre-diabetes stages (4 weeks of age or 9 weeks of age, 
respectively) had delayed disease and a reduced overall percentage incidence. In the 
pancreas, the infiltration was significantly smaller in mice treated with 2H7 for the first 
two months, when compared to controls. By the end of the observations, however, there 
was no difference in the score of insulitis in treated and control mice. Nevertheless, this 
analysis was done by histology and the quality of the infiltration was not investigated at 
that time (Hu et al. 2007). 
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Diabetic mice (receiving daily insulin to remain as healthy as possible for the 
experiments) also received one cycle of injections. Five of fourteen hCD20/NOD mice 
receiving 2H7 returned to euglycaemia after the treatment and the daily insulin 
injections were withdrawn. In contrast, no mice in the control group had blood glucose 
levels that reverted to normal (Hu et al. 2007). 
These experiments showed not only that B cells are important at the onset and 
development of type 1 diabetes, but they also confirmed the effect of B cell depletion as 
a treatment. However the effects lasted longer than the period when the cells were 
absent and it was postulated that the mechanisms involved were other than simple 
deletion of pathogenic B cells. 
The adoptive co-transfer of whole splenocyte populations or B cells alone or CD4 T 
cells alone from 2H7-treated mice to NOD/SCID mice (also receiving spleen cells from 
diabetic mice to trigger the disease), conferred protection against diabetes, when 
compared to mice receiving the same populations of cells from IgG-control treated 
hCD20/NOD mice. Together with the increased percentage of transitional B cells, 
CD4
+
CD25
+
Foxp3
+
 T cells and CTLA-4
+
 cells, these results showed that after B cell 
depletion, the repopulated B cell compartment was more regulatory and modulated the 
T cell compartment as well (Hu et al. 2007). 
The increased interest in regulatory B cells in the past years led to questions about how 
B cell depletion affects these populations. Obtaining the answer to some of these 
questions is the subject of this chapter. 
 
5.1.3 Objectives 
The aims of the experiments shown in this chapter were: 
1) To study the effect of B cell depletion and repopulation on the subpopulations of B 
cells in hCD20 NOD mice, particularly regulatory B cell subsets; 
2) To evaluate cytokine production after B cell depletion in young hCD20 NOD mice; 
 
Our hypothesis was that regulatory B cells could be important in the protection against 
type 1 diabetes seen in mice treated with anti-CD20. 
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5.2 Experimental design 
 
5.2.1 B cell depletion protocol 
The experiments shown here were designed based on the work done by Hu and 
colleagues (Hu et al. 2007) and the results from previous chapters. 
Female NOD mice have a higher incidence of diabetes and are usually chosen for the 
study of type 1 diabetes. For that reason, B cell depletion was not performed in male 
hCD20/NOD mice for these studies. 
The cycle of injections was modified in two aspects from the methods described by Hu 
and colleagues: 1) Pilot experiments showed that 4 intravenous (i.v.) injections 
compared with 1 i.v. and 3 intraperitoneal (i.p.) injections induced a similar degree of 
depletion, so we decided to have a cycle with 1 intravenous and 3 administrations via 
the intraperitoneal route, to reduce stress for the mice. 2) The second, third and fourth 
injections were reduced from 0.25mg/mouse to 0.2mg/mouse. Once again, the 
amplitude of the depletion was not affected. 
To study the effect of B cell depletion, mice were injected when they were pre-diabetic 
(6-8 weeks old – young group). Depletion of diabetic mice, although done previously by 
other groups, proved to be difficult. It was rare to have two hCD20/NOD mice with 
hyperglycaemia at the same time (one control, one depleted) and different 
concentrations of insulin (administered daily to keep diabetic mice healthy) were 
needed, to avoid hypoglycaemia and death. Therefore, diabetic mice were not included 
in our studies reported here. 
Female hCD20/NOD mice received one cycle of injections (anti-hCD20 antibody, clone 
2H7 or an IgG control, clone MPC-11) and the time points chosen had the last injection 
as the start point. Cells from spleen, pancreatic and mesenteric lymph nodes, Peyer’s 
patches and bone marrow were studied at 24h, 1 week, 8 weeks, 12 weeks after last 
injection (Figure 5.1) and spleen cells were also collected 30 weeks after the last 
injection, for functional studies. Data from all organs were also collected at the 4
th
 
week, but it is not shown here because of similarity to results seen 1 week after the last 
injection. 
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By 12 weeks, B cells had returned and mice were repopulated in the bone marrow and 
the lymphoid organs. Pancreata from these mice were collected for the study of the 
effect of B cell depletion on the quality of lymphocyte infiltration by Joanne Boldison, 
collaborating in this project. 
   
 
Figure 5.1 Experimental design for the studies of B cell depletion and 
repopulation in NOD mice expressing human CD20.  Female hCD20/NOD mice 
received one cycle of injections with 2H7 antibodies or control IgG. One cycle 
comprised 4 injections and the time points for experiments were de termined after 
the last injection. The organs chosen for the investigations were: spleen, 
pancreatic and mesenteric lymph nodes, Peyer’s patches and bone marrow. The 
subpopulations chosen for investigation are also listed.  
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5.2.2 B cell markers analysed by flow cytometry 
Figure 5.2 shows an example of the gating strategy used for spleen B cells for the flow 
cytometric plots used to investigate subpopulations in this chapter. The same gates were 
used for the other lymphoid organs, with the exception of CD19
+
CD24
hi
CD38
hi 
(Figure 
5.2c). Although more than 90% of all B cells express CD24 and CD38 in the lymph 
nodes, Peyer’s patches and bone marrow, this population of B cells is not as prominent 
as seen in the spleen. Therefore, the markers CD24 and CD38 were analysed separated, 
by their median of fluorescent intensity (MFI). The MFI demonstrates the level of 
expression of the markers on the cells, so a greater MFI indicates more expression of 
these markers on the surface of the cells. These gating strategies were also used for all 
further analysis. 
In addition to the surface markers studied previously in chapter 3 (T2, MZ, CD1d
hi
CD5
+
 
and CD24
hi
CD38
hi
), the analysis of more markers was possible for these experiments: 
IgM, IgD, CD43, CD138 and Tim-1 were studied. IgM and IgD are isotypes of the 
membrane-bound antibody (BCR) expressed on the surface of B cells, CD43 is a 
marker present in pro-B cells in the bone marrow and also in B-1 B cells in the 
periphery (Wells et al. 1994). CD138 is a marker for plasma cells and Tim-1 is believed 
to be involved with IL-10 production (Ding et al. 2011). 
At each time point, lymphocytes were stained for surface markers. At the 8
th
, 12
th
 and 
30
th
 week after the last injection, in addition to extracellular molecules, the cytokine 
production in the spleen by intracellular staining was also analysed by flow cytometry.  
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Figure 5.2 Example of flow cytometric plots used for the B cell depletion 
analysis in the spleen. These experiments were performed ex vivo with cells from 
lymphoid organs of female hCD20/NOD mice and stained with monoclonal 
antibodies. For every sample, 30,000 CD19 cells were acquired. The division of B 
cells into Follicular B cells (FO), Marginal zone (MZ) and Transitional B cells 
(T2) is shown in (a); CD1d
hi
CD5
+
 and CD5
hi
 are shown in (b). The intersection of 
these two populations was calculated as a Boolean gate and called CD1d
hi
CD5
hi
 in 
this chapter (not shown). Figure (c) represen ts the CD24
hi
CD38
hi
 gate in the 
spleen. The expression of CD43, a marker for B -1 cells, is shown in (d). Figures 
(e) and (f) illustrate the two immunoglobulin isotypes expressed on the B cell 
surface and exerting the B cell receptor functions: IgM and IgD,  respectively. 
Lastly, figure (g) shows the expression of CD138, marker for plasma cells and (h) 
shows the expression of Tim-1, a receptor believed to be involved in the 
production of IL-10. Gates were set based on FMOs and isotype controls – Figure 
A2, in the appendix.  
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5.3 Expression of hCD20 in different populations and organs 
To confirm that the phenotype of our hCD20/NOD mice was similar to those described 
in the literature, we analysed the percentage of B cells expressing human CD20 in the 
organs to be studied and the markers of interest (described previously and shown in 
Figure 5.2). Figure 5.3a shows the percentage of hCD20
+
 cells in total B cells (CD19, 
the first column) and all subpopulations studied in the spleen. Although the percentage 
of B cells expressing hCD20 was close to 100%, the highest frequencies were seen in 
Transitional B cells (CD21
hi
CD23
hi
) and CD24
hi
CD38
hi
 cells, while CD19
+
CD43
+
 cells 
had the lowest percentage of cells expressing hCD20. 
In the pancreatic lymph nodes (PLN), Figure 5.3b, CD19
+
CD43
+
 cells and CD5
hi
 cells 
were seen at a lower frequency, in contrast to the higher percentage found in the spleen.  
As MZ and T2 subsets were only seen in the spleen in mice, the percentages of hCD20 
expressed in the marginal zone cells (including CD1d) and transitional B cell 
phenotypes were not investigated in lymph nodes and bone marrow. 
The same pattern observed in PLNs was also seen in mesenteric lymph nodes (MLN - 
Figure 5.4a). Compared to the LNs and spleen, Peyer’s patches (PP - Figure 5.4b) had 
lower percentages of hCD20 expressed in their B cells (an average of around 89%, 
while the other organs were 94-96%).  
In the bone marrow, Figure 5.4c, the cells were more heterogeneous. This was expected, 
as the bone marrow contains B cells at different stages of development, some of them 
expressing CD20 and others not. As expected, the percentages were comparable to the 
spleen in the B cells expressing CD21, CD23 and IgD, as they are the cells that have 
been recirculating. CD43
+
 B cells again had the lowest frequencies of hCD20, followed 
by CD19
+
CD5
hi 
cells. In this case, the percentage of cells expressing hCD20 was lower 
than 50%. 
It is interesting to note that, in contrast to the literature, CD138
+
 B cells in our 
hCD20/NOD mice had high expression of hCD20 (> 90% in the spleen, LNs and 
Peyer’s patches). Nevertheless, these CD138+ cells were gated in CD19+ B cells, so they 
are considered short-lived plasmablasts and not fully mature plasma cells (Nutt et al. 
2015). In the bone marrow, the percentage of CD19
+
CD138
+
 cells expressing hCD20 
was around 40%. Thus, these plasmablasts are likely to become plasma cells. 
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Figure 5.3 Frequency of human CD20 in B cells and their subpopulations. 
Spleen cells (a) and cells from pancreatic lymph nodes (b) were stained for CD19, 
hCD20 and other B cell markers, for ex vivo analysis by flow cytometry. Each 
symbol represents one mouse. CD19, the first column, represents the whole B cell 
population and all the following markers were analysed on cells gated using these 
individual markers. “FO” represents the column for follicular B cells 
(CD21
low
CD23
hi); “MZ” represents marginal zone B cells (CD21hiCD23 low) and T2 
represents transitional 2 B cells (CD21
hi
CD23
hi
). The assay was performed in four 
hCD20 female mice aged 11 weeks old.   
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Figure 5.4 Frequency of human CD20 in B cells and their subpopulations.  
Cells from mesenteric lymph nodes (a), Peyer’s patches (b) and bone marrow (c) 
were stained for CD19, hCD20 and other B cell markers, for ex vivo analysis by 
flow cytometry. Each symbol represents one mouse. CD19, the first column, 
represents the whole B cell population and all the following mar kers were 
analysed on cells gated using these individual markers. “FO” represents the 
column for follicular B cells (CD21
low
CD23
hi
). The assay was performed in four 
hCD20 female mice aged 11 weeks old.  
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As the majority of the B cell subpopulations had a high hCD20 expression and a similar 
percentage of cells expressing hCD20, we also investigated the MFI of hCD20 on each 
B cell subset. 
In the spleen (Figure 5.5a), the highest MFI of hCD20 on the cells was seen in T2 B 
cells. Unexpectedly, the MFI in CD138
+
 cells was also high, compared to the other 
subpopulations. In the PLNs (Figure 5.5b), on the other hand, there was less variation in 
the MFIs (between 1300 and 2300) on the B cells. 
In the MLNs (Figure 5.6a), the variation was larger than in the PLNs and the highest 
MFIs were again seen in CD138
+
 B cells. B cells from Peyer’s patches (Figure 5.6b) not 
only had lower frequencies of hCD20, but also lower MFIs, when compared to the LNs 
and spleen. 
In the bone marrow (Figure 5.6c), as seen for the percentages, the results were very 
heterogeneous. The MFI in cells expressing FO markers was very similar to those 
observed in the spleen. In this organ, the MFI in CD138
+
 was low, combined with a low 
frequency of cells expressing the marker. 
 
In summary, the investigation of the expression of hCD20 in the whole population and 
subpopulations of B cells showed that in the spleen, LNs and Peyer’s patches, the 
expression was high in all subsets (with a lower frequency observed only in CD43
+
 B 
cells). Therefore, any heterogeneity in depletion effects observed was unlikely to be 
related to the level of expression of hCD20 on the cells. 
The MFI results showed that B cells in the spleen express more hCD20 than in the LNs 
and Peyer’s patches. The results in cells from the bone marrow were more diverse than 
the other organs. However this is not surprising, as the B cell population in the bone 
marrow comprises B cells in developmental stages prior to CD20 expression and 
plasmablasts/plasma cells. 
Given the levels of depletion were different in the lymphoid organs studied, the effects 
of this depletion and repopulation were studied separately in the spleen, lymph nodes 
and bone marrow and these are described in turn in the following sections. 
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Figure 5.5 MFI of human CD20 in B cells and their subpopulations.  Spleen 
cells (a) and cells from pancreatic lymph nodes (b) were stained for CD19, hCD20  
and other B cell markers, for ex vivo analysis by flow cytometry. Each symbol 
represents one mouse. CD19, the first column, represents the whole B cell 
population and all the following markers were analysed on cells gated using these 
individual markers. “FO” represents the column for follicular B cells 
(CD21
low
CD23
hi); “MZ” represents marginal zone B cells (CD21 hiCD23 low) and T2 
represents transitional 2 B cells (CD21
hi
CD23
hi
). The assay was performed in four 
hCD20 female mice aged 11 weeks old.  
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Figure 5.6 MFI of human CD20 in B cells and their subpopulations.  Cells from 
mesenteric lymph nodes (a) , Peyer’s patches (b) and bone marrow (c) were stained 
for CD19, hCD20 and other B cell markers, for ex vivo analysis by flow 
cytometry. Each symbol represents one mouse. CD19, the first column, represents 
the whole B cell population and all the following markers were analysed on cells 
gated using these individual markers. “FO” represents the column for follicular B 
cells (CD21
low
CD23
hi
). The assay was performed in four hCD20 female mice aged 
11 weeks old.  
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5.4 Effect of B cell depletion and repopulation in the Spleen 
After analysing the expression of human CD20 in hCD20/NOD mice, the effects of B 
cell depletion and repopulation in the lymphoid organs were studied. The results are 
presented divided by markers. 
It is important to clarify some aspects of the data described here: For these experiments, 
similar to the protocol for previous experiments, we aimed to analyse 30,000 CD19
+ 
cells for each sample. This was not achievable for hCD20-depleted mice and so, in these 
cases; the samples were run completely (until the FACS tube was dry). The percentage 
for all subpopulations, in all groups and samples, was calculated using CD19
+
 B cells of 
the sample as 100%. Thus, the percentages in the depleted groups represented 
percentages in a smaller total number of cells. 
When frequencies were equal in control and depleted mice, it indicated that, although 
the number of cells was smaller in 2H7 group, the subpopulation was proportionally 
depleted. Lower percentages indicated susceptibility to depletion. However, higher 
percentages in treated mice did not indicate higher numbers than controls, but rather a 
higher proportion of the subset in a depleted environment. In other words, while all 
other subpopulations were depleted, the ones showing higher frequencies were less 
depleted and became the dominant subpopulations. The diagram in Figure 5.7 
summarizes these observations. 
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Figure 5.7 Visual representation of possible proportional variations in 
subpopulations after B cell depletion. It was not possible to evaluate B cell 
subpopulations in lymphoid organs (represented here by black, green and red 
circles) from mice that were to receive treatment. However we considered tha t, at 
time point -9, all hCD20/NOD mice were the same (a). After receiving anti -
hCD20 (2H7), treated mice were B cell -depleted. In these mice, the B cell 
subpopulation frequencies varied in 3 different ways (b): Some populations were 
depleted proportionally (represented here by the green circles). Although their 
numbers were lower in depleted compared to control mice, the percentage was 
similar. Some subsets were more susceptible to depletion (black circles) and the 
percentages were much lower than the percentages seen in Controls (as well as 
their numbers). On the other hand, other populations were resistant to depletion. 
In these cases (represented by the red circles), although the number of cells was 
lower than in control mice, the proportion was higher because they were in a 
depleted environment where other cells were removed.  
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5.4.1 Extracellular markers: Total B cells (CD19) 
When 6-8 w.o. hCD20/NOD mice were injected with one cycle of either 2H7 or the 
control IgG, the differences in the percentages were evident 24h after the last injection. 
The total number of B cells (Figure 5.8) significantly decreased from 1.9 x 10
7
 cells in 
the spleen of control mice to 1.2 x 10
6
 cells in depleted mice 24h after the last injection, 
indicating 94% depletion. This level of depletion was also seen 1 week after the last 
injection, and were still low at 4 weeks (not shown), and just 8 weeks later, the first 
signs of repopulation were observed: the numbers in depleted mice had increased such 
that there was 60% depletion (2x10
7
 cells in control mice versus 8x10
6
 cells in depleted 
mice). By the 12
th
 week after the last injection, both groups had numbers of B cells 
around 2.8x10
7
 cells and the values were not statistically different. 
 
 
Figure 5.8 Effect of B cell depletion and repopulation in the total number of 
spleen B cells of young mice. 6-8 week-old female transgenic NOD mice 
expressing human CD20 received a cycle of 4 injections of either control IgG (in 
pink) or anti-human CD20 (clone 2H7 – in turquoise). Spleens from hCD20/NOD 
mice were collected at the time points, erythrocytes were lysed and lymphocytes 
were stained for extracellular markers ex vivo. Total lymphocytes were counted 
with Trypan Blue and the total numbers were multiplied by the percentage of 
CD19
+ 
cells determined by flow cytometry for each sample. Each time point 
illustrates mean of 6-8 mice and standard error. Data were analysed by t-test.
 
* p < 0.05; ** p < 0.01; *** p < 0.001 
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Figure 5.9 Effect of B cell depletion and repopulation in spleen B cells of 
young mice. 6-8 week-old female transgenic NOD mice expressing human CD20 
received a cycle of 4 injections of either control IgG (represented in pink) or anti -
human CD20 (clone 2H7 – represented in turquoise). Spleens from hCD20/NOD 
mice were collected at the determined time points, erythrocytes were lysed and 
lymphocytes were stained for extracellular markers ex vivo. The subsets analysed 
were: CD19
+
 (a); CD21
low
CD23
hi
 (b); CD21
hi
CD23
low
 (c); CD21
hi
CD23
hi
 (d); 
CD1d
hi
CD5
+
 (e); CD5
hi
 (f); CD1d
hi
CD5
hi
 (g) and CD24
hi
CD38
hi
 (h). The 
percentage of CD19
+
 cells (a) is the percentage of whole splenocytes , whereas the 
percentages for the subsets (b-h) are percentages of the CD19
+
 B cells. Each time 
point illustrates a mean of 6-8 mice and standard error. The percentages of cells at 
each time point were compared between the depleted and control group and th e 
data were analysed by t-test. 
* p < 0.05; ** p < 0.01; *** p < 0.001 
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The percentage of total B cells (CD19
+
; Figure 5.9a) in the spleen decreased 
significantly from 29% in control mice to 3% in 2H7-depleted mice. This represented a 
depletion of 90% of B cells in the spleen after 4 injections. One week after the last 
injection, the depletion process was still occurring in young mice. At this time, the 
percentage of B cells was reduced by 94%. By eight weeks, the cells were starting to 
return and 12 weeks after the last injection, the cells were fully returned and there was 
no significant difference between the groups. 
 
5.4.2 Extracellular markers: CD21 and CD23 
This depletion observed in the number and percentage of total B cells also caused 
different effects in the subpopulations. All the percentages shown here for subsets are 
considering CD19
+
 B cells (the first graph (a) in the first figure for all organs) as 100%. 
Thus, although the percentages might be higher or lower in the depleted group, the 
number of cells is very likely to be always lower in the 2H7 group, during depletion. 
Twenty-four hours after the last injection, the proportion of follicular zone B cells 
(CD21
low
CD23
hi
 – Figure 5.9b) significantly increased in depleted mice, compared to 
control mice. The difference between the two groups was lost 1 week after the last 
injection. Eight weeks after the last injection, the percentage of FO B cells decreased 
and was significantly lower than in control mice. By the 12
th
 week, it was back to 
similar levels (non-significant, when compared to the control group). Compared to MZ 
and T2 B cells, it seemed like FO B cells were less susceptible to depletion. 
Marginal zone B cells (CD21
hi
CD23
low
 – Figure 5.9c) were significantly depleted 24h 
after the last injection. The depletion was very striking and even 8 weeks after the last 
injection, the levels in depleted mice were lower than 5% (in contrast to the 15-20% in 
control mice). The proportion, however, was back to normal after 12 weeks. 
The percentages of T2 B cells (CD21
hi
CD23
low
 – Figure 5.9d), 24h after the last 
injection, were variable in 2H7 mice, but there was no significant difference observed 
when compared to the control mice. One week later, the percentage of T2 B cells 
continued to be lower in depleted mice. However, 8 weeks after the last injection, there 
was a significant increase in transitional B cells in depleted mice, compared to control 
mice. This could be explained as the new B cells arriving from the bone marrow to 
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repopulate the spleen express this phenotype. By 12 weeks, both control and depleted 
mice had similar percentages of transitional B cells. 
 
5.4.3 Extracellular markers: CD1d and CD5 
As a confirmation of the depletion of the marginal zone, the percentage of CD1d
hi
CD5
+
 
cells also decreased significantly (Figure 5.9e), 24h and 1 week after the last injection. 
As discussed in chapter 3, CD1d
hi
 cells are located in the marginal zone, which was 
depleted in mice receiving anti-hCD20 antibody. Eight weeks after the last injection, the 
percentage of cells expressing CD1d
hi
CD5
+
 was similar in control and depleted mice. 
This result did not correlate to the pattern seen in the marginal zone, but it was likely to 
be an outcome of new T2 cells in the spleen. The frequencies were similar in both 
groups when cells were completely repopulated. 
On the other hand, the proportion of CD5
hi
 cells (Figure 5.9f) significantly increased in 
depleted mice 24h after the last injection. CD5 is a marker for B-1a cells and these cells 
are more resistant to depletion (Hamaguchi et al. 2005). The resistance of CD5
hi
 cells 
was even more accentuated 1 week after the depletion, when compared to control mice. 
Eight weeks after the last injection, with the return of other subpopulations, the 
difference between the frequencies of CD5
hi
 B cells in depleted and control mice was 
similar to the first measurement. By 12 weeks, there was no statistically significant 
difference between the groups. 
The proportions of CD1d
hi
CD5
hi
 (the intersection between the gates for CD1d
hi
CD5
+
 
and CD5
hi
) was not altered by the depletion at the early stage (Figure 5.9g). One week 
after the last injection, the percentages of CD1d
hi
CD5
hi
 B cells followed the pattern seen 
in CD5
hi
 B cells, being significantly higher in depleted mice. The higher proportion was 
maintained in the 2H7 group 8 weeks later and returned to levels similar to control mice 
by the 12
th
 week. 
 
5.4.4 Extracellular markers: CD24 and CD38 
The percentages of B cells expressing CD24
hi
CD38
hi
 (Figure 5.9h) were similar in 
depleted and control mice 24h after the last injection. As these markers are mainly 
expressed in Transitional 2 B cells, this finding was not a surprise, as it followed the 
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pattern of results seen in Figure 5.9d. One week after the last injection, the frequency of 
CD24
hi
CD38
hi 
B cells decreased in depleted mice, being significantly lower than control 
mice. Eight weeks later, however, the proportion of B cells expressing CD24
hi
CD38
hi 
increased significantly. This observation followed again the pattern seen in T2 B cells. 
By the 12
th
 week after the last injection, the percentages were similar in both groups. 
In addition to the regulatory subsets, we also investigated the effect of the depletion on 
cells expressing other B cell markers. 
 
 
Figure 5.10 Effect of B cell depletion and repopulation in spleen B cells of 
young mice. 6-8 week-old female transgenic NOD mice expressing human CD20 
received a cycle of 4 injections of either control IgG (represented in pink) or anti -
human CD20 (clone 2H7 – represented in turquoise). Spleens from hCD20/NOD 
mice were collected at the determined time points, erythrocytes w ere lysed and 
lymphocytes were stained for extracellular markers ex vivo. The subsets analysed 
were: CD43 (a); IgD (b); IgM (c); CD138 (d) and Tim-1 (e). Each time point 
illustrates mean of 6-8 mice and standard error. The percentages of cells at each 
time point were compared between the depleted and control group and the d ata 
were analysed by t-test. 
* p < 0.05; ** p < 0.01; *** p < 0.001  
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5.4.5 Extracellular marker: CD43 
The first new marker added to the panel (compared with those studied in experiments 
reported in chapter 3) was CD43. B cells expressing this marker (Figure 5.10a) were 
resistant to depletion and even 24h after the last injection, the percentage was 
significantly higher in the 2H7 group. As explained previously, this did not mean the 
number of cells was increased, but rather that the proportion of these B cells expressing 
CD43 was higher due to the depletion of other subpopulations. The higher proportion 
was seen one week after the last injection; however, eight and twelve weeks later, the 
proportions were back to normal and there was no difference between control and 
depleted mice. 
 
5.4.6 Immunoglobulin expression: IgD and IgM 
Almost 100% of B cells in control mice expressed IgD (Figure 5.10b). In depleted mice, 
the percentages significantly decreased 24h and 1 week after the last injection. The 
percentages, however, returned to levels comparable to the control group 8 weeks after 
the last injection. 
Following the results seen in B cells expressing IgD, the percentage of CD19
+
IgM
+
 was 
significantly lower in depleted mice at the first two time points (Figure 5.10c). Eight 
weeks after the last injection, although there was no alteration in the mean for depleted 
mice, the percentage in control mice decreased, which, by comparison, made the 
frequencies in the 2H7 significantly higher. However, it is not clear whether the 
apparent decrease in the IgM at 8 weeks in the control group is a true difference, as this 
is not in keeping with the trend and not easily explainable.  By 12 weeks after the last 
injection, both groups had similar percentages and the results were not significantly 
different. 
 
5.4.7 Extracellular marker: CD138 
Although most of the CD138
+
 B cells expressed hCD20 in our colony, no significant 
difference was observed in the percentage of cells in depleted mice, compared to control 
mice 24h after the last injection (Figure 5.10d). After one week, with the depletion of 
other subpopulations and the resistance of B cells expressing CD138, the percentage 
was significantly higher in depleted mice. By eight weeks, the difference between the 
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groups was smaller, but depleted mice still had significantly higher percentages. The 
frequencies were back to similar levels in both groups 12
th
 week after the last injection. 
 
5.4.8 Extracellular marker: Tim-1 
B cells expressing Tim-1 were also resistant to depletion; a finding observed even 24h 
after the last injection, as the frequencies in the 2H7 group were significantly higher, 
compared to the control group. This pattern was also seen one week after the last 
injection. However, eight weeks after the last injection, the difference in the proportions 
between the groups was not observed.  
 
5.4.9 Summary of effects of anti-hCD20 B cell depletion on cellular subsets ex vivo  
The use of anti-hCD20 to deplete B cells affected splenic B cell subpopulations 
differently. Some subsets were susceptible to depletion, as occurred with the B cells in 
the marginal zone, which were severely depleted (confirmed by the depletion also 
observed in CD1d
hi
CD5
+
 cells) when compared to control mice. On the other hand, B 
cells expressing CD5
hi
, CD43
+
, CD138
+
 or Tim-1 were resistant to depletion, a result 
demonstrated by the higher frequencies of these cells in depleted mice especially at the 
first two time points, when repopulation had not commenced. 
The total of B cells and the majority of subpopulations were completely repopulated by 
the 12
th
 week, but some of them had similar frequencies to control mice even 8 weeks 
after the last injection. These finding suggests that the return of B cell subsets to the 
spleen does not occur with the same kinetics.  
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5.4.10 Cytokine production and in vitro effects on subsets following anti-hCD20 B 
cell depletion in spleen B cells 
5.4.10.1 Eight weeks after the last injection 
As the percentage of B cells was returning to control levels in the depleted mice, spleen 
cells were cultured for 24h, either unstimulated, or stimulated with LPS or anti-CD40. 
3h before harvesting, they received monensin, PMA and ionomycin, following the 
protocol described in previous chapters. LPS and anti-CD40 were chosen to represent 
two different pathways by which to stimulate B cells: via TLR (LPS) and mimicking T 
cell/costimulatory interaction (anti-CD40). In addition to the analysis of cytokine 
production, the effect of depletion and repopulation on other B cell markers that 
indicated changes in B cell subsets was also evaluated. 
Figures 5.11a, 5.11b and 5.11c illustrate the percentage of CD19
+
 cells after in vitro 
culture. When compared to the frequency of B cells ex vivo (Figure 5.9a), the 
percentage of B cells doubled similarly in both groups. Therefore, the 50% significant 
difference between control and 2H7 groups was preserved and it was stimulant 
independent. 
A number of additional surface markers were examined, and the first of these was 
CD40. CD40 in B cells (and other APCs) is activated by interaction with CD40L in T 
cells, which leads to cytokine production (Mauri et al. 2003). Although the percentages 
of unstimulated CD19
+
CD40
+
 cells were low and similar in control and depleted mice 
(Figure 5.11d), stimulation with LPS increased the frequency of B cells expressing 
CD40 (Figure 5.11e). The percentage was not significantly different in either group. 
When B cells were stimulated with anti-CD40 (Figure 5.11f), the percentage of 
CD19
+
CD40
+
 cells was similar to those in unstimulated cells in control cultures. In 
depleted mice, the percentage was significantly lower when compared to the control 
group. It was also lower when compared to the percentage of unstimulated B cells in 
depleted mice. 
The expression of hCD20 after cell culture was also examined. When B cells were 
cultured without stimulant (Figure 5.11g), or with LPS (Figure 5.11h) or anti-CD40 
(Figure 5.11i), spleen cells from control mice had a significantly higher frequency of B 
cells expressing hCD20 than mice treated with 2H7. Because hCD20 was not assessed 
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in cells when studied directly ex-vivo, it is not known if this reduction was pre-existent 
before culture.  
 
 
Figure 5.11 Effect of B cell depletion and repopulation in vitro in B cells of 
young mice. 6-8 week-old female transgenic NOD mice expressing human CD20 
received a cycle of 4 injections of either control IgG (represented in pink) or anti -
human CD20 (clone 2H7 – represented in turquoise). Eight weeks after the last 
injection, spleens were collected, erythrocytes were lysed and removed and spleen 
cells were cultured for 24h with LPS, anti-CD40 or left unstimulated; PMA, 
ionomycin and monensin were added for the last 3 hours and then cells were 
stained for extracellular markers and intracellular cytokines. The subsets analysed 
were: CD19 (a-c); CD40 (d-f) and human CD20 (g-i). Each graph illustrates 
individual mice and the mean. Data were analysed by t-test. n = 6-8.
 
* p < 0.05; ** p < 0.01; *** p < 0.001 
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In these experiments CD80 (B7-1) and CD86 (B7-2), were also analysed. These 
markers are costimulatory molecules that bind to CD28 or CTLA-4 in T cells. They are 
expressed in APCs (Lim et al. 2012). 
The percentage of B cells expressing CD80 was low in unstimulated cells in general, 
being significantly lower in depleted mice (Figure 5.21a). When stimulated with LPS 
(Figure 5.12b) or anti-CD40 (Figure 5.12c), the percentages increased in both groups. 
However, the increase was smaller in depleted mice. In LPS-stimulated B cells, 
percentages were not significantly different between the groups, but in B cells from 
depleted mice stimulated with anti-CD40, the percentage of CD19
+
CD80
+
 cells was 
significantly lower than in the control group. 
The significantly lower expression in depleted mice was also observed for CD86. For 
this costimulatory molecule, statistically significant differences between control and 
2H7-treated mice were observed in unstimulated (Figure 5.12d), LPS- (Figure 5.12e) 
and anti-CD40-stimulated B cells (Figure 5.12f). 
The expression of CD138 was analysed ex vivo and again in vitro; however, the 
percentages were very low after cells were cultured for 24h (Figures 5.12g-i). The 
percentage in depleted mice was marginally higher when cells were cultured with LPS, 
but there was no significant difference in CD138
+
 cells between groups for any of the 
stimulants studied.  
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Figure 5.12 Effect of B cell depletion and repopulation in vitro in B cells of 
young mice. 6-8 week-old female transgenic NOD mice expressing human CD20 
received a cycle of 4 injections of either control IgG (represented in pink) or anti -
human CD20 (clone 2H7 – represented in turquoise). Eight weeks after the last 
injection, spleens were collected, erythrocytes were lysed and removed and spleen 
cells were cultured for 24h with LPS, anti-CD40 or left unstimulated; PMA, 
ionomycin and monensin were added for the last 3 hours and then cells were 
stained for extracellular markers and intracellular cytokines. The subsets analysed 
were: CD80 (a-c); CD86 (d-f) and human CD138 (g-i). Each graph illustrates 
individual mice and the mean. Data were analysed by t-test. n = 6-8.
 
* p < 0.05; ** p < 0.01; *** p < 0.001 
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The cytokine production by B cells was analysed under the same conditions described 
for the in vitro markers. 
Eight weeks after the last injection, the percentage of B cells producing IL-10 was 
significant lower in B cells from depleted mice. This difference was observed in 
unstimulated (Figure 5.13a), LPS- (Figure 5.13b) and anti-CD40-stimulated cells 
(Figure 5.13c). We observed that the control mice had increased percentage of 
CD19
+
IL-10
+
 cells on stimulation with LPS and even more with anti-CD40 stimulation, 
the depleted mice responded to LPS stimulation but were less responsive to anti-CD40 
stimulation. Considering that the the marginal zone of NOD mice is the main source of 
B10 cells (as seen in Chapter 3) and that this region was the most affected by depletion, 
it would explain the lower frequencies of IL-10-producing B cells in depleted mice. 
On the other hand, the production of TGF-β by B cells of mice treated with 2H7 was 
higher than the production by the B cells of mice treated with control IgG. Although all 
percentages were small, depleted mice had significantly higher percentages of B cells 
producing TGF-β when compared to control mice, both the unstimulated (Figure 5.13d) 
and LPS-stimulated cells (Figure 5.13e). Anti-CD40 treatment (Figure 5.13f) also 
induced a higher percentage of TGF-β in the 2H7 group, but this was not statistically 
different from the control cells. 
The stimulation of B cells producing IL-6, under these culture conditions, were also 
significantly increased in depleted mice, in comparison to control mice. However, it 
should be noted that the percentages were small, but significantly smaller in mice that 
received control IgG, when cells were unstimulated (Figure 5.13g) or stimulated with 
anti-CD40 (Figure 5.13i). In LPS-stimulated cells (Figure 5.13h), there was no 
significant difference.  
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Figure 5.13 Effect of B cell depletion and repopulation in vitro in cytokine 
production by B cells of young mice. 6-8 week-old female transgenic NOD mice 
expressing human CD20 received a cycle of 4 injections of either control IgG 
(represented in pink) or anti -human CD20 (clone 2H7 – represented in turquoise). 
Eight weeks after the last injection, sp leens were collected, erythrocytes were 
lysed and removed and spleen cells were cultured for 24h with LPS, anti-CD40 or 
left unstimulated; PMA, ionomycin and monensin were added for the last 3 hours 
and then cells were stained for extracellular markers and intracellular cytokines. 
The cytokines analysed were: IL-10 (a-c); TGF-β (d-f) and IL-6 (g-i). Each graph 
illustrates individual mice and the mean. Data were analysed by t-test. n = 6-8.
 
* p < 0.05; ** p < 0.01; *** p < 0.001 
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5.4.10.2 Twelve weeks after the last injection 
Twelve weeks after the last anti-hCD20 injection in young mice, surface markers and 
cytokine production were evaluated in vitro again. 
Although the percentage of CD19
+ 
cells ex vivo was reconstituted in depleted mice, 
when cultured for 24h, with no stimulant (Figure 5.14a), LPS (Figure 5.14b) or anti-
CD40 (Figure 5.14c), treated mice had significantly lower frequencies of B cells in the 
cultures. 
For B cells expressing CD40, the same pattern seen 8 weeks after the last injection was 
also observed four weeks later: CD40 was upregulated when cells were stimulated with 
LPS and anti-CD40 did not change the percentages of cells expressing CD40 at either 
time point when compared to unstimulated cells. Moreover, there was no significant 
difference in the percentages for any stimulation (Figures 5.14d-f). 
There was similar expression of hCD20 in the in vitro cultured cells, as had been 
observed in ex vivo B cells. All cells, in both groups and for all stimulants, expressed 
high percentages (close to 100%) of hCD20 and there was no significant difference 
between control and depleted (now repopulated) mice (Figures 5.14g-i). 
Although most of the markers had returned to normal levels, and were expressed 
equally in both groups, when B cells were repopulated in 2H7-treated mice, the 
expression of CD80 and CD86 were still reduced. 
Unstimulated cells in depleted mice had significantly lower percentages of 
CD19
+
CD80
+
 cells (Figure 5.15a). When cells were stimulated with LPS (Figure 5.15b) 
and anti-CD40 (Figure 5.15c), the percentages were still lower in depleted mice, 
although not statistically significant. The percentages of CD19
+
CD86
+
 cells were also 
lower in unstimulated cells from the 2H7-treated group, although this was not 
significant (Figure 5.15d). When stimulated with LPS (Figures 5.15e) and anti-CD40 
(Figures 5.15f), the percentages of B cells expressing CD86 were significantly lower in 
depleted mice, compared to control. 
After repopulation, the percentage of CD138
+
 B cells was similar in control and 
depleted mice (no significant difference between the groups). However, for all 
stimulants (Figures 5.15g-i), the overall percentages were lower in the 2H7-depleted 
group.  
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Figure 5.14 Effect of B cell depletion and repopulation in vitro in B cells of 
young mice. 6-8 week-old female transgenic NOD mice expressing human CD20 
received a cycle of 4 injections of either control IgG (represented in pink) or anti -
human CD20 (clone 2H7 – represented in turquoise). Twelve weeks after the last 
injection, spleens were collected, erythrocytes were lysed and removed and spleen 
cells were cultured for 24h with LPS, anti-CD40 or left unstimulated; PMA, 
ionomycin and monensin were added for the last 3 hours and then cells were 
stained for extracellular markers and intracellular cytokines. The subsets analysed 
were: CD19 (a-c); CD40 (d-f) and human CD20 (g-i). Each graph illustrates 
individual mice and the mean. Data were analysed by t-test. n = 6-8.
 
* p < 0.05; ** p < 0.01; *** p < 0.001 
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Figure 5.15 Effect of B cell depletion and repopulation in vitro in B cells of 
young mice. 6-8 week-old female transgenic NOD mice expressing human CD20 
received a cycle of 4 injections of either control IgG (represented in pink) or anti -
human CD20 (clone 2H7 – represented in turquoise). Twelve weeks after the last 
injection, spleens were collected, erythrocytes were lysed and removed and spleen 
cells were cultured for 24h with LPS, anti-CD40 or left unstimulated; PMA, 
ionomycin and monensin were added for the last 3 hours and then cells were 
stained for extracellular markers and intracellular cytokines. The subsets analysed 
were: CD80 (a-c); CD86 (d-f) and human CD138 (g-i). Each graph illustrates 
individual mice and the mean. Data were analysed by t-test. n = 6-8.
 
* p < 0.05; ** p < 0.01; *** p < 0.001 
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For CD19
+
IL-10
+
 cells, after the population was reconstituted, unstimulated (Figure 
5.16a) and LPS-stimulated (Figure 5.16b) cells from depleted mice were able to reach 
similar levels of cytokine production seen in control mice. Cells stimulated with anti-
CD40 (Figure 5.16c), however, had lower percentages of B cells producing IL-10 in 
depleted mice, compared to control mice. As observed in Figures 5.16d-f, this was not 
related to lower frequency of CD40 expression in these mice. 
Although the production of TGF-β and IL-6 by B cells was higher in depleted mice at 
the previous time-point, 12 weeks after the last injection they were similar and not 
significantly different in the control and 2H7 groups (Figures 5.16d-i). 
 
5.4.11 Summary for in vitro surface markers and intracellular cytokines in B cells 
from the spleen 
The most important findings for surface markers in B cells cultured for 24h related to 
the frequencies of CD80 and CD86, important markers in APCs. Even 12 weeks after 
the last injection, when the majority of the markers returned to percentages similar to 
the control group, the frequencies of CD80 and CD86 were significantly lower in 
depleted mice. 
The frequency of cytokines varied during the two time points studied and the 2H7 group 
had significantly lower percentages of B cells producing IL-10, and higher percentages 
of CD19
+
TGF-β+ cells 8 weeks after the last injection. The percentages of IL-6 
producing B cells were very small.  However, twelve weeks after the last injection, the 
frequencies were mostly similar in both groups. 
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Figure 5.16 Effect of B cell depletion and repopulation in vitro in cytokine 
production by B cells of young mice. 6-8 week-old female transgenic NOD mice 
expressing human CD20 received a cycle of 4 injections of either control IgG 
(represented in pink) or anti -human CD20 (clone 2H7 – represented in turquoise). 
Twelve weeks after the last injection, spleens were collected, erythrocytes were 
lysed and removed and spleen cells were cultured for 24h with LPS, anti-CD40 or 
left unstimulated; PMA, ionomycin and monensin were added for the last 3 hours 
and then cells were stained for extracellular markers and intracellular cytokines. 
The cytokines analysed were: IL-10 (a-c); TGF-β (d-f) and IL-6 (g-i). Each graph 
illustrates individual mice and the mean. Data were analysed by t-test. n = 6-8.
 
* p < 0.05; ** p < 0.01; *** p < 0.001 
 
 
  
149 
 
5.5 Effect of B cell depletion and repopulation in the Lymph Nodes 
 
As observed in Figures 17 and 18, the variations caused by B cell-depletion affected 
PLNs, MLNs and Peyer’s patches (PPs) in a similar manner. Therefore, the results for 
these three lymph nodes are shown together. 
  
5.5.1 Extracellular markers: Total B cells (CD19) 
As observed for the spleen, the effect of anti-hCD20 treatment in lymph nodes was 
observed even 24h after the last injection. The percentage of B cells in the pancreatic 
lymph nodes of depleted mice was around 1.6%, reduced from 12% in control mice 
(Figure 5.17 a1); this represented a depletion of 87% of total B cells. The depletion seen 
in the MLNs was even greater than in the spleen and PLNs. While the percentage of 
total B cells was 13.9% in control mice, depleted mice had only 0.7% B cells – a 
depletion of 95% (Figure 5.17 a2). The depletion in the Peyer’s patches was not as 
efficient as in other lymph nodes. The difference between the percentage of CD19
+
 cells 
in the control group (35.3%) and 2H7 group (8.7%) was only 75%, 24h after the last 
injection (Figure 5.17 a3). 
These statistically significant reductions were maintained during the first 3 time points 
and returned to control levels by the 12
th
 week in the three organs studied. 
 
5.5.2 Extracellular markers: CD21 and CD23 
As explained at the beginning of the chapter, B cells expressing marginal zone and T2 
phenotypes are rare in the lymph nodes, even in control mice, so these populations were 
not described (including the expression of CD1d). CD21
low
CD23
hi
 (FO) B cells were 
significantly depleted in the lymph nodes of the 2H7 group. Following the pattern seen 
for the total number of B cells (Figure 5.17a), this depletion was observed for the first 3 
time points and the percentages returned to levels similar to the control group 12 weeks 
after the last injection (Figure 5.17 b1-3).  
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5.5.3 Extracellular markers: CD5 
The striking decrease of some populations made the proportion of resistant cells 
significantly higher. One example is seen in Figure 5.17 a1-2: The percentage of the 
remaining B cells expressing CD5
hi
 in the PLNs and MLNs reached its peak, one week 
after the last injection at more than 30%. However, the number decreased as the new B 
cells started to repopulate the pancreatic lymph nodes and was similar to control mice 
by the 12
th
 week.  
Compared to MLNs and PLNs, the resistance of CD5
hi
 B cells to depletion in Peyer’s 
patches was not as evident. The frequencies after depletion were no higher than 15% 
and varied within the groups (large error bar). By 12 weeks, the percentages were back 
to similar levels in depleted and control mice (Figure 5.17 c3).  
 
5.5.4 Extracellular markers: CD24 and CD38 
As the B cells in the PLNs do not express T2 and MZ phenotype, they do not express 
CD24
hi
CD38
hi 
B cells in the same way as the spleen. However, the expression of CD24 
and CD38 was close to 100% in all groups, so the MFIs of these markers were analysed 
separately. 
B cells that remained in the PLNs and MLNs after the treatment expressed more CD24 
than B cells from control mice, as observed in figure 5.17 d1-2. The expression peaked 
at the 8
th
 week after the last injection. When the B cell population was repopulated, the 
expression of CD24 showed no difference compared to control mice. The differences in 
the expression of CD24 on B cells from depleted and control mice were more evident in 
the Peyer’s patches. The remaining B cells in the 2H7 group expressed significantly 
more CD24 than B cells from the control group (Figure 5.17 d3). 
The expression of CD38 on the B cells in the PLNs and PPs did not vary during 
depletion, except for the first week after the last injection, when the expression was 
significantly lower in B cells from depleted mice (Figure 5.17 e1 and e3). In the MLNs, 
the results for the expression of CD38 were very heterogeneous during the depletion 
period, varying in control and depleted mice (Figure 5.17 e2). 
 
 
152 
 
5.5.5 Extracellular marker: CD43 
B cells expressing CD43 were resistant to depletion in all three LNs. From 24h until the 
8
th
 week after the last injection, the percentages of CD19
+
CD43
+
 cells were significantly 
higher in the depleted group, compared to control mice. As the lymphoid organs were 
being repopulated, the percentages decreased to control mice levels by the 12
th
 week 
(Figure 5.18 a1-3). 
 
5.5.6 Extracellular marker: IgD and IgM 
With the depletion of FO B cells, B cells expressing IgD and IgM were also reduced in 
the LNs. The percentage of IgD
+
 B cells in the 2H7 group was significantly decreased 
for the first 3 time points and increased to control levels with repopulation (Figure 5.18 
b1-3). 
The expression of IgM also decreased in depleted mice. However, the percentage in 
control mice seemed to decrease for the last two time points. It is difficult to point to the 
reason, but it could be an age effect. By 12 weeks, both depleted and control mice had 
the same frequency of B cells expressing IgM in all three LNs (Figure 5.18 c1-3). 
5.5.7 Extracellular marker: CD138 
As discussed previously, in our colony almost 100% of the CD19
+
CD138
+
 B cells 
expressed hCD20. However these cells were still resistant to depletion; a result 
demonstrated by the significantly higher percentages of B cells expressing CD138, in 
the PLNs and MLNs, one week after the last injection and 8 weeks after the last 
injection in the PPs of mice treated with anti-CD20 (Figure 5.18 d1-3). The percentages 
returned to the low levels exhibited by control mice on the 12
th
 week after the last 
injection.   
5.5.8 Extracellular marker: Tim-1 
Because of a change in the antibody panel, the expression of Tim-1 was not analysed at 
the last time point. Tim-1 was substituted in the panel by hCD20, to investigate the 
expression of this marker ex vivo, as a comparison to in vitro data. However, B cells 
expressing Tim-1 had significantly higher percentages in the 2H7 group during the 
depletion period, indicating that this population was resistant to the effect of anti-
hCD20 (Figure 5.18 e1-3). 
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5.5.9 Summary 
The results for the depletion of B cells in the LNs followed the same patterns seen in the 
spleen, although the depletion of total B cells in the Peyer’s patches was not as efficient 
as in the lymph nodes. In the absence of marginal zone and T2 B cells, the cells 
depleted were the FO B cells. Depletion was also demonstrated by the reduction of B 
cells expressing IgD and IgM. CD5
hi
, CD43, CD138 and Tim-1 B cells were resistant to 
depletion. The expression of CD24 was higher in depleted mice, while the expression of 
CD38 remained the same for both groups.  
 
5.6 Effect of B cell depletion and repopulation in the Bone marrow  
5.6.1 Extracellular markers: Total B cells (CD19) 
The results for B cell depletion in the bone marrow were different from the other 
organs. Bone marrow is the site of B cell origin; however, the percentage of CD19
+
 B 
cells was, in general, lower than in the other organs. While the percentage in control 
mice was 5.2%, depleted mice had 3.5% of total B cells (Figure 5.19a). This difference 
was not statistically significant and represented a depletion of only 32% of the B cells in 
the bone marrow of treated mice. One week after the last injection, the difference 
between the groups increased to 60%. However, as the organ that generates the new B 
cells that will repopulate the secondary lymphoid organs, the percentage of CD19
+
 cells 
in the bone marrow returned to control levels earlier than the other organs studied. 
 
5.6.2 Extracellular markers: CD21 and CD23 
Unlike other lymphoid organs, the percentage of FO B cells in the bone marrow was 
lower than 50% of all B cells. These recirculating CD21
low
CD23
hi
 B cells were almost 
completely extinct from the bone marrow of depleted mice for the first 8 weeks and 
returned to the frequencies seen in the control group by the 12
th
 week after the last 
injection (Figure 5.19b). 
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Figure 5.19 Effect of B cell depletion and repopulation in bone marrow B cells 
of young mice. 6-8 week-old female transgenic NOD mice expressing hCD20 
received a cycle of 4 injections of either control IgG (represented in pink) or anti -
hCD20 (clone 2H7 – represented in turquoise). Bone marrows from hCD20/NOD 
mice were collected at the determined time points, erythrocytes were l ysed and 
lymphocytes were stained for extracellular markers ex vivo. The subsets analysed 
were: CD19 (a); CD21
l ow
CD23
hi
 (b); CD5
hi
 (c); CD24 (MFI) (d) and CD38 (MFI) 
(e). Each time point illustrates the mean of 6-8 mice and standard error. Data were 
analysed by t-test.  
* p < 0.05; ** p < 0.01; *** p < 0.001 
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5.6.3 Extracellular markers: CD5 
Interestingly, the depletion in the bone marrow did not alter the percentage of CD5
hi
 B 
cells (Figure 5.19c), which did not become a dominant population, as seen elsewhere. 
The numbers in both groups varied throughout the whole experiment. 
 
5.6.4 Extracellular markers: CD24 and CD38 
The expression of CD24 on B cells from control mice and on the remaining B cells 
from depleted mice was similar throughout the whole experiment and no significant 
difference was detected (Figure 5.19d). On the other hand, the expression of CD38 on B 
cells from mice treated with anti-hCD20 was significantly lower than control B cells for 
the first 3 time points (Figure 5.19e) 
 
5.6.5 Extracellular marker: CD43 
The only marker being expressed in a significantly higher proportion of B cells in 
depleted mice was the CD43
+
 (Figure 5.20a). This high expression, however, returned 
to control levels faster than in the other lymphoid organs and frequencies were similar 
in both groups by the 8
th
 week. 
 
5.6.6 Extracellular markers: IgD and IgM 
The percentages of B cells expressing IgD (Figure 5.20b) and IgM (Figure 5.20c) in 
depleted mice followed the pattern seen for FO B cells in the bone marrow for the first 
week after depletion: The proportions were significantly lower in depleted mice. By the 
8
th
 week after the last injection, however, the frequencies started to increase and it was 
likely that this was because of the newly generated transitional B cells. 
 
5.6.7 Extracellular marker: CD138 
As expected, the highest percentages of B cells expressing CD138 were seen in the bone 
marrow (varying around 20% in control mice). The depletion did not affect the 
percentage of CD19
+
CD138
+
 cells, which varied the same way as the control group 
(Figure 5.20d). 
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5.6.8 Extracellular marker: Tim-1 
As illustrated in Figure 5.20e, the percentage of B cells expressing Tim-1 in the bone 
marrow was not affected by B cell depletion in treated mice. The percentages in both 
groups decreased at the 1
st
 week and increased together by the 8
th
 week after the last 
injection. 
 
5.6.9 Summary 
Bone marrow total B cells were the most resistant B cells to depletion, comparing all 
the lymphoid organs studied. Eight weeks after the last injection, total B cells in the 
bone marrow of depleted mice reached the same percentages seen in control mice.  
The main populations affected were the B cells expressing follicular zone phenotype, 
and cells expressing IgD and IgM. Resistance to depletion was observed in CD43
+
 B 
cells, while the depletion had a less clear effect on B cells expressing CD5
hi
, CD138
+
 
and Tim-1
+
. 
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Figure 5.20 Effect of B cell depletion and repopulation in bone marrow B cells 
of young mice. 6-8 week-old female transgenic NOD mice expressing hCD20 
received a cycle of 4 injections of either control IgG (represented in pink) or anti -
hCD20 (clone 2H7 – represented in turquoise). Bone marrows from hCD20/NOD 
mice were collected at the determined time points, erythrocytes were l ysed and 
lymphocytes were stained for extracellular markers ex vivo. The subsets analysed 
were: CD43 (a); IgD (b); IgM (c); CD138 (d) and Tim-1 (e). Each time point 
illustrates the mean of 6-8 mice and standard error. Data were analysed by t-test. 
* p < 0.05; ** p < 0.01; *** p < 0.001   
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5.7 The effects of B cell depletion and repopulation in older hCD20 NOD mice 
To determine the further effects of B cell depletion, hCD20 NOD mice depleted during 
the pre-insulitis period (6-8w.o.) were observed for > 30 weeks after the last injection. 
Ideally the control group would be hCD20 NOD mice injected with MPC-11 (control 
IgG). However, in this case, control group comprised hCD20 NOD mice that were not 
treated with either MPC-11 or 2H7. 
 
5.7.1 Incidence of type 1 diabetes  
The first observation about these older hCD20 mice was the incidence of type 1 
diabetes (Figure 5.21). Concordant with the findings in the literature, we observed that 
treatment with 2H7 delayed the onset of type 1 diabetes (the first hyperglycaemic 2H7-
treated mouse was detected 10 weeks after the first control mouse); the 2H7-treated 
group also had an overall reduced incidence of diabetes (58% in the control group 
versus 44% in the depleted group). The differences were not statistically significant, 
which was likely to be due to the number of mice. A new experiment has been set up, 
with mice injected with MPC-11 and 2H7, and is currently ongoing (end in May/2017). 
 
5.7.2 Effects of the interaction between CD8 T cells, DCs and B cells from hCD20 
mice 
 
5.7.2.1 Experimental design  
One of the possibilities as to why B cell depletion decreased the incidence of type 1 
diabetes was that the new B cells that repopulate the lymphoid organs have a more 
regulatory profile than prior to depletion. To test this theory, we used the system 
described in chapter 4 (section 4.2) to analyse the potential of B cells from hCD20 mice 
previously depleted and repopulated to interfere with the activation of CD8 T cells by 
DCs. 
Briefly, dendritic cells were purified from PI homo mice and used to present proinsulin 
to T cells. These DCs were stimulated with LPS for 18h and were then added in culture 
for 3 days with CD8 T cells from G9 mice. LPS-stimulated or unstimulated B cells were 
also added to the system. 
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LPS-stimulated and unstimulated B cells derived from 3 groups of mice: 1) > 35w.o. 
euglycaemic hCD20 mice that did not receive any injection (n=3; Control) and 2) > 
35w.o. euglycaemic hCD20 mice that received 1 cycle of anti-hCD20 when they were 
6-8 w.o (n=3; 2H7). A third group was added due to the detection of one hyperglycemic 
hCD20 mouse from the 2H7 group on the day of the experiment. Hence, the third group 
comprised one > 35w.o. hyperglycaemic hCD20 mouse that had received 1 cycle of 
anti-hCD20 (n=1; 2H7 diabetic). 
As a consequence of such small numbers, it was not possible to apply statistics to the 
graphs and data shown here are preliminary and partial. As explained previously, these 
experiments are being repeated and the aim is to increase the number of mice and 
include the group “Control diabetic” for future analysis. 
 
 
 
Figure 5.21 Incidence of type 1 diabetes in hCD20 NOD mice. Six to eight 
week-old hCD20 mice were injected with 1 cycle of 2H7 (n=9, represented in 
turquoise) or had no injections (n=12, represented in pink). Mice were observed 
for 35 weeks after the last injection for the evaluation of the incidence of type 1 
diabetes. Diabetes was confirmed after two consecutive weeks of positive 
glycosuria and blood glucose over 13.9 mmol/L. Data were analysed by log rank 
test. The arrow indicates when the cycle of anti -hCD20 was injected in the 2H7-
treated group. 
5.7.2.2 CD8
+
 T cell proliferation and activation 
An example of the gating strategy for the graphs is shown in the previous chapter 
(Figure 4.2). The difference here was the activation marker was changed to CD44, as 
1 cycle 
anti-hCD20 
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the time point for analysis of activation was later than the optimal for examination of 
CD69. 
As explained in Chapter 4, as a consequence of the variability of the efficiency of the 
CFSE labelling from one experiment to the other, all data from experimental groups 
were normalized to the control (CD8 T cells + DCs alone) and the percentages in Figure 
5.22a represent the increase or decrease from this control parameter, with the addition 
of unstimulated or LPS-stimulated B cells. 
Although the addition of unstimulated B cells to the system did not induce alteration in 
CD8 T cell proliferation, CD8 T cells from cultures that included LPS-stimulated B 
cells showed a decreased percentage of proliferation in all 3 groups. 
The activation of the CD8 T cells was also evaluated (Figure 5.22b), as the percentage 
of cells expressing CD44. There was an increase in the frequency of activated cells 
following addition of unstimulated B cells, compared to wells with CD8 T cells and 
DCs alone, but the difference was not striking. The presence of stimulated B cells in the 
cell culture led to the decrease of the percentage of activated CD8 T cells. This 
decrease, however, was observed in all 3 groups of B cells, whether they were derived 
from control treated, 2H7 non-diabetic or the 2H7 diabetic mouse. 
 
5.7.2.3 Viable CD8 T cells 
In a new approach to the gating strategy (Figure 5.23a), the percentage of viable CD8 T 
cells was used to determine whether the cells were being killed in the presence of 
stimulated B cells, as a reason for the decreased proliferation. For all 3 groups the 
percentage of viable CD8 T cells was lower in the presence of LPS-stimulated B cells 
compared to unstimulated B cells and CD8 T cells cultured with DCs and no B cells 
(Figure 5.23b); however the difference was not as remarkable as seen for the 
proliferation, which could suggest the death of CD8 T cells was not the only reason for 
the differences seen in Figures 5.22. Nevertheless, it would be interesting to determine 
how many of these cells had induced apoptosis.  
162 
 
 
Figure 5.22 Effect of stimulated and unstimulated B cells on the activa tion of 
CD8 T cells by DCs. After culture for one week, bone marrow DCs from PI homo 
mice were stimulated with LPS for 18h. Splenic B cells from hCD20 mice were 
stimulated with LPS for 24h or left unstimulated. Spleen CD8 T cells (from G9 
mice) were purified on the day of the set -up of the experiment and labelled with 
CFSE for the evaluation of CD8 proliferation. The experimental procedure was as 
follows: 2x10
5
 CD8 T cells, 4x10
5
 DCs and 1.4x10
6 
stimulated or unstimulated B 
cells were added to each culture. After 72h of incubation, cultures were harvested 
for flow cytometric staining. Forty eight hours after the set -up, supernatants were 
collected. The percentage of CD8 T cells proliferating and activated CD8 T cells 
are shown in (a) and (b), respectively. The data shown are represented as mean 
and standard error. n=3 for control and 2H7 groups and n=1 for 2H7 diabetic, 
done over 2 experiments.   
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Figure 5.23 Effect of stimulated and unstimulated B cells on the death of CD8 
T cells. After culture for one week, bone marrow DCs from PI homo mice were 
stimulated with LPS for 18h. Splenic B cells from hCD20 mice were stimulated 
with LPS for 24h or left unstimulated. Splenic CD8 T cells (from G9 mice) were 
purified on the day of the experiment set -up and labelled with CFSE for the 
evaluation of viable CD8 T cells. The experimental procedure was as follows: 
2x10
5
 CD8 T cells, 4x10
5
 DCs and 1.4x10
6 
stimulated or unstimulated B cells 
were added to each culture. After 72h of incubation, cultures were harvested for 
flow cytometric staining. Forty-eight hours after the set-up, supernatants were 
also collected. One example of the gating strategy for the evaluation of viable 
cells is found in (a): Lymphocytes  Single cells  Exclusion of any CD4 T 
cells in the culture  Exclusion of DCs (CD11b -CD11c -)  Distinction between 
CD8 T cells and B cells (CD19)  Viable CD8 T cells. The data in (b) are 
represented as mean and standard error. n=3 for control and 2H7 groups and n=1 
for 2H7 diabetic, done over 2 experiments.   
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5.7.2.4 Cytokines in the supernatants 
To investigate the mechanisms by which stimulated B cells were reducing the 
proliferation and activation of CD8 T cells, in contrast to unstimulated B cells, we 
investigated the concentration of cytokines in the supernatants. In agreement with the 
previous findings, we observed that cell cultures where LPS-stimulated B cells were 
added had lower levels of pro-inflammatory cytokines and more IL-10 (Figures 5.24a-
d). 
It is interesting to observe the differences between the groups. When B cells from the 
diabetic mouse were added to the cell culture, the concentration of IFN-γ was much 
higher, even with LPS-stimulated B cells (Figure 5.24a). 
IL-10 was produced mainly by B cells, as the concentration of IL-10 produced by CD8 
T cells + DCs alone was very low (Figure 5.24b) and, as expected, the stimulation with 
LPS boosted the production. Higher concentrations of IL-10 were seen with stimulated 
B cells derived from control hCD20 mice. Most of all the IL-6 in the culture was 
produced by DCs (Figure 5.24c). However, the addition of unstimulated B cells 
increased the concentrations, except when the unstimulated B cells were from the 
euglycaemic 2H7-treated group. For the diabetic mouse (from the 2H7-treated group), 
even the addition of stimulated B cells caused the increase of IL-6. The results for TNF-
α (Figure 5.24d) were similar to IL-6. 
 
5.7.3 Interaction between CD8 T cells and B cells from hCD20 mice as APC with 
G9 peptide as antigen 
As a decrease in the costimulatory molecules (CD80 and CD86) was observed in B cell-
depleted mice 8 and 12 weeks after the last injection (Figures 5.12 and 5.15), we 
decided to use the system to evaluate the function of B cells as APCs.  
For these experiments DCs were not used; LPS-stimulated B cells were cultured with 
CD8 T cells. The G9 peptide (insulin B chain, amino acids 15-23) was added in two 
concentrations (1μg/ml and 0.5 μg/ml), as the antigen to be presented. Cell cultures 
were incubated for 72h and the parameters analysed, as well as the gating strategies, 
were the same as described above for B cells as bystander cells.  
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Figure 5.24 Effect of stimulated and unstimulated B cells on the secretion of 
cytokines. After culture for one week, bone marrow DCs from PI homo mice were 
stimulated with LPS for 18h. Splenic B cells from hCD20 mice were stimulated 
with LPS for 24h or left unstimulated. Splenic CD8 T cells (from G9 mice) were 
purified on the day of the experimental set -up and labelled with CFSE for the 
evaluation of CD8
+
 T viable cells. The experimental procedure was as follows: 
2x10
5
 CD8 T cells, 4x10
5
 DCs and 1.4x10
6 
stimulated or unstimulated B cells 
were added to each well. Forty-eight hours after the set-up, supernatants were also 
collected and cytokines were measured. The concentration of IFN -γ  is shown in 
(a), IL-10 in (b), IL-6 (c) and TNF-α (d). Dashed lines indicate the levels of the 
cytokines produced by CD8 T cells + DCs. The data are represented as mean and 
standard error. n=3 for control and 2H7 groups and n=1 for 2H7 diabetic, done 
over 2 experiments.  
 
5.7.3.1 CD8 T cell proliferation, activation and frequency of viable cells 
For these experiments, both concentrations used (1μg/ml and 0.5μg/ml) led to almost 
100% proliferation of CD8 T cells (Figure 5.25a). Less proliferation was observed when 
the unstimulated B cells derived from the diabetic mouse were in the cultures using 
0.5μg/ml of peptide. On the other hand, the activation of CD8 T cells (CD44+ cells) was 
higher in the presence of stimulated and unstimulated B cells from this same diabetic 
mouse (Figure 5.25b), than in the other 2 groups. However, the biological effect of such 
small differences is debatable. 
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The percentage of viable CD8 T cells did not vary among the groups and was around 
80% for all of groups (Figure 5.25c). 
 
 
Figure 5.25 Effect of stimulated and unstimulated B cells, acting as APCs, in 
the proliferation and activation of CD8 T cells. Splenic B cells from hCD20 
mice were stimulated with LPS for 24h or left unstimulated. Splenic CD8 T cells 
(from G9 mice) were purified on the day of the set -up of the experiment and 
labelled with CFSE for the evaluation of CD8 proliferation. The experimental 
procedure was as follows: 2x10
5
 CD8 T cells, 1.4x10
6 
LPS-stimulated or 
unstimulated B cells and G9 peptide were added together in each culture. After 
72h of incubation, cultures were harvested for flow cytometric staining. Forty 
eight hours after the set-up, supernatants were also collected. We analysed the 
proliferation (CFSE
+
 cells - a), activation (CD44
+
 cells - b) and frequency of 
viable cells (c) in CD8 T cells. The data are represented as mean and standard 
error. n=3 for control and 2H7 groups and n=1 for  2H7 diabetic, done over 2 
experiments.   
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5.7.3.2 Expression of co-stimulatory molecules in B cells from hCD20 mice 
Contrasting with the results shown previously (where the expression of CD80 and 
CD86 on the B cells was lower in mice treated with 2H7), when added in culture with 
peptide and CD8 T cells, the percentage of B cells (from > 35 w.o. mice) expressing 
both costimulatory molecules was similar for all 3 groups. The expression of CD80 
(Figure 5.26a) was somewhat smaller when the concentration of the peptide was lower. 
The percentage of B cells expressing CD86 (Figure 5.26b) was higher than the 
percentage of CD19
+
CD80
+
 cells in all groups. 
 
 
Figure 5.26 Expression of costimulatory molecules in stimulated and 
unstimulated B cells, acting as APCs to CD8 T cells. Splenic B cells from 
hCD20 mice were stimulated with LPS for 24h or left unstimulated. Splenic CD8 
T cells (from G9 mice) were purified on the day of the set-up of the experiment 
and labelled with CFSE for the evaluation of CD8 proliferation. The experimental 
procedure was as follows: 2x10
5
 CD8 T cells, 1.4x10
6 
LPS-stimulated or 
unstimulated B cells and G9 peptide were added together in each culture.  After 
72h of incubation, cultures were harvested for flow cytometric staining. Forty 
eight hours after the set-up, supernatants were also collected. We analysed the 
expression of CD80 (a) and CD86 (b) on B cells.  The data are represented as mean 
and standard error. n=3 for control and 2H7 groups and n=1 for 2H7 diabetic, 
done over 2 experiments.  
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5.7.3.3 Cytokine production in B cells working as APCs from hCD20 mice 
Although the percentages of proliferation, activation and viable CD8 T cells were very 
similar for the 2 concentrations of the peptide, the concentration of cytokines secreted 
into the supernatants varied between wells that received 1μg/ml or 0.5μg/ml of G9 
peptide. 
The concentration of IFN-γ (Figure 5.27a) was higher in wells with 1μg/ml and the 
greatest difference between the two concentrations was observed in the cultures 
containing B cells from the diabetic mouse. 
Control hCD20 mice, not injected with anti-hCD20, had lower concentrations of IFN-γ 
and higher IL-10 (Figure 5.27b), compared to the 2H7-treated mice. 
IL-6 was not secreted in great quantities when DCs were not present; the concentrations 
were similar between the two euglycaemic groups and lower in the culture containing B 
cells from the diabetic mouse (Figure 5.27c). 
 TNF-α (Figure 5.27d) followed the same pattern seen for the concentrations of IFN-γ. 
 
5.7.4 Summary 
The protective effect of B cell depletion against type 1 diabetes in NOD mice described 
in the literature was reproduced here when 6-8 week old mice were injected with anti-
hCD20, showing reduced incidence and delayed onset of the disease. 
To investigate whether this protection could be related to altered regulatory B cell 
function, we analysed B cells from > 35 w.o. (protected) hCD20 mice, treated with 2H7 
or control untreated hCD20 mice. These B cells were tested using the system described 
in chapter 4 (section 4.2), where antigen-specific DCs presented antigen to antigen-
specific CD8 T cells, while B cells were functioning as bystanders, interacting with the 
cells, but not acting as APCs. 
Although there were differences in the proliferation and activation of CD8 T cells and 
the secretion of cytokines when LPS-stimulated and unstimulated B cells were 
compared, the differences were seen in all groups, including the one mouse that had 
become diabetic from the 2H7-treated group. There were no striking differences 
between the groups when B cells were the antigen-presenting cells either, and where 
there was a small difference, lower IFN- and higher IL-10 in the control group. These 
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results suggest that if there is a role for regulatory B cells in the protection seen in B cell 
depleted mice, it might not be due to the effect of B cells on CD8 T cells and DCs. 
The results, however, require further confirmation as a greater number of mice, over 
more than one experiment, are needed for more definite conclusions. 
 
 
Figure 5.27 Effect of stimulated and unstimulated B cells, as APCs, on the 
secretion of cytokines. Splenic B cells from the spleen of hCD20 mice were 
stimulated with LPS for 24h or left unstimulated. Splenic CD8 T cells (from G9 
mice) were purified on the day of the set -up of the experiment and labelled with 
CFSE for the evaluation of CD8 proliferation. The experimental procedure was as 
follows: 2x10
5
 CD8 T cells, 1.4x10
6 
LPS-stimulated or unstimulated B cells and 
G9 peptide were added together in each culture. After 72h of incubation, cultures 
were harvested for flow cytometric staining. Forty -eight hours after the set -up, 
supernatants were also collected and cytokines were measured with the multiplex 
assay kit (MSD). The concentration of IFN-γ  is shown in (a), IL-10 in (b), IL-6 
(c) and TNF-α (d). The data are represented as mean and standard error. n=3 for 
control and 2H7 groups and n=1 for 2H7 diabetic, done over  2 experiments.   
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5.8 Discussion 
 
Anti-CD20 monoclonal antibodies were first used to deplete B cells as a treatment for 
lymphomas, and because of their efficacy, the use was extended for autoimmune 
diseases. 
Rituximab (chimeric anti-CD20) has already been tested in clinical trials for SLE, 
arthritis and type 1 diabetes and caused few adverse events, but the effect has often been 
partial (Pescovitz et al. 2014; Cohen and Keystone 2015; Mok 2015). Therefore, it is 
important to study the mechanisms of action of this treatment on the immune system as 
a whole, in an effort to find ways to improve its efficacy. 
To study the effects of an antibody similar to rituximab in the type 1 diabetes 
experimental model, a transgenic NOD mouse strain expressing human CD20 (here 
designated hCD20 NOD mice) was generated (Hu et al. 2007). 
The aims of this study were to: 1) Evaluate the effects of B cell depletion and 
repopulation in B cell subsets, especially regulatory subsets; 2) Examine the production 
of cytokines by B cells after the depletion and 3) Determine whether the protection 
against type 1 diabetes seen in depleted mice was due to the effect of B cells on CD8 T 
cells or DCs. 
Six to eight week-old hCD20 NOD mice received one cycle (4 injections in 9 days) of 
either anti-hCD20 (2H7) or control IgG (MPC-11) and the depletion was followed for 
12 weeks after the last injection. B cells were evaluated in the spleen, lymph nodes and 
bone marrow and the most interesting findings are discussed below. 
Different organs showed different degrees of depletion and the order was: MLN B cells 
were almost 100% depleted, followed by spleen and PLNs (90%), then Peyer’s patches 
(75%) and bone marrow was where B cell depletion was least efficient (peaking at 60% 
one week after the last injection). The efficacy of the depletion depended more on the 
blood circulation in the organs than the expression of hCD20 on B cells (as more than 
95% of all B cells outside the bone marrow express this marker); “hidden” organs 
provide protection against depletion, one example being the peritoneal cavity, where B-
1 and B-2 cells are generally more resistant to depletion (Gong et al. 2005; Hamaguchi 
et al. 2005), and these B cells were not studied in this thesis. 
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The bone marrow, however, should not be analysed the same way as other lymphoid 
organs. They are the location for the generation of new B cells after depletion, and 
comprise cells at different stages of development, and therefore their population is 
mixed in the expression of hCD20. The disturbance of homeostasis of the number of B 
cells in the periphery is manifest by a decrease of recirculating FO B cells in the BM 
and this leads to a faster proliferation of pro/pre B cells, which will repopulate the 
remaining lymphoid organs (Shahaf et al. 2016). 
Table 5.1 summarizes the subpopulations of B cells analysed in the lymphoid organs 
and how B cell depletion affected each of them. 
In the spleen, the proportion of B cells with Follicular zone phenotype was generally 
similar in control and depleted groups throughout the experiments. Marginal zone and 
T2 B cells were more susceptible to depletion. This observation was made not only 
based on the reduction of the major phenotypes (CD21
hi
CD23
low
 and CD21
hi
CD23
hi
, 
respectively), but also on the depletion of CD1d
hi
 and CD24
hi
CD38
hi
 B cells. Not 
surprisingly, Transitional B cells returned to normal proportions by the 8
th
 week after 
injection. As the immature phenotype of B cells entering the spleen from the bone 
marrow, they were likely to be an earlier subset repopulating the spleen. In the lymph 
nodes, depletion lasted longer than in the spleen. B cells with MZ or T2 phenotype are 
rare in the LNs, so the depletion was observed largely in the FO B cells. As observed in 
the analysis of hCD20 expression in CD19
+
 B cells, these differences were not due to 
lower expression of the target molecule in specific subpopulations. 
The reported susceptibility of B cells in the spleen to depletion is contradictory in the 
literature. Some publications describe MZ B cells as susceptible, agreeing with our data 
(DiLillo et al. 2008), while other show the opposite (Gong et al. 2005). The discrepancy 
could be due to different mouse strains (as discussed in previous chapters, the marginal 
zone in the spleen of NOD mice is thicker than in other strains) or age at which anti-
CD20 is administered. 
In all organs, B cells expressing CD5
hi
 and CD43 were resistant to depletion. This 
meant that, in an environment where other populations were being reduced, the 
depletion of these subsets was occurring in a less clear manner, leading to a higher 
proportion/percentage. Both CD5
hi
 and CD43 are markers related to B-1 B cells that 
were described previously in the literature as a subpopulation resistant to B cell 
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depletion (Hamaguchi et al. 2005). As discussed earlier, this resistance was not due to 
the lack of hCD20 expressed on these B cells. B-1 B cells are self-renewing, thus 
intrinsic mechanisms to resist depletion would be indispensable to avoid total 
extinction. Whilst Hamaguchi and colleagues postulated that B-1 B cells in the 
peritoneal cavity were not depleted because this environment lacked effector cells to 
remove anti-CD20 coated cells, this clearly does not apply in the spleen and lymph 
nodes.  Further studies on intrinsic protection of these cells may be of importance 
(Hamaguchi et al. 2005). 
One interesting finding in our study was the expression of hCD20 by almost all 
CD19
+
CD138
+
 cells in the secondary lymphoid organs and a lower percentage of 
CD19
+
CD138
+
hCD20
+
 cells in the bone marrow. Regardless of their expression of 
hCD20, these cells were resistant to depletion, resulting in higher frequencies of B cells 
expressing CD138
+
 in depleted mice during depletion. Reports in the literature showed 
that anti-CD20 did not affect the basal production of immunoglobulins and that the 
stable numbers of long-lived plasma cells during depletion were not derived from 
resistant mature B cells or memory cells, once they were susceptible to depletion (Ahuja 
et al. 2008; DiLillo et al. 2008). This data and the data from B-1 B cells could suggest 
that the populations that are resistant to depletion are self-renewable (and therefore are 
more resistant to apoptosis) and are involved with producing antibodies (including 
natural antibodies, in the case of B-1 B cells). 
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Table 5.1 Summary of the effect of B cell depletion on the subpopulations 
studied, in different lymphoid organs  
 
Spleen PLN MLN PP BM 
CD19 depleted Depleted depleted depleted depleted** 
Follicular 
zone 
No clear 
difference 
Depleted depleted depleted depleted 
Marginal 
zone 
depleted -- -- -- -- 
Transitional 
cells 
depleted* -- -- -- -- 
CD1d
hi
CD5
+
 depleted -- -- -- -- 
CD5
hi
 resistant resistant resistant resistant 
No clear 
difference 
CD1d
hi
CD5
hi
 resistant -- -- -- -- 
CD24
hi
CD38
hi
 depleted * -- -- -- -- 
CD24 (MFI) -- 
higher in 
2H7 group 
higher in 
2H7 group 
higher in 
2H7 group 
No clear 
difference 
CD38 (MFI) -- 
No clear 
difference 
No clear 
difference 
lower in the 
2H7 group 
lower in the 
2H7 group 
CD43 resistant resistant resistant resistant resistant 
IgD depleted * depleted depleted depleted depleted 
IgM depleted depleted depleted depleted depleted 
CD138 resistant resistant resistant resistant 
No clear 
difference 
Tim-1 resistant resistant resistant resistant 
No clear 
difference 
* Returned first, before other depleted subpopulations 
** Returned first, before other depleted lymphoid organs 
 
 
When B cells were examined after a 24h culture period with LPS, anti-CD40 or left 
unstimulated, the reduced percentage of cells expressing the costimulatory molecules 
CD80 and CD86 in the B cell depleted mice (figure 5.12) may partially explain why B 
cell depletion leads to protection against type 1 diabetes. The percentages of B cells 
expressing these costimulatory proteins were lower in depleted mice even 12 weeks 
after the last injection, when all other markers studied were back to levels comparable to 
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the control group. On the other hand, when the function of B cells as APCs was 
assessed in >35 w.o. hCD20 NOD mice, there was no difference in the frequency of 
CD80 and CD86 between euglycaemic control and depleted and hyperglycaemic 
depleted mice. However, this finding does not remove the possibility that the reduction 
of B cells expressing CD80 or CD86 earlier, during the depletion, modulated the system 
when B cells functioning as APCs were more important for the onset of the disease. In a 
primate model of multiple sclerosis, it was demonstrated that anti-CD20 administration 
led to an environment in the lymphoid organs less favourable for T cell homing to the 
brain, with the remaining B cells expressing less costimulatory molecules (Kap et al. 
2014). Moreover, transgenic mice with CD80/CD86
-
/
- 
B cells were resistant to the 
induction of arthritis, in a similar way to mice lacking B cells (O'Neill et al. 2007). 
Although showing the data in percentage/proportion demonstrated the difference 
between susceptible and resistant B cell subpopulations, it is important to note that a 
study of the absolute numbers would also contribute for the analysis. It would show the 
absolute level of depletion of each subpopulation and allow comparison of numbers of 
cells between the subpopulations in control and depleted mice. Therefore, the analysis 
of absolute numbers would ideally also be performed. 
Lastly, the production of cytokines by remaining and repopulated B cells was analysed. 
During depletion, the production of IL-10 was compromised, probably as a result of 
depleted marginal zone cells and CD1d
hi
 B cells. The percentages of TGF-β+ and IL-6+ 
B cells was very low, but higher in depleted mice. When the spleen was repopulated, 
the frequency of B cells producing IL-10 returned to similar levels compared to the 
control. The percentages of TGF-β and IL-6 were similar too, 12 weeks after the last 
injection. 
Indeed, when B cell depletion was analysed in transgenic hCD20 NOD mice expressing 
only specific TCRs for a peptide from chromogranin A (BDC 2.5 Tg mice), these CD4 
T cells were more aggressive in vitro during the period when the B cells were depleted.  
BDC2.5 T cells from treated mice also caused accelarated diabetes when transferred to 
NOD.scid mice, compared to the control group. Nevertheless, in the BDC 2.5 
Tg/hCD20 NOD model, the returning B cells were more suppressive (Xiang et al. 
2012). Our findings that IL-10-producing B cells are depleted during anti-CD20 
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treatment is in agreement with previous observations that T cells are not well regulated 
during depletion. 
B cell depletion enhances Treg functions after repopulation (Hu et al. 2007; Olalekan et 
al. 2015). However, here we were not able to demonstrate higher frequencies of B cells 
producing anti-inflammatory cytokines in the spleen of 2H7 treated mice or that B cells 
from these mice were more regulatory, after repopulation, in an experimental system 
testing DC activation of insulin-specific CD8 T cells. Nevertheless, our results do not 
exclude the possibility that B cell regulation of CD8 T cell function may not be as 
efficient as regulation of CD4 T cell function. 
Future work in progress for this project includes the use of anti-CD20 to deplete B cells 
in 12-15 w.o. hCD20 NOD. The aim is to determine the effect of B cell depletion in a 
later stage of type 1 diabetes development.  
In another part of this project, being developed by Joanne Boldison, the effect of B cell 
depletion on the insulitis of hCD20 NOD mice is being studied. Early results suggest 
that B cell depletion also caused the reduction of T cells in the pancreas infiltration. 
Finally, the depletion of B cells (that affects MLNs and PPs, as observed in this chapter) 
could modulate the quality of the gut microbiota, which would then modulate the 
immune system differently.  This is also under investigation, results of which are not yet 
available. 
In conclusion, the use of anti-hCD20 to deplete B cells in hCD20 NOD mice led to the 
alteration of subpopulation proportions in the lymphoid organs. The treatment also 
delayed and reduced the incidence of type 1 diabetes. Our studies did not identify an 
association between this protection and IL-10 producing B cells, but suggested a role 
for the reduction of costimulatory proteins in remaining B cells during depletion and the 
early stages of repopulation. 
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6.  Discussion 
 
The main aim of this thesis was to study regulatory B cells in type 1 diabetes, using the 
NOD mouse model.  A number of studies were carried out using different approaches. 
We demonstrated, in Chapter 3, that naturally protected NOD mice (more than 35 
weeks old that had not developed diabetes) had similar frequencies of B cells producing 
the pro-inflammatory cytokine IL-6 and the regulatory cytokine TGF-β, when compared 
to diabetic NOD mice. However, those mice that did not show signs of hyperglycaemia 
had higher baseline percentages of IL-10-producing B cells than diabetic mice and age-
matched congenic B6
g7
 mice, the control strain (not diabetes-prone), and responded 
more to stimuli that increased the frequency of IL-10-producing cells, including LPS.  
Moreover, evaluating their regulatory potential in Chapter 4, B cells from protected 
NOD mice led to less degranulation of CD8 T cells and reduced production of IL-12p70 
by DCs, when compared to diabetic mice. Another interesting finding was that LPS-
stimulated B cells had greater suppressive effects compared to unstimulated B cells, 
even when B cells were from diabetic mice.  
When investigating the role of regulatory B cells on the protection conferred by 
transient B cell depletion, we observed, as shown previously, that mice that had been B 
cell-depleted developed a lower incidence of diabetes.  Nevertheless, IL-10-producing B 
cells were susceptible to depletion, similar to other B cell populations and the 
repopulated B cells had similar regulatory potential, when interacting with CD8 T cells 
and DCs, to those found in the non-depleted mice. 
Based on the idea that regulatory B cells need inflammation to produce IL-10 (Rosser et 
al. 2014; Menon et al. 2016), it is difficult to determine whether the increased frequency 
of CD19
+
IL-10
+
 cells seen in protected NOD mice is a cause or consequence of 
protection. Did the higher percentage of IL-10-producing B cells lead to protection from 
diabetes or were they increased as a result of inflammation that was then kept under 
control by other regulatory cells? Unfortunately, it is not possible to follow splenic B 
cell production of IL-10 over time to examine the fate of mice at an intermediate age, 
and follow those mice longitudinally until they became diabetic or became part of the 
protected pool of NOD mice. At the time that these 13-17 w.o. mice were evaluated in 
chapter 3, they could have become either diabetic or been protected. In one study in 
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humans, although the total number of B cells in peripheral blood did not change in 
patients with type 1 diabetes, compared to healthy controls, they also had fewer B10 
cells (Deng et al. 2016). Thus, investigating the percentage of IL-10-producing B cells 
during type 1 diabetes development in patients, from the time that they develop islet-
autoantibodies to the first signs of disease as well as “slow progressors”, who develop 
islet-autoantibodies but who do not develop diabetes, might explain whether these 
regulatory cells are the cause or consequence of protection. 
The observations made in relation to regulatory B cells in these studies raised questions 
to direct the future of this line of research.  An interesting finding in chapter 3 was the 
variation caused by different stimulants in B cells from diabetic mice: B cells were able 
to respond, producing IL-10, to LPS and CpG (although less than in protected mice); 
but when stimulated with anti-CD40, the percentage was close to zero. With this in 
mind, as the IL-10 response by B cells from the diabetic was less compared to the 
protected older mice, it would be of importance to activate B cells with different 
stimulants and test their effects on dendritic cells and CD8 T cells. Our hypothesis is 
that the difference in suppression between B cells from protected and diabetic NOD 
mice after anti-CD40 stimulation would be even greater, while CpG-stimulated B cells 
would produce similar outcomes to those which was observed with LPS. Another 
important combination of stimulants to be tested would be aIgM and anti-CD40. The 
stimulation of naïve B cells by both of these together is known to generate germinal 
centre B cells and, further, plasma cells, but not regulatory B cells (Yanaba et al. 2009; 
Vinuesa et al. 2010).  
The relevance of these stimulants in vivo should also be taken into consideration. The 
importance of CD40 stimulation in NOD mice is easily tracked back to the interaction 
with T cells. As discussed in chapter 3, in patients with SLE, the unresponsiveness of B 
cells to anti-CD40 was due to a problem in STAT3 signalling, not downregulation of 
the co-stimulatory molecule on the surface of B cells (Blair et al. 2010). Further 
investigation in patients with type 1 diabetes and NOD mice could give insights into the 
relation between impairment in CD40 signalling and the development of disease. 
However, the role of LPS or CpG in a model for type 1 diabetes is more difficult to 
explain. The concept of lymphocytes producing regulatory cytokines after bacterial/viral 
encounter is not new. The “Old Friends” theory postulates that the immune system 
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suppresses responses against some types of microbes because they evolved together 
with humans and needed to be tolerated. Thus, infections or symbiotic interactions with 
certain bacteria or helminths are associated with protection against autoimmune 
diseases, allergy and asthma in humans (Rook 2012). One of the mechanisms proposed 
for tolerating these microbes is the induction of regulatory T and B cells, which would 
provide a more suppressive environment and regulate autoimmune diseases better 
(Correale et al. 2008; Zaccone et al. 2009). 
For B cells specifically, studies have shown that they produce IL-10 during Salmonella 
infection, for example, in a Myd88-dependent manner (Neves et al. 2010). Although 
TLR ligands activate effector cells, they may also activate regulatory type cells, as 
shown in T cells (Sutmuller et al. 2006); when expressed in B cells, these receptors 
seem to also control the extension of inflammatory responses, by the secretion of 
regulatory cytokines. Moreover, B cells are also known to produce IL-35 (another 
regulatory cytokine) during bacterial infection, limiting the immune system efficacy 
(Shen et al. 2014). 
The importance of gut microbiota modulating immune responses has also been a recent 
subject of study that ties together bacteria and autoimmunity. The quality of fecal 
bacteria was shown to be different in islet-autoantibody positive children when 
compared to controls (de Goffau et al. 2013). It has been suggested that an unbalanced 
ratio of Bacteroides and Firmicutes, favouring the former, might lead to susceptibility 
to type 1 diabetes (Davis-Richardson and Triplett 2015; Hu et al. 2015). Among other 
mechanisms, this could suggest that perhaps the ability of B cells from diabetic mice to 
produce IL-10, when activating TLRs, is impaired by the reduced expression of these 
receptors or by the absence of the “right” bacteria to activate the regulatory response. 
It is broadly agreed that IL-10-producing B cells are mainly found within the 
CD1d
hi
CD5
+
 subpopulation, after LPS stimulation (Yanaba et al. 2008). However, the 
studies discussed above demonstrated that, upon infection, CD19
+
CD138
+
 B cells are 
the subset responsible for regulatory cytokine production (Shen et al. 2014). In our 
experiments, the lack of one unified marker for Bregs was the reason why B cells were 
not sorted before the set-up in chapter 4. Choosing one subset would not have allowed 
study of the regulatory function of B cells as a whole, especially for IL-10 independent 
mechanisms. 
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Despite the observation that the levels of IL-10 were significantly increased with the 
addition of B cells to the cultures containing CD8 T cells and DCs in chapter 4, IL-10-
independent mechanisms could also be responsible for the regulation.  
The first possible alternative to IL-10 could be TGF-β. Although, in chapter 4, we were 
not able to detect this cytokine intracellularly by flow cytometry or secreted in the 
supernatant, by ELISA, the possibility that membrane bound TGF-β could have been 
part of the response should not be discarded, as its function inducing CD8 T cell anergy 
was described by (Parekh et al. 2003). Interestingly, in our experiments, IL-10-
producing B cells and TGF-β-producing B cells were not the exact same cells, but 
expressed the same putative regulatory markers, i.e., they showed low percentages of 
IL-10/TGF-β double positive B cells (shown as Figures A3 and A4 in the Appendix). 
Understanding the signalling pathways behind this “choice” of producing one cytokine 
or the other might reveal some important details about regulatory B cells.  
Another cytokine-independent regulatory mechanism could be by cell-cell contact, 
through upregulation of suppressive surface markers. As a mechanism used for evasion, 
Salmonella infected B cells, for example, upregulate the expression of PD-1L 
(Programmed death-1 ligand – a molecule from the CD28/CTLA-4 family); this 
molecule can suppress CD8 T cell activity (Lopez-Medina et al. 2015). In humans, 
stimulation of B cells by CpG-DNA upregulated the expression of PD-1L as well (Kubo 
et al. 2012). The addition of PD-1 and PD-1L to the flow cytometric panel would help 
to evaluate if that is the case in our model. 
Furthermore the upregulation of the markers Fas-FasL, receptors for the induction of 
apoptosis, could have also been responsible for the suppression observed in our 
experiments. Indeed, there was a significantly lower percentage of viable CD8 T cells in 
cultures where LPS-stimulated B cells from NOD mice were added, which was 
attributed to TGF-β-producing B cells previously in the literature (Tian et al. 2001). 
It will also be important to evaluate more closely the effect of LPS-stimulated B cells on 
dendritic cells. Examples of how B cells might regulate DCs may include 
downregulation of co-stimulatory molecules and induction of apoptosis. 
Transwell assays, isolating B cells from directly interacting with T cells and DCs, 
would highlight how much of the results were due to regulatory cytokines versus the 
importance of cell-cell contact. However, it is also important to note that cell-cell 
180 
 
contact could also result in cytokine production. CD8 T cells, for example, could be 
binding to B cells through CD40-CD40L, promoting more IL-10 production by LPS-
stimulated B cells. The main findings and questions for future investigations based on 
the results in chapters 3 and 4 are illustrated in Figure 6.1. 
As we did not demonstrate an increase in splenic IL-10-producing B cells in hCD20 
NOD mice treated with anti-CD20, the IL-10 independent mechanisms described 
previously may also be relevant for the protection conferred by transient B cell 
depletion, as well as the reduced co-stimulatory molecules CD80 and CD86 on 
repopulating B cells. 
One important observation in respect of these anti-CD20 experiments was the resistance 
by B-1 cells to depletion. Although we did not evaluate how the depletion affected 
peritoneal B cells (comprising mostly B-1 cells, but also some B2 cells), studies done 
by others have shown that 1) they are resistant to depletion (Hamaguchi et al. 2005) and 
2) these peritoneal B-1 cells are able to produce greater levels of IL-10 (Maseda et al. 
2013). Thus, the idea that after depletion of other B cells, these cells were more able to 
regulate the immune responses should not be ruled out. 
The modifications in the immune system caused by the temporary absence of B cells 
should also be considered. Xiang and colleagues showed that, during B depletion, 
BDC2.5 CD4 T cells were more aggressive than in age-matched non-treated mice. 
However, they also showed that the returning B cell population were able to increase 
the population of Foxp3+ Treg cells in a cell-cell contact manner (CD5
+
 B cells were 
shown to be responsible for the increase in regulatory properties) (Xiang et al. 2012).  
If T cells become more inflammatory during the depletion but yet the incidence of the 
disease decreases, B cell depletion could regulate the immune system in a manner other 
than a direct effect on T cells. Indeed, one study showed that B cell depletion also 
expanded a population of myeloid-derived suppressor cells (MDSCs – Gr1+CD11b+), 
known for reducing T cell responses in autoimmune diseases and transplantation. These 
Gr1
+
 cells are IL-10-producing cells (Hu et al. 2012). Thus, despite anti-CD20 treatment 
not increasing splenic IL-10-producing B cells, there may be effects on induction of 
other regulatory populations, including regulatory T cells and Gr1
+
 cells. 
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Figure 6.1 Diagram of the main findings and the possible mechanisms for the 
suppression seen in chapter 4. Results in chapter 3 demonstrated that the 
frequency of B cells producing IL-10 was higher in > 35 w.o. naturally protected 
NOD mice, when compared to diabetic NOD mice. In chapter 4, we showed that 
when LPS-stimulated B cells from these protected NOD mice were added to the 
culture with dendritic cells and antigen-specific CD8 T cells, they were able to 
suppress the activity of CD8 T cells and DCs (the main findings are listed below 
the cells). These results could be associated with the higher levels of IL -10 
secreted by LPS-stimulated B cells. Alternatively, some IL-10-independent 
mechanisms for this suppression are listed in the panel shown with the dashed -line 
border and include: Secretion of TGF-β and IL-35 and the upregulation of 
suppressor receptors. 
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Finally, the outcome of anti-CD20 treatment should also be studied in the population of 
immune cells infiltrating the pancreatic islets. As discussed previously, B cells play 
many roles in the maintenance of insulitis, as APCs (Noorchashm et al. 1999) and/or 
enhancing CD8 T cell survival (Brodie et al. 2008). And although the majority of 
studies investigating islet infiltration were performed in experimental models, B cells 
were also detected in human pancreatic islet inflammation (In't Veld 2014). Thus, B cell 
depletion could also interfere locally with the β-cell destruction and the evaluation of 
anti-CD20 effect on pancreatic infiltration is currently ongoing in our lab. 
Taken all together, these results showed the possible involvement of regulatory B cells 
as one of the mechanisms by which naturally protected NOD mice do not develop type 
1 diabetes. On the other hand, as no difference were found after repopulation following 
B cell depletion therapy, they are unlikely to be as important for the protection that is 
induced by anti-CD20 treatment. Thus, although we set out to test the hypothesis that 
regulatory B cells may increase following B cell depletion, this does not seem to be the 
mechanism of protection. However depletion of the B cells, which allows other 
populations of cells including regulatory T cells and Gr 1 cells to expand, may then be 
acting indirectly with other immune cells with more efficacy (Figure 6.2). 
As in the machinery of a clock, the immune responses that interact causing the 
development of type 1 diabetes have to be seen in their entirety, taking every gear as an 
important piece and, the function of each cell, being dependent on another cell. What 
we have demonstrated here was that there is one “gear” component of regulatory B cells 
in the immune system and, when working efficiently, its role may be to induce other 
regulatory mechanisms to prevent type 1 diabetes in NOD mice. However, a reduction 
or absence of regulatory B cell activity would allow effector cells to continue their islet 
destruction. Future work will be required to determine if this regulatory B cell 
component can be boosted to help to prevent type 1 diabetes.  
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Figure 6.2 Diagram illustrating the main findings of chapter 5 and some 
possible effects of B cell depletion by anti -CD20 treatment. In agreement with 
data from the literature, the administration of anti -CD20 to young NOD mice led 
to delayed onset of type 1 diabetes  and reduced incidence. Our aim was to 
investigate whether IL-10-producing B cells were modulating this protection. 
Because these cells were susceptible to depletion, it is unlikely that they were 
functioning to directly influence type 1 diabetes during th e depletion period. 
However, other mechanisms were described in the literature and they have shown 
the effect of B cell depletion on other immune cells. How anti -CD20 treatment 
affects pancreatic islet-infiltrating cells and the gut microbiota are two ques tions 
for future work.  
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7. Appendix 
 
Figure A1 FMO and isotype controls for chapter 3 . These flow cytometric gates 
are the negative control for the gating strategy showed in Figures 3.2 and 3.16. 
Methods were described previously. 
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Figure A2 FMO and isotype controls for chapter 5. These flow cytometric gates 
are the negative control for the gating strategy showed in Figures 5.2. Methods 
were described previously.  
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Figure A3 Percentage of B cells (CD19) double positive for IL-10
+
 and TGF-
β+.  Spleens from female NOD mice were collected, erythrocytes were lysed and 
removed and spleen cells were cultured for 24h unstimulated (a) or stimulated 
with LPS (b), anti-CD40 (c), CpG (d) or anti-CD40/CpG (e); PMA, ionomycin and 
monensin were added for the last 3 hours and then cells were stained for 
extracellular markers and intracellular IL -10 and TGF-β. The percentages of 
double positives were calculated using Flow Jo analysis software, by Boolean 
Gate, as the percentage of CD19
+
IL-10
+
 and CD19
+
TGF-β+ that overlap. Each 
symbol represents an individual mouse and a median bar is shown. The 
explanatory diagram is shown in (f).  
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Figure A4 Frequency of regulatory markers expression in TGF-β-producing B 
cells. Spleens from 30-35 w.o. female NOD and B6
g7
 mice, as well as diabetic 
female NOD mice, were collected, erythrocytes were lysed and removed and 
spleen cells were cultured for 24h unstimulated (a-b) or stimulated with LPS (c-
d), anti-CD40 (e-f), CpG (g-h) or anti-CD40/CpG (i-j); PMA, ionomycin and 
monensin were added for the last 3 hours and then cells were stained for 
extracellular markers and intracellular cytokines. Samples were examined by flow 
cytometry. Frequencies of CD1d
hi
CD5
+
 expression in CD19
+
TGF-β+ cells are 
shown in (a,c,e,g and i) and frequencies of CD24
hi
CD38
+
 expression in 
CD19
+
TGF-β+ cells are shown in (b,d,f,h and j). Each symbol represents an 
individual mouse and a median bar is shown. 
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